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great relevance in order to find novel and suitable therapeutic strategies. Our experimental approach
to investigate MYC-regulated genes consisted of using a model of MB-derived cells and profiling them
by cDNA microarray upon genetic manipulation aiming at either over-expressing or down- regulating
MYC. We defined a list of 209 candidates with potential relevance to MYC- dependent cellular responses
in MB. The gene expression analysis we performed brought to our attention components of the bone
morphogenetic protein (BMP) signaling pathway, which plays a crucial role during the development of
the cerebellum. Our investigation shows for the first time the existence of a functional link between
the over- expression of MYC and abnormal regulation of the BMP pathway in a model of MB. Taken
together, the studies presented in this dissertation have investigated novel strategies to target the onco-
gene MYC and its target genes in ETs. Further validation, as well as translation to clinical studies, can,
in the future, shed more light on the biology of these pediatric tumors and contribute to an improve-
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in verschiedenen Modellsystemen intensiv untersucht wurden, sind die transkriptionellen Targets, welche
die Effekte der Überexpression von MYC im Medulloblastom charakterisieren, weitgehend unbekannt.
Um Medulloblastom- spezifische MYC-regulierte Gene zu finden, wurden MB Zellen mit einer MYC –
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faktor BMP7 MYC-abhängig induziert wird und es sich hierbei um ein direktes MYC-Target handelt.
In der vorliegenden Dissertation wurden neue “Targeting-Strategien” für das Onkogen MYC in embry-
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Summary 
MYC and its target genes have become attractive targets for cancer therapy, due to the 
correlations of the oncogene with high grade malignancy and poor prognosis in different 
types of tumors. My research investigations focused on novel strategies to target the 
oncogene MYC and/or its target genes, in the context of MYC-overexpressing embryonal 
tumors (ET), and in particular in medulloblastoma (MB). 
Searching for molecules potentially useful as MYC inhibitors, we studied the quassinoids, a 
group of compounds known in medicine for their wide spectrum of activities. Quassinoids 
showed anti-cancer properties including cytotoxicity, protein synthesis inhibition, induction 
of apoptosis, and the capacity to down-regulate the oncogene MYC. Therefore, considering 
that future research into chemical modifications is likely to generate more active and less 
toxic derivatives of natural quassinoids, this family represents a source of promising small 
molecules targeting key pro-survival signaling pathways necessary for the life of a cancer 
cell. 
In this context, we investigated the wide range of biological activities exerted by a semi-
synthetic quassinoid analogue named NBT-272. This compound induces in vitro and in vivo 
down-regulation of MYC and a complex pattern of cellular responses, functionally related to 
interference with key cell survival pathways playing a role in the pathogenesis of several 
ETs. Our findings increase the present level of understanding of the anti-tumor mechanisms 
of action of the quassinoids, and in particular of the derivative NBT-272. 
Our studies also focused on a different approach for targeting MYC. S2T1-6OTD is a 
molecule able to suppress both mRNA and protein expression of MYC, acting through the 
stabilization of the quadruplex structure in the promoter sequence of the oncogene. We 
studied the S2T1-6OTD–mediated cellular effects in a representative set of childhood MB 
and atypical teratoid/rhabdoid tumor cells. S2T1-6OTD reduces the activity of MYC in a 
cell-type specific manner, together with a negative effect on cell viability and proliferation of 
several tumor cell lines. Altogether, our results suggest that S2T1-6OTD may represent a 
potential effective and innovative therapeutic strategy for childhood brain tumors. 
 
Although the MYC functions during normal development and oncogenesis in various systems 
have been extensively investigated, the transcriptional targets mediating MYC effects in MB 
are still elusive. A better knowledge about the MYC’s effector genes involved in MB onset 
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and progression is of great relevance in order to find novel and suitable therapeutic strategies. 
Our experimental approach to investigate MYC-regulated genes consisted of using a model 
of MB-derived cells and profiling them by cDNA microarray upon genetic manipulation 
aiming at either over-expressing or down-regulating MYC. We defined a list of 209 
candidates with potential relevance to MYC-dependent cellular responses in MB. The gene 
expression analysis we performed brought to our attention components of the bone 
morphogenetic protein (BMP) signaling pathway, which plays a crucial role during the 
development of the cerebellum. Our investigation shows for the first time the existence of a 
functional link between the over-expression of MYC and abnormal regulation of the BMP 
pathway in a model of MB. 
Our results provide evidence of the induction of BMP7 as a MYC-dependent mechanism and 
indicate this growth factor as a direct target of MYC and as potential effector protein during 
MYC-driven neoplastic transformation of MB precursor cells. The functional relevance of the 
BMP-dependent signaling pathway in MB was evaluated by targeting the BMP pathway via 
specific siRNA-mediated silencing of BMP7 and employing a small-molecule inhibitor able 
to prevent the activation of BMP-downstream elements. This new information not only 
contributes to a better understanding of the pro-survival functions of MYC during MB 
development, but it also suggests a rationale for targeting BMP pathways as a therapeutic 
intervention strategy for MB patients with MYC amplification/overexpression. 
Taken together, the studies presented in this dissertation have investigated novel strategies to 
target the oncogene MYC and its target genes in ETs. Further validation, as well as 
translation to clinical studies, can, in the future, shed more light on the biology of these 
pediatric tumors and contribute to an improvement of therapies. 
 
Zusammenfassung 
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Zusammenfassung 
Das Onkogen MYC und die dadurch regulierten Gene stehen seit geraumer Zeit im 
Forschungsinteresse für die Entwicklung neuer Krebstherapien, da MYC mit dem Auftreten 
hochgradig maligner Tumore und schlechter Prognose in unterschiedlichen Krebsarten 
korreliert. Im Mittelpunkt meiner Forschung stand die Untersuchung neuer „Targeting-
Strategien“ für das Onkogen MYC in embryonalen Tumoren inklusive Medulloblastom, dem 
häufigsten kindlichen malignen Hirntumor. 
Auf der Suche nach potenziellen MYC-Inhibitoren stiessen wir auf die Gruppe der 
Quassinoide, die für ihr breites Wirkungsspektrum inklusive Zytotoxizität, Hemmung der 
Proteinbiosynthese, Induzierung von Apoptose und Herunterregulierung des Onkogens MYC 
bekannt sind. In diesem Kontext untersuchten wir die biologischen Aktivitäten des weniger 
toxischen semi-synthetischen Quassinoid-Analogs NBT-272. Dieses Molekül induziert 
Herunterregulierung von MYC in vitro und in vivo und ein komplexes Muster zellulärer 
Antwortmechanismen. Die Ergebnisse unserer Arbeit erweitern das momentan vorhandene 
Wissen über die Wirkungsweise der Quassinoide und charakterisieren das Krebshemmende 
NBT-272. 
Als weitere„Targeting-Strategie“ für das Onkogen MYC untersuchten wir das Molekül S2T1-
6OTD, welches sowohl die mRNA- als auch die Protein-Expression von MYC supprimiert, 
indem es die Quadruplex-Struktur in der Promotor-Sequenz des Onkogens stabilisiert. Unser 
Interesse galt den S2T1-6OTD-induzierten zellulären Effekten in einem repräsentativen Set 
von pädiatrischen Medulloblastom- und Atypisch Teratoid/Rhabdoid Tumorzellen. S2T1-
6OTD senkte die Aktivität von MYC abhängig vom Zelltyp gemeinsam mit einem negativen 
Effekt auf die Zellvitalität und -Proliferation.  
Obwohl die Funktionen von MYC sowohl in der normalen Entwicklung als auch in 
onkogenen Prozessen bereits in verschiedenen Modellsystemen intensiv untersucht wurden, 
sind die transkriptionellen Targets, welche die Effekte der Überexpression von MYC im 
Medulloblastom charakterisieren, weitgehend unbekannt. Um Medulloblastom-spezifische 
MYC-regulierte Gene zu finden, wurden MB Zellen mit einer MYC –Überexpression und 
MB Zellen, in denen MYC herunterreguliert war, einer cDNA Microarray Analyse 
unterzogen. Aus diesem Versuch konnten wir eine Liste von 209 Genen mit potentieller 
MYC-abhängigen Relevanz erstellen, die u. a. Gene des „Bone Morphogenetic Protein“ 
(BMP) -Signalwegs beinhaltete. Dieser Signalweg spielt eine wichtige Rolle in der 
Zusammenfassung 
 4
Entwicklung des Kleinhirns. Unsere Forschung zeigte zum ersten Mal eine Verbindung 
zwischen der Überexpression von MYC und einer Dysregulierung des BMP-Signalwegs im 
Medulloblastom. Unsere Ergebnisse lassen darauf schliessen, dass der Wachstumsfaktor 
BMP7 MYC-abhängig induziert wird und es sich hierbei um ein direktes MYC-Target 
handelt. Um die funktionelle Relevanz des BMP-abhängigen Signalwegs im Medulloblastom 
zu beurteilen, wurde der Signalweg durch das Ausschalten von BMP7 mithilfe von siRNAs 
herunterreguliert oder durch einen Inhibitor gehemmt. Zusammengefasst führen diese neuen 
Informationen zu einem besseren Verständnis der „Pro-Survival“ Funktionen von MYC 
während der Medulloblastom-Entstehung. Zudem bilden sie die Grundlage, um BMP-
Signalwege in Patienten mit Medulloblastom zu hemmen, die eine MYC-Amplifikation oder 
-Überexpression aufweisen. 
In der vorliegenden Dissertation wurden neue “Targeting-Strategien” für das Onkogen MYC 
in embryonalen Tumoren untersucht. Dadurch wurde das Verständnis der Biologie dieser 
Tumoren verbessert und es wurden Grundlagen geschaffen für die Entwicklung von 
zukünftigen Therapiemöglichkeiten. 
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Introduction 
Embryonal tumors of the central nervous system 
Central nervous system (CNS) tumors are highly malignant and characterized by poorly 
differentiated neuroepithelial cells with the potential capacity for divergent differentiation 
[1]. Brain tumors are the most common form of solid tumors in childhood and are second in 
incidence only to leukemia among all cancers in patients younger than 15 years of age [2, 3]. 
The rate is inversely proportional to age, with 3.5 to 4 cases every 100,000 children younger 
than 5 years compared to 2.5 cases every 100,000 children between 10 and 15 years old. The 
occurrence of brain tumors is higher in boys than in girls, with a ratio of 55:45 [4]. 
Approximately 50% of all childhood brain tumors arise in the posterior fossa. In this region 
of the brain, the most common tumors are medulloblastoma (MB), cerebellar astrocytoma, 
ependymoma, and brain stem glioma [5]. The generic term “primitive neuroectodermal 
tumor” (PNET) has been historically used to define embryonal tumors (ET), regardless of 
their site of origin in the CNS [6]. PNET are high-grade undifferentiated neuroepithelial 
tumors with a primitive embryonal cellular morphology [7, 8]. However, growing evidences 
suggest that ET are not a uniform group, but rather a heterogeneous group of neoplasms 
identified by distinct tumor location, different histopathologic origin, and various patterns of 
differentiation [7]. In 2007, the World Health Organization (WHO) classified the tumors of 
the CNS in the following subgroups: MB, CNS PNET (medulloepithelioma, 
ependymoblastoma, CNS neuroblastoma and CNS ganglioneuroblastoma) and atypical 
teratoid/rhabdoid tumor [9]. 
 
Medulloblastoma 
MB is the most common malignant brain tumor in children [8], accounting for approximately 
20% of primary CNS neoplasms and 40% of all posterior fossa tumors (Fig.1). It is a highly 
invasive embryonal neuroepithelial tumor that arises in the posterior fossa, usually from the 
cerebellar vermis in the roof of the IV ventricle. In a minority of cases, particularly in older 
children, MB arises in a cerebellar hemisphere. 
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Figure 1. Sagittal gadolinium-enhanced MRI scan. MB tumor 
indicated by arrow. (Adapted from [10]) 
 
MB is characterized by an aggressive clinical behavior 
and a high-risk of leptomeningeal dissemination [11, 
12]. The Central Brain Tumor Registry of the United 
States reported that the incidence of MB in patients up 
to 19 years old ranges from 0.48 (girls) to 0.75 (boys) 
every 100,000 patients per year. In the European Union 
there are approximately 650 new cases per year [10]. 
MB tumors present two peaks of incidence, i.e. between 3 and 4 years and between 8 and 9 
years of age [13]. Although MB can also occur in adults, it accounts for less than 1% of the 
adult CNS tumors [14]. 
Multimodal therapy (surgery, radiotherapy and chemotherapy) has improved the overall 
survival rate, and the expected disease-free five-year survival rate has risen to more than 
60%. Using current treatments, approximately 80% of patients without disseminated disease 
can be cured, although about 30% of patients are still incurable. Moreover, many patients 
suffer from severe cognitive and neurological dysfunctions. Growth deficiency is observed in 
70-80% of patients, thyroid and gonadotropin hormonal deficiency may also occur [13, 15]. 
Clinical symptoms of MB are ataxia, hydrocephalus, and increased intracranial pressure 
(ICP), caused by the progressive occlusion of the fourth ventricle. Initial signs of increased 
ICP are usually subacute, non-specific, and non-localized (i.e. headaches, vomiting, and 
lethargy). Infants may also be affected by irritability, anorexia, and developmental delay. 
Later signs are generally the effects of tumor invasion into the surrounding tissues. Tumor 
infiltration of the brain stem or increased ICP may result in diplopia (the simultaneous 
perception of two images of a single object), and facial weakness. 
 
Staging and risk stratification 
Staging and subsequent patients’ stratification are crucial in the management of MB 
treatment [8]. Molecular markers and histopathological sub-classification do not currently 
influence the therapeutic strategy and only clinical variables are used in the therapeutic 
stratification of MB patients [10]. Current staging classification requires analysis of the 
cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) of the brain and the entire 
spine. Assessment of the CSF for disseminated disease is crucial, because up to 30% of 
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children show disseminated disease at presentation [16]. M0 staging is assigned if there is no 
evidence of metastasis, whereas the M1 stage denotes malignant cells in the CSF. Patients 
with tumors that are visible on MRI have M2/M3 classification. M4 stage is assigned if there 
is extraneural spread (e.g. bone and bone marrow), which is very uncommon. 
Patients are generally divided into risk-adapted schemes on the basis of age at diagnosis, 
extent of postoperative residual tumor volume and tumor metastasis [8, 17, 18] (Fig.2). 
Patients older than 3 years are assigned to the average-risk category (or standard-risk), if they 
are at stage M0 with less than, or equal to, 1.5 cm2 of post-operative residual tumor. Average-
risk patients account for 60–70% and, within them, the 5-year survival rate after craniospinal 
radiotherapy and chemotherapy is currently 70-80% [19]. High-risk patients include those 
with disseminated disease at diagnosis (stage M1-M4) and/or with greater than 1.5 cm2 tumors 
as residual disease. The 5-year survival rate for this group is currently 30-60% [20]. 
A third group are patients younger than 3 years old. This group has the worst prognosis, 
regardless of M stage and extent of the post-operative residual disease. The 5-year survival 
rate is approximately 30%, although patients harboring metastasis have even lower survival 
rate. Poor outcomes in infants can be due to various factors, including increased risk of 
metastatic disease at presentation, increased rate of subtotal resection, and the impossibility to 
receive craniospinal radiation therapy [16]. 
Introduction 
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Figure 2. Treatment scheme for MB. A generalised algorithm for the stratifi cation and treatment of MB on 
the basis of age and risk stratifi cation. (Adapted from [13]) 
 
Several molecular and histopathological biomarkers have been identified and may allow a 
more accurate prediction of MB outcome, such as the β-catenin status as a favorable-risk 
marker, MYC gene amplification and large-cell histology as high-risk markers, together with 
the expression levels of the genes encoding for neurotrophin-3 receptor (TrkC), erythroblastic 
leukemia viral oncogene homolog 2 (Erbb2), survivin, and p53 [21-25]. These markers may 
be incorporated into future stratification schemes resulting in better risk-adapted therapies. 
 
Treatment 
Despite the recent improvements of survival rates, the delivery of more patients-tailored 
therapies with intensified treatment of poor-risk diseases and reduced therapy for favorable-
risk cases is still one of the major goals in pediatric neuro-oncology. The standard therapeutic 
approach for MB consists of surgical resection, followed by adjuvant treatment with both 
postoperative craniospinal radiotherapy (CSRT) and chemotherapy [10]. 
Introduction 
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Surgical resection of MB has led to improved survival in randomized trials, particularly in 
children with localized disease [17, 26]. One of the most challenging aspects of surgical 
resection of MB is its vicinity to the brainstem, which has a substantial risk when complete 
resection is attempted. 
Post-surgical treatments in patients older than 3 years include chemotherapy and 
radiotherapy, with distinct regimens for standard-risk and high-risk patients. The tendency of 
MB tumors to spread by the CSF led to the early use of CSRT, supplemented with local boost 
radiotherapy. Previously, conventional radiotherapy protocols for average-risk and high-risk 
groups required 36 Gy of photon radiation to the craniospinal axis, with a boost to the 
posterior fossa to a total dose of 54–55.8 Gy. The aim of irradiation of the craniospinal axis is 
to eliminate possible residual microscopic diseases, not detected by the CSF analysis or by 
MRI. Due to severe radiotherapy-mediated long-term effects in many MB patients, efforts 
have been undertaken to reduce the doses of craniospinal irradiation in some patients [19, 27-
29]. For high-risk patients with disseminated disease, there is no evidence that the dose or 
volume of radiotherapy can be reduced [30]. Radiation therapy is delayed or avoided to 
children younger than 3 years, because of the severe side-effects on the developing brain [7, 
8]. 
MB is a chemosensitive tumor and there is evidence of the benefits of chemotherapy for 
patients belonging to both standard- and high-risk groups [31]. Chemotherapy can augment, 
delay, or even prevent the need for radiation treatment, and, after resection, chemotherapy 
alone can be curative in patients with non-metastatic MB [26]. A range of chemotherapeutic 
drugs have been used in the treatment of MB and different regimens have shown significant 
benefits. The most common is a combination of vincristine combined with radiotherapy and 
CCNU (Lomustine), cisplatin and vincristine, or cyclophosphamide, cisplatin, and vincristine 
following radiotherapy [19, 32]. After treatment with appropriate doses of craniospinal and 
local boost radiation and adjuvant chemotherapy, more than 75% of children with average 
risk MB can be expected to survive 5 years after diagnosis, with the majority being 
completely cured [13]. 
 
Histopathologic and cytogenetic features 
MB can be subdivided into the following histological variants: classic, desmoplastic/nodular, 
large-cell, anaplastic and MB with extensive nodularity (MBEN) [33, 34]. About 70-75% of 
MBs present a classic phenotype, composed of sheets of packed small round or ellipsoid 
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cells, occasionally forming neuroectodermal rosettes, with high nuclear-to-cytoplasmatic 
ratio and frequent mitoses (Fig.3; panel A) [7]. About 15-25% of the tumors are 
desmoplastic/nodular MBs. This subtype displays a biphasic architecture that consists of 
regions with dense intercellular reticulin and nodular reticulin-free zones (Fig.3; panel B). 
Desmoplasia, a pericellular deposition of collagen, occurs in up to 50% of the tumors in very 
young children, and it is a strong predictor of low risk disease in early childhood [7]. MBEN 
is a distinctive type of desmoplastic MB and comprises around 5% of all tumors. It occurs 
mostly in infants and differs from the desmoplastic nodular variant by exhibiting extensive 
nodularity and advanced neuronal differentiation within the nodules [7, 9]. The large-cell 
variant of MB accounts for less than 5% of cases and has been associated with poor prognosis 
[33]. The cells are large and round with a prominent single nucleolus (Fig.3; panel C) [35]. 
Large-cell MBs contain regions where the round cells give way to densely packed polyhedral 
cells forming a paving-like pattern. Mitotic and apoptotic indices among these cells are 
higher than in other MB subtypes [36]. Historically, large-cell and anaplastic MBs have been 
described as a single subtype of MB, large-cell/anaplastic (LCA), accounting for 10-15% of 
patients. However, in 2007 the WHO classification of CNS tumors, defined anaplastic and 
large-cell MBs as two distinct entities [9]. Anaplastic MB accounts for about 10% of cases 
and represents the most aggressive subtype (Fig.3; panel D). It is characterized by increased 
nuclear size, marked nuclear pleomorphism and a high mitotic count. Anaplastic MB is 
associated with high degree genomic instability, and deregulated expression of the oncogene 
c-MYC, thus leading to poor prognosis [7, 37, 38]. 
 
Introduction 
 11
 
Figure 3. Histological features of MB. A. Classic MB: sheets of small round blue cells with scant cytoplasm. 
B. Desmoplastic MB: nodular areas of densely packed, reticulin-rich cells. C,D. Large cell (C) and anaplastic 
(D) MBs are shown. Histological features show prominent and pleomorphic nuclei with large areas of necrosis 
and high mitotic rate. Cells stained with haematoxylin and eosin. (Figure adapted from [13]) 
 
Recently, five MB subgroups (A-E) have been defined based on the distinct genetic profiles, 
specific genetic alterations, pathway signatures, and clinical-pathological features [39]. 
Subgroup A is characterized by signaling alteration in the wingless (WNT) pathway. More 
specifically, many genes of this pathway and related target genes have been found over-
expressed (e.g. MYC, RUNX2, and GAD1). Mutations in β-catenin were identified in all 
tumors of the A subgroup, but not in any other MB tumor subtype. The A type is also 
characterized by exclusive expression, or overexpression, of members of the transforming 
growth factor beta (TGF-β) and bone morphogenetic protein (BMP) pathways (i.e. BMP4, 
BMP7, BAMBI, SMAD3, TGFβI, and INHBA). Cluster B is marked by the sonic hedgehog 
(SHH) signaling, mutations of PTCH1 (sonic hedgehog receptor, Patched), and low levels of 
the oncogene OTX2 (orthodenticle homeobox 2). Clusters A and B share increased 
expression of genes involved in protein biosynthesis, cell-cycle, Notch and platelet-derived 
growth factor (PDGF) pathways. Cluster C and D are marked by an increased expression of 
neuronal differentiation genes, whereas clusters D and E by expression of photoreceptor 
genes [39, 40]. 
Comparative genomic hybridization (CGH) analysis identified several subgroup-specific 
chromosomal aberrations. Monosomy of chromosome 6 occurs only in type A tumors, 
whereas loss of 9q mostly occurs in type B tumors. Aberrations of chromosome 17 are 
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associated with type C and D tumors. Loss of the inactivated X-chromosome is highly 
specific for female cases of type C, D, and E tumors. 
Metastatic disease at diagnosis is significantly associated with the subtype E and, to a lower 
extent, to subtypes C and D. Patients below 3 years of age are classified as type B, D, or E 
tumor. The type B includes most desmoplastic cases [39, 40]. 
Abnormalities of the chromosome 17 are the most common chromosomal aberrations in MB. 
Isochromosome 17q (i17q) is observed in about 35% of classic and LCA, and 12% of 
nodular/desmoplastic [34, 41]. The presence of i17q in tumors is associated with a poor 
clinical outcome, suggesting that it may contribute to the development of aggressive variants 
of MB [7]. Isolated loss of 17p is observed in an additional ~20% of cases. Gain of 
chromosome 7 affects approximately 40% of cases [42]. Monosomy of chromosome 6 
frequently occurs in tumors with favorable prognosis, mainly classic subtype [43]. Extensive 
non-random losses of either chromosomes 8, 9, 10q, 11, or 16q are observed in 
approximately 30% of cases [42, 44]. 
Alterations in gene expression have been described in different MB subsets [41]. MYCN (at 
2p24) and c-MYC (at 8q24) genes are the most commonly amplified loci, which have been 
documented across multiple studies. Each event occurs in 5 to 15% of MB cases, and is 
associated with adverse clinical prognosis [21, 33, 34]. A recent study showed that MB cells 
transduced with c-MYC adopt a severely anaplastic phenotype when grown as xenografts in 
nude mice, suggesting a causative relationship between c-MYC expression and the LCA 
phenotype [37]. Additional gene amplifications affecting other genetic loci were identified in 
MB, although with lower frequency, e.g. amplification of OTX2, Notch2, TERT, MYCL1, 
PDGFRA, KIT, MYB, and CDK6 [45-48]. 
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Origins of MB: disorders of cerebellar development 
Normal cerebellum development 
The cerebellum derives from the alar (dorsal) plate of the neural tube and resides in the 
metencephalon, positioned along the anterior/posterior axis of the neural tube [49]. The 
cellular architecture of the cerebellum derives from two distinct germinal zones: the 
ventricular zone, a thin layer lining the fourth ventricle and the inner region of the cerebellar 
anlage, and the external granule layer (EGL), in the vicinity of the dorsal portion of the neural 
tube, a region known as rhombic lip (Fig.4) [50]. 
 
Figure 4. Schematic representation of embryonal cerebellar development. Progenitor cells located in the 
ventricular zone (vz, primary germinal zone) migrate radially to give rise to Purkinje cells. Progenitor cells 
located in the rhombic lip (RL) migrate dorsally to populate the external granular layer (EGL, secondary 
germinal zone). (Adapted from [51]) 
 
Distinct populations of neural precursor cells are present in the cerebellum: GABAergic 
neurons, glutamatergic projection neurons and granule neuron precursor (GNP) cells. The 
precursor cells of the GABAergic neurons, including Purkinje cells and interneurons, are 
located within the primary germinal zone in the roof of the IV ventricle; glutamatergic 
projection neurons of the deep cerebellar nuclei and GNP cells derive from the rhombic lip 
[52-54]. Recently, an additional stem cell population has been described. These cells express 
neural stem cell markers (CD133 and Nestin) and display the potential to generate astrocytes, 
oligodendrocytes, and neurons [55]. 
The distinct precursor cell populations show different properties and require different 
combinations of intrinsic and extrinsic signaling molecules to function properly. The 
signaling systems regulating the precursor cells of GABAergic neurons and glutamatergic 
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projection neurons are still elusive. In contrast, the signals regulating GNP cells have been 
extensively investigated. 
During development, specification, proliferation and differentiation of GNPs are 
physiologically regulated by a complex network of signaling pathways, including SHH, 
WNT, BMP, and Notch cascades (Fig.5) [56, 57]. In the rhombic lip, a subgroup of BMPs 
(BMP6, BMP7, and Gdf7) are secreted by cells in, and adjacent to, the roof plate and provide 
a signal for specification of GNP cells [54], while SHH signals secreted from Purkinje cells 
drive their proliferation [58-60]. GNPs first migrate over the cerebellar surface to form the 
EGL and later migrate inwards, through the Purkinje layer, to form the internal granular layer 
(IGL) [61]. Prior to form the IGL, a distinct subgroup of BMP cytokines (BMP2 and BMP4) 
suppresses the proliferative response mediated by SHH and promotes cell-cycle exit and 
differentiation of GNP cells [62]. The Notch and WNT pathways also coordinate 
proliferation and differentiation of GNP cells by regulating the neurogenic transcription 
factor activity and by maintaining neural progenitor cells [63]. The phosphatidylinositol 3-
kinase (PI3K) and basic fibroblast growth factor (bFGF) pathways take also part to the 
signaling modulation, respectively potentiating and inhibiting the response of GNP cells to 
SHH.
 
Figure 5. Signaling pathways involved in cerebellar development. (A) Bmp6, Bmp7, and Gdf7 provide a 
signal for specification of granule cell. (B) GNP cells within the external germinal layer proliferate in response 
to SHH secreted from Purkinje cells. GNP cells proliferation may be potentiated by PI3K and Notch signaling. 
(C) BMP2 promotes GNP cycle exit by suppressing the proliferative response mediated by SHH. Increasing 
Numb expression and decreasing Notch2 expression causes GNP cells to leave the cell-cycle and differentiate 
into mature granule cells. (D) White-matter stem cells may be sensitive to mitogenic signals mediated by basic 
fibroblast growth factor. (E) GABAergic precursor cells may depend upon WNT signals. (Adapted from [7]) 
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Aberrant signal transduction in medulloblastoma tumorigenesis 
MB is associated with alterations of the fine-tuned balance of the described signaling 
pathways that are physiologically involved in cerebellum development, which is 
characterized by a complex spatio-temporal regulation of survival, proliferation, and 
differentiation of multipotent neural progenitor cells, and it is driven by a variety of 
extracellular signaling molecules, growth factors and cytokines [51, 64]. Even though the 
precise cells of origin of MB remain still to be fully determined, there is now considerable 
evidence that tumorigenesis of a subset of tumors can be related to aberrant regulation of the 
fate of GNP cells [13, 51]. In fact, MBs often arise on the surface of the cerebellum, where 
the EGL is located, and frequently express markers of GNP cells. Moreover, the extended 
embryonic and postnatal period of GNP proliferation makes these cells highly susceptible to 
transforming mutations, which is a prerequisite for neoplastic transformation [13, 65]. The 
involvement of an altered development of GNP cells in the onset of MB is also supported by 
studies on patched mutant mice models of MB [64, 66-68]. 
Beside the subset of MBs arising from aberrant GNP cells in the EGL, Sutter et al. recently 
described the formation of MB tumors from postnatal neural stem cells (NSC) not expressing 
granule cells markers [69]. NSC were isolated from mice cerebellum and injected 
subcutaneously in mice, upon inactivation of the tumor suppressor genes Rb and p53. The 
resulting tumors were characterized by high expression of Sox2 and Sox9 genes, in contrast to 
GNP-derived MBs which generally show activation of MYCN, GLI and PTCH2 [69]. 
 
The following sections describe the most commonly aberrant signaling pathways in MB 
(Fig.6). A particular emphasis will be dedicated to the oncogene MYC and to the BMP 
pathway, for the relevance they have in development and progression of MB and in the 
present study. 
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Figure 6. Schematic representation of signaling pathways in MB. Sonic hadgehog pathway in blue: Hh, 
Sonic hedgehog; Ptch, patched; Smo, smoothened; SuFu, suppressor of fused. Notch pathway in red/orange: 
NICD, Notch intracellular domain; CBF, C promoter-binding factor. Wingless pathway in green: Wnt, 
wingless; LRP, LDL-receptor-related protein; GSK, glycogen synthase kinase; TCF/LEF, T-cell 
factor/lymphoid enhancer factor; APC, adenomatous polyposis coli. Receptors tyrosine kinases and IGF 
signalings in purple: HGF, hepatocyte growth factor; IGF, insulin-like growth factor; IGF-R, insulin-like 
growth factor receptor; MAPK, mitogen-activated protein kinase; PI3K, phosphotidylinositol-3-kinase; CDK, 
cyclin-dependent kinase; P, phosphorylated state. (Adapted from [64]) 
 
Sonic hedgehog pathway 
SHH is a member of a family of evolutionarily conserved proteins. During normal cerebellar 
development, SHH ligand is secreted by Purkinje neurons and promotes proliferation of GNP 
cells in the EGL in a concentration-dependent manner [70, 71]. As GNP cells migrate 
through the Purkinje layer to the IGL, the reduced concentration of SHH, together with the 
presence of other factors, mediates cell-cycle arrest and differentiation [50, 72]. 
The SHH-receptor Patched (PTCH) and its associated transmembrane protein Smoothened 
(SMO) control the response to the SHH signal. PTCH is mainly expressed in EGL precursor 
cells and, in absence of SHH, it represses the activity of SMO, thereby preventing the 
transcription of target genes (Fig.7) [73]. The transcriptional response is mediated by the 
glioma-associated oncogene homolog 1 (GLI) family of transcription factors [74]. In the 
cytoplasm, GLI forms a protein complex with the serine/threonine kinase Fused (FU) and the 
suppressor of Fused (SUFU). This complex promotes ubiquitination and degradation of GLI, 
leading to repression of the pathway. In the presence of SHH, PTCH is blocked and no longer 
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preventing SMO from recruiting SUFU and other interacting proteins, with the effects of 
releasing GLI that translocates into the nucleus and activate target genes transcription (Fig.7) 
[56, 75, 76]. 
The role of SHH in MB was discovered by identifying inactivating mutations of the gene 
encoding PTCH1 on chromosome 22, resulting in the familial nevoid basal cell carcinoma 
(Gorlin’s syndrome). Patients with Gorlin’s syndrome are prone to develop MB [77, 78]. The 
role of SHH in MB tumorigenesis is supported by several observations. Aberrant SHH 
pathway activation by genetic mutations occurs in more than 15% of MBs. Mutations of 
PTCH1 occur in 10% of cases, whereas SMO activating mutations in 5% of cases [79, 80]. 
SUFU mutations have also been sporadically reported [81]. Deletion of chromosome 17p, the 
most commonly aberrant chromosome in MB, is associated with a reduced expression of the 
human orthologue of mouse REN (KCTD11), a negative regulator of tumor growth that 
inhibits SHH [82]. Moreover, mice in which the SHH pathway is aberrantly activated 
developed cerebellar tumors that resemble the histologic features and the genotype of human 
MB [68, 83]. 
Recent studies using unsupervised hierarchical cluster analysis of gene expression microarray 
data from two independent series of MBs showed that approximately 25% of the tumors were 
associated with activation of members and targets of the SHH pathway [39, 40]. SHH 
pathway activation is often observed in nodular/desmoplastic MBs [84]. 
 
Wingless pathway 
WNT is a family of growth factor receptors acting through gene regulation and cell-cell 
control mechanisms. The WNT signaling is crucial for normal cerebellum development 
because it coordinates fate and proliferation of neural progenitor cells [70]. WNT regulates 
intra-cellular localization of the nuclear transcription factor β-catenin (Fig.7). Upon binding 
of WNT proteins to their receptor Frizzled (FRZ), a signaling cascade involving glycogen 
synthase kinase 3 (GSK3), adenomatous polyposis complex (APC) and AXIN1, takes place 
preventing proteosomal degradation of β-catenin [70, 85]. Consequently, β-catenin 
translocates into the nucleus and activates the DNA-binding HMG box lymphoid enhancer 
binding factor 1/T cell-specific factor (LEF1/TCF) transcription factors, inducing in turn the 
expression of downstream genes, such as Cyclin D1 and MYC (Fig.7) [86]. 
The involvement of deregulated WNT pathway in MB emerged from genetic studies on the 
Turcot’s syndrome, a tumor predisposition syndrome characterized by the development of 
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bowel tumors and increased frequency of primary CNS tumors, in particular MB and 
glioblastoma [87]. 
A significant subset of MBs is characterized by an aberrant activation of the WNT pathway 
[39, 40]. Approximately 10% of MB cases contain mutations in the gene encoding β-catenin 
(CTNNB1); aberrant stabilization of nuclear β-catenin protein occurs in 18–30% of cases 
[88]. Nuclear β-Catenin accumulation is associated with a better overall and event-free 
survival and it has been shown to be an independent marker of favorable clinical outcome 
[29, 88]. Mice with deletion of WNT1 do not show any cerebellar development, supporting 
the idea of a critical role for WNT signals in regulating cerebellum precursor cells [89, 90]. 
 
 
Figure 7. SHH and WNT pathways in medulloblastoma and mutations in specific proteins associated with 
pathway activation. Extracellular ligands WNT (wingless) and SHH (sonic hedgehog); transmembrane 
receptors FRZ (Frizzled) and PTCH (Patched); intracellular signaling cascade and nuclear transcriptional 
response. *Mutations in specific proteins associated with pathway activation, which have been reported in MB. 
(Adapted from [10]) 
 
Receptor tyrosine kinases 
Receptor tyrosine kinases (RTK) are a large family of cell surface receptors with intrinsic 
protein tyrosine kinase activity [91]. RTK are activated by a variety of ligands and have 
pleiotropic effects on cell behavior, controlling cell-cycle, cell growth, proliferation, 
differentiation, cell migration, and apoptosis. Aberrations of members of the RTK family are 
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associated with MB development and have been considered for development of novel 
therapeutic strategies for MB (Fig.6) [92-94]. 
TrkC was the first RTK member to be significantly associated with prognosis in MB. TrkC 
mRNA expression is a powerful predictor of a favorable clinical outcome in MB patients [92, 
95, 96]. Based on the intra-nodular localization observed in nodular/desmoplastic MB, TrkC 
signaling appears to be involved in apoptosis and neuronal differentiation of MB cells. MB 
patients expressing functional TrkC may be more prone to programmed cell death or to 
terminal neuronal differentiation [64]. 
Erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene 
homolog) (ErbB2, also known as HER2/neu) encodes a member of the epidermal growth 
factor (EGF) receptor family of RTKs. ErbB2 is expressed in more than 86% of MBs and 
several studies demonstrated that elevated expression of ErbB2 is associated with reduced 
MB patients’ survival [97]. ErbB2 can up-regulate the expression of pro-metastatic genes, 
thus leading to a more aggressive tumor behavior (Fig.6) [93]. Various approaches targeting 
ErbB2 are currently under investigation (e.g. ErbB tyrosine kinase inhibitors and monoclonal 
antibodies, e.g. Trastuzumab) [93]. 
Mesenchymal epithelial transition factor (c-Met), also known as hepatocyte growth factor 
receptor (HGFR), is a proto-oncogenic RTK (Fig.6). c-Met mRNA expression levels 
significantly correlate with MB poor clinical outcome. c-Met and its ligand hepatocyte 
growth factor (HGF) play an important role in promoting MB malignancy. In particular, HGF 
induces tumor cell proliferation, anchorage-independent growth, and cell-cycle progression 
beyond the G1-S checkpoint. HGF also protected MB cells against apoptosis induced by 
chemotherapy. Moreover, MB xenograft models with HGF-over-expression exhibit increased 
tumor cells’ invasion and morphologic changes that resembled human LCA MB [98]. 
 
Notch pathway 
Notch signaling pathway is essential for proper development during embryogenesis. Various 
components of this pathway are expressed in the developing cerebellum and the signaling 
appears to be crucial in determining the cerebellar GNP cells’ fate and proliferation. The 
cross-talk of the Notch cascade with the other main signaling pathways implicated in the 
cerebellum development orchestrates the entire network of signaling molecules involved [64, 
99, 100]. 
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Notch ligands (Jagged-1 and -2) bind to one of four notch receptors (Notch1–4) inducing the 
cleavage of Notch intracellular domain (NCI). The released NCI translocates into the nucleus, 
forms a complex with DNA binding proteins (CBF1), and activates the transcription of 
effector genes (Fig.6) [101]. 
Aberrant activation of the Notch pathway is associated with MB tumorigenesis. Notch1 was 
found amplified in 15% of MBs and Notch2 is expressed at high levels in a subset of tumors 
and it is associated with poor prognosis. Expression of truncated, constitutively active Notch2 
in embryonal brain tumor cell lines induces an increase of cell proliferation, soft agar colony 
formation, and xenograft tumor growth [47]. 
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MYC 
MYC [v-myc myelocytomatosis viral oncogene homolog (avian)] is a family of genes (c-
MYC, MYCN, L-MYC) which are key regulators of many biological processes, including cell 
growth and division (regulation of chromatin modification), cell-cycle progression 
(modulation of cyclins, cyclin-dependent kinases, cyclin-dependent kinase inhibitors and 
phosphatases), cell differentiation (modulation of growth arrest genes) and cell metabolism 
(glycolysis, amino acid biosynthesis and transport, synthesis of macromolecules and DNA 
metabolism) [102-105]. 
MYC is expressed during embryogenesis and in adult tissues with high proliferative capacity 
(such as skin, epidermis, and gut) [106] and it is almost undetectable in quiescent adult cells 
[107]. MYCN shows the highest mRNA expression in embryonal brain, kidney, and lung 
[108], whereas c-MYC levels are comparatively constant in these organs throughout 
development [109]. The knockout of either MYC gene resulted to be lethal in vivo. The 
mouse embryos die in the earliest developmental phases, confirming the essential role of 
these genes during mammalian embryogenesis [110, 111]. 
 
 
Figure 8. Cellular processes controlled by MYC during normal condition and during tumorigenesis. Myc 
is a key regulator of many biological activities including cell growth and division, cell-cycle progression, 
apoptosis; cell differentiation, cell metabolism, angiogenesis, cell adhesion and motility. Deregulation of Myc 
may result in apoptosis, genomic instability, uncontrolled cell proliferation, escape from immune surveillance, 
growth factor independence, and immortalization. (Adapted from [105]) 
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MYC is a pleiotropic multifunctional transcription factor, responsible for activation and 
repression of a large number of target genes [112]. Analysis of the in vivo MYC-binding sites 
in the genome showed that MYC regulates about 10-15% of genomic loci in mammals [113, 
114]. 
Through the transcriptional activation/repression of its target genes in a context-specific 
manner, MYC modulates diverse, sometimes opposing, groups of cellular processes. Up-
regulated genes are mostly promoting cell growth, such as those involved in ribosome 
biogenesis, protein synthesis, and metabolism. Most frequently down-regulated genes are 
involved in cell-cycle arrest, cell adhesion, and cell-cell communication. The ability of MYC 
to stimulate cell growth and abrogate cell-cycle inhibitors is a crucial function for both 
normal development and tumorigenesis [115, 116]. 
During the life of a normal cell, the expression of MYC genes is strictly regulated. However, 
it can be abnormally activated by gene amplification, chromosomal translocation, DNA 
rearrangement, transcriptional up-regulation, and point mutation, all events leading to a 
constitutive over-expression of the oncogene [103, 117]. As a result of MYC de-regulated 
expression, tumorigenesis can be induced [118]. 
Deregulation of MYC contributes to several aspects of tumor cell biology: uncontrolled cell 
proliferation, inhibition of cell differentiation, induction of growth factor independency, neo-
vasculogenesis, cell adhesion, promotion of metastasis, genomic instability, escape from 
immune surveillance, and immortalization [105, 111, 112, 119-121]. Elevated or deregulated 
expression of MYC family members has been detected in a wide range of human cancers, and 
they are frequently associated with aggressive and poorly differentiated tumors [103, 122]. 
MYC proteins consist of an N-terminal transactivation domain (TAD), responsible for 
assembly of the transcription machinery, a central region implicated in transcriptional 
repression, apoptosis, transformation, and DNA binding, and a C-terminal domain (CTD) that 
is critical for DNA binding and protein interactions [123, 124]. The CTD encompasses a 
basic region, required for binding to the consensus E-box elements, and a helix-loop-helix 
leucine zipper (HLHz) domain, necessary for dimerization with the partner protein MAX 
[124]. 
MYC-MAX heterodimers activate transcription of target genes [125] by binding to 
CACA/GTG sequences (a subset of the general E-box consensus sequence CANNTG, 
recognized by all HLHz proteins [126]). MYC-MAX heterodimerization is required for 
binding not only to the E-box sequence, but also to non-consensus binding sites. In fact, only 
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a minority of MYC-MAX binding sites in vivo contain the consensus sequence CACGTG. 
Other transcription factors (e.g. specificity protein-1 (SP1), nuclear factor Y (NF-Y), and 
transcription factor II-I (TFII-I)) are required for recruitment of MYC-MAX to non-
consensus binding sites [127-129]. 
MAX can also form homodimers or heterodimers with members of the MAD family of 
proteins (MAD1, MXI1/MAD2, MAD3, MAD4 and MNT). MAD is a group of related 
HLHz proteins which compete with MYC for binding available MAX molecules, thus 
decreasing formation of MYC-MAX complexes [125, 130, 131]. 
MYC-MAX complexes are often predominant in proliferating cells, whereas complexes 
between MAX and MAD or MNT are predominant in resting or differentiated cells [112, 
125]. 
MIZ1 is a zinc finger protein that modulates the biological function of MYC, binding to the 
HLH domain of MYC. Specific binding and inhibition of the transcriptional activator MIZ1 
is one of the main mechanisms involved in MYC-mediated gene repression [132, 133]. 
A non-transcriptional function of MYC on chromatin was postulated based on the finding 
that about half of all MYC-bound sites are intergenic (>10 kb away from transcriptional start 
sites) [134]. Apparently the relative concentration of MYC and MAD proteins takes part in 
the determination of the active or inactive state of the chromatin for gene transcription. The 
transcriptional activation by MYC involves recruitment of co-activator molecules, including 
transformation/transcription domain-associated protein (TRRAP) and histone acetyl 
transferases (HAT) [135]. TRRAP is an adapter protein found in various multiprotein 
chromatin complexes with histone acetyltransferase activity, which gives a specific tag for 
epigenetic transcription activation. HATs-mediated acetylation of NH2-terminal lysine 
residues in the histones is associated with a more open (active) local chromatin structure, i.e. 
permissive conformation for enhanced transcription of specific target genes. On the other 
hand, MAD-MAX dimers recruit histone deacetylases (HDAC) [136] to the same E-boxes 
previously occupied by MYC-MAX dimers, thus leading to histone deacetylation and a more 
condensed (inactive) local chromatin structure. During tumorigenesis, aberrant high levels of 
MYC increase the expression of target genes that contribute to lock the chromatin in an 
abnormal active state. Data supporting this hypothesis showed that cells lacking the oncogene 
present more condensed chromatin structure, whereas MYC over-expression consistently 
leads to histone hyperacetylation [137]. 
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MYC deregulation in medulloblastoma 
Amplification of c-MYC in a MB cell line (D341) was discovered in 1988 by Friedman et al. 
[138]. Subsequently, several reports on amplification of both c-MYC and MYCN in MB 
followed [8, 21, 23, 37, 75, 139, 140]. MYC is expressed in up to 64% of MBs and amplified 
in 5 to 10% of MB patients, with this rate increasing to 17% in the high-risk sub-group of 
patients [33, 64]. Amplification of the c-MYC gene and high levels of the gene product have 
both been used as clinical indicators of poor prognosis [23, 95]. In contrast, low expression of 
c-MYC, alone or in combination with high TrkC mRNA levels, has been proved to be strong 
predictors of a favorable outcome in MB [23, 92]. 
The LCA phenotype is a histo-pathological prognostic factor for MB, indicative of a very 
aggressive clinical behavior and outcome [37, 141]. Different groups associated the 
amplification of c-MYC gene locus with MB LCA phenotype [21, 33, 142, 143]. Stearns et al. 
showed that increased c-MYC activity induces anaplasia and they established a causative link 
between c-MYC and anaplastic changes in MB [37]. MB cell lines engineered to stably 
overexpress the oncogene showed increased rates of growth, apoptosis, and ability to form 
colonies. In vivo, c-MYC over-expression in xenograft models led to development of 
significantly larger tumors with a cellular phenotype resembling the LC/A subtype of MB. 
The critical role of c-MYC in the development of LCA MBs was described as a multistep 
process, in which the oncogene may play a role in the initiation of some MBs, and its 
increased expression and activity is primarily observed as tumors progress and become more 
aggressive [37]. 
Although MYC does not represent a signaling pathway “per se”, it is a central mediator of 
almost all the pathways involved in cerebellar development and MB onset, including SHH, 
WNT, c-Met, Notch, and IGF-R (Fig.6) [7, 64]. 
MYC mRNA and protein levels increase rapidly upon mitogenic stimulation, driven by 
growth factors, mitogens, and other transcription factors like β-catenin [7, 64]. Also c-Met 
induces c-MYC. In particular, HGF induces cell-cycle progression, cell proliferation, 
apoptosis, and increase in cell size in a MYC-dependent manner, regulating MYC levels via 
transcriptional and post-transcriptional mechanisms [64, 98]. 
Moreover, MYCN modulates the effects of SHH activation on the proliferation of GNP cells, 
acting as the main conveyor of SHH-directed mitogenic activity, through the induction of 
Cyclin-D1 and Cyclin-D2 [59]. MYCN is up-regulated by SHH signaling through an increase 
of transcription and stabilization of MYCN protein [144], thus altering the regulation of the 
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cell-cycle [145]. Although the mechanism is not yet fully understood, it appears that SHH 
signaling increases activation of PI3K, which inhibits GSK-3β via phosphorylation, in turn 
having the effect of stabilizing MYCN. Similarly, when SHH signaling is decreased, 
activated GSK-3β leads to phosphorylation and degradation of MYCN [72]. 
The correlation between MYC and MB is further supported by the critical role of MYC 
during cerebellum development, in particular determining the GNP cells’ fate [146]. In vivo, 
MYC plays a role in maintaining the GNP cell population by directing a rapid cell turn-over, 
activating cellular metabolism and inhibiting differentiation. In mice, double knock-out 
(DKO) of c-Myc and N-Myc strongly impairs brain growth, particularly that of the 
cerebellum. Granule neurons are almost absent from the Myc DKO cerebellum and show an 
aberrant cell fate, failing to migrate inward from the EGL to the IGL, and undergoing an 
abnormal differentiation within the EGL [146]. Moreover, conditional inactivation of MYCN 
in neural progenitors leads to a smaller and disorganized cerebellum [115, 147]. 
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Bone morphogenetic proteins 
In 1965, Marshall Urist discovered that decalcified bone matrix fragments have bone 
induction activity when transplanted into rats and rabbits [148]. More than 20 years later, the 
proteins capable of inducing bone and cartilage formation were isolated and named bone 
morphogenetic proteins (BMP) [149]. Nowadays, about twenty different BMP members have 
been identified and sub-grouped according to their amino acid sequence similarity and 
function: BMP-2/4 group, BMP-5/6/7/8 group (osteogenic protein 1 group), growth and 
differentiation factor (GDF)-5/6/7 group and BMP-9/10 group (Fig.9) [150]. Additional to 
induction of bone and cartilage tissues, these proteins can regulate tooth, kidney, skin, hair, 
muscles, haematopoietic, and neuronal development [151, 152]. 
BMPs are cytokines belonging to the TGF-β family, which are able to regulate various 
cellular processes, including migration, proliferation, apoptosis, differentiation, iron 
metabolism, and vascular homeostasis [153, 154]. 
BMPs are generated as large precursor proteins composed of an N-terminal signal peptide, 
which directs the protein to the secretory pathway, a pro-domain that ensures proper folding, 
and a C-terminal mature peptide. Specific serine endo-proteases cleave the signal peptides. 
The generated mature ligand is secreted. Each monomer is stabilized by three intramolecular 
disulfide bonds, formed between six highly conserved cysteines (cysteine knot motif). The 
active forms of BMPs are homo- and hetero-dimers, covalently linked via a disulfide bond, 
requiring a seventh conserved cysteine within each monomer [153, 155]. 
BMPs act both in paracrine and autocrine manners to promote the recruitment of cell surface 
type I and type II serine/threonine kinase BMP receptors [154, 156]. Type I receptors include 
BMPR1A/Alk-3 (BMP receptor type 1A, also named Activin like kinase-3), BMPR1B/Alk-6 
(BMP receptor type 1B, also named Activin like kinase-6), Alk-2/ActR1A (Activin like 
kinase-2, also named Activin receptor type 1A) and Alk-1. BMPR1A and Alk-2 are widely 
expressed in various types of cells. The expression of BMPR1B shows a more restricted 
expression profile and that one of Alk-1 appears to be limited to endothelial cells [157]. Type 
I receptors form heteromeric complexes with three type II receptors which are widely 
expressed in mammals’ tissues: BMP receptor type II (BMPRII), Activin receptors type IIA 
and type IIB (ActRII or Acvr2A and ActRIIB or Acvr2B) [155, 156]. Type I and type II 
receptors present structural similarities, including a short extracellular domain, a single 
membrane-spanning domain and an intracellular domain containing a serine-threonine kinase. 
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Upon ligand binding, type II receptors trans-phosphorylate the glycine/serine-rich region 
(GS-box) of the associated type I receptor which, in turn, transduces the signal activating 
downstream effector proteins [157, 158]. 
Unlike TGF-β, which displays high affinity for type II receptors and does not stably interact 
with type I receptors, BMPs bind independently and with different affinities to both type I 
and type II receptors [159]. In particular, BMP2 and BMP4 show high affinity for the type I 
receptors BMPR1A and BMPR1B [160, 161], whereas BMP7 preferentially binds to the type 
II receptors ActRIIA and ActRIIB [162]. These differences in specificity determine formation 
of distinct oligomers of receptors, thus leading to selective activation of specific signaling 
cascades [163-165]. 
 
 
Figure 9. Relationship between BMPs, receptors and SMAD proteins in signal transduction. Relationships 
between subgroups of BMP ligands, type II and type I receptors, and Smad proteins in signal transduction. 
BMP-2/4 subgroup binds to BMPR-IA and BMPR-IB, whereas OP-1 subgroup binds strongly to ALK-2, and 
weakly to BMPR-IB. BMP-9/10 bind to ALK-1 and ALK-2, and GDF subgroup preferentially binds to BMPR-
IB. R-SMADs and Co-SMADs are shared by all BMP ligands. (Adapted from [156]) 
 
 
Signal transduction: SMAD-dependent and SMAD-independent pathways and 
modulators. 
 
SMADs are the major signal transducers for BMP receptors. They owe their name to the 
homology with Sma proteins from nematode Caenorhabditis elegans and Mad (mothers 
against decapentaplegic) proteins from the fly Drosophila melanogaster. SMADs are 
subdivided into three subtypes: receptor-activated SMADs (R-SMADs), common-mediator 
SMAD (Co-SMAD), and inhibitory SMADs (I-SMADs). 
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The R-SMAD (SMAD1, SMAD5, and SMAD8) activation is mediated by engagement of 
activated type I BMP receptors, which phosphorylate a conserved SSXS motif on the CTD of 
specific R-SMAD. BMPR1A/Alk-3 and BMPR1B/Alk-6 can activate all three SMADs 
(1/5/8), whereas Alk-2 can only phosphorylate SMAD1 and 5 [154]. 
SMAD4 is the Co-SMAD shared by BMP and TGF-β signaling pathways. In the cytoplasm, 
SMAD4 assembles with activated R-SMADs to form a heteromeric complex, which 
translocates into the nucleus to regulate gene transcription (Fig.10). 
I-SMAD (SMAD6 and SMAD7) inhibit the phosphorylation of R-SMADs by competing 
with R-SMADs for the binding to phosphorylated type I receptors [151, 166]. 
R-SMADs contain two conserved domains, linked by a variable proline-rich region. The N-
terminal MH1 domain is responsible for DNA binding and for other protein-protein 
interactions; the C-terminal MH2 domain contains the SXSS-motif mediating R-SMAD 
specificity, receptor recognition, nuclear translocation, and oligomerization [167]. 
Unphosphorylated, inactive R- SMADs adopt an autoinhibitory structure in which their MH1 
and MH2 domains interact. Upon phosphorylation at the C-terminus, R-SMADs are activated 
and relieved from this structure. Subsequently, the signal peptide for nuclear translocation is 
exposed, the affinity for SMAD4 increases, and the complex translocates into the nucleus 
[166]. 
When cells are in a non-stimulated state, SMAD4 is uniformly distributed throughout the cell 
compartments, R-SMADs are principally located in the cytoplasm and the I-SMADs are 
mainly in the nucleus. Upon ligand binding, R-SMADs and SMAD4 accumulate in the 
nucleus, although they are constantly shuttled between the nucleus and the cytoplasm [168]. 
SMADs bind to DNA weakly. The required high affinity and specificity for the 
transcriptional activation are obtained through the involvement of additional DNA binding 
factors, co-repressors and activators [169]. 
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Figure 10. BMP signaling, from the plasma membrane to the nucleus. BMP ligands bind to heterotetrameric 
complex of type II and type I receptors, and RGM proteins serve as co-receptors for BMPs. R-SMADs exist in 
the cytoplasm through interaction with membrane anchoring proteins, e.g. CD44 and endofin. Upon 
phosphorylation by type I receptors, R-SMADs form complexes with co-SMAD (SMAD4), translocate into the 
nucleus and regulate transcription of target genes through interaction with transcription factors (DNA-binding 
proteins) and transcriptional co-activators. (Adapted from [156]) 
 
 
Although the SMAD pathway represents the main downstream signaling cascade, BMPs can 
also activate distinct SMAD-independent pathways (i.e. mitogen-activated protein kinase 
(MAPK) pathway) [154, 170]. 
The physiological responses to each BMP are tissue- and cell-specific. In fact, the 
microenvironment plays a key role in modulating the temporal and spatial expression of each 
BMP and its receptors. [155]. The presence or absence of a variety of antagonists [171, 172] 
and modulators [173, 174], and the concomitant cross-talk of the BMPs with other pathways 
(e.g. WNT, PI3K, and Notch) contribute to the regulation of the whole signaling network 
[154, 175]. 
The concentration of each BMP is a key factor for the biological responses. Several 
extracellular antagonists bind to specific BMPs regulating the bioavailability of each 
molecule for the receptors [176-178]. Like the BMP ligands, the antagonists are homodimeric 
proteins containing a cystine knot motif, which stabilizes their structure. Antagonists are 
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subgrouped according to their cystine knot motif: the Chordin/Noggin family, Twisted 
Gastrulation and the DAN/Cerberus family [179]. Other known BMP-antagonists are named 
Follistatin, Gremlin, Sclerostatin, Chordin-like, etc. Most of the antagonists appear to be 
synthesized together with BMP ligands and their expression is frequently controlled by the 
BMP itself, as a self-regulated feed-back loop [174]. 
The signal transduction is also regulated by many co-receptors. Co-receptors that potentiate 
BMP signaling include the repulsive guidance molecules (RGMa and RGMc), Dragon 
(RGMb), the RTK c-Kit, and the TGF-β/BMP type III receptors Endoglin and Betaglycan. 
BMPs are negatively regulated by the decoy-receptor BAMBI (BMP and activin membrane-
bound protein) and the RTK Ror2 and TrkC (Fig. 10) [155]. 
 
BMPs: roles in tumorigenesis 
Alterations of the BMP pathway have been described in several tumor systems including 
breast, prostate, ovarian, lung, and colon cancers, as well as in MB, glioblastoma, and 
osteosarcoma [180-187]. BMPs take part in the modulation of potential carcinogenic 
processes such as cell proliferation, apoptosis, differentiation, metastasis, and angiogenesis. 
Similarly to other TGF-β members, BMPs show a dual role in cancer development, showing 
both pro- and anti-tumorigenic effects [188, 189]. For instance, BMP signaling has been 
shown to inhibit tumorigenesis of several tumor types, including brain tumors, basal cell 
carcinomas of the skin and gastric cancer [185, 190, 191]. On the other hand, there are 
evidences showing that BMPs can promote proliferation, motility and invasiveness of various 
cancer models, including colon, melanoma and prostate cancer [192-195]. The discrepant 
data originates most likely from the complexity of the BMP signaling network, strongly 
dependent on the microenvironment. The physiological responses to each BMP are different 
at the molecular level, depending on the type of cell and/or tissue and can be widely altered 
by the aberrant tumor microenvironment [189, 196]. 
Prostate cancer studies have shown that expression of BMPs increases with the tumor 
progression. Furthermore, it is common, in advanced phases of prostate cancer, to find high 
expression of BMPs associated with bone metastasis [153]. In particular, BMP6 is detected 
exclusively in malignant epithelial prostate cells in patient samples with metastases, and in 
isolated skeletal metastases from prostate carcinomas [197]. 
BMPs have also been shown to have an impact on the behavior of breast cancer and the 
expression levels of components of the BMP signaling correlate with the degree of breast 
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cancer malignancy [198]. The analysis of the expression of BMPs in breast carcinomas 
demonstrated a differential expression pattern and their potential prognostic value [182, 196]. 
In particular, the BMP2 transcript level was found lower and the BMP7 level higher in breast 
tumors compared to normal tissues. The BMP2 transcript was also significantly lower in 
tumors from patients with moderate and poor prognosis than in those from patients with a 
good prognosis [153]. Moreover, several studies demonstrate the involvement of different 
BMPs and their receptors in highly metastatic breast cancer cells. BMP7 appears to be 
associated with accelerated bone metastasis in breast cancer [199]. 
Moreover, BMP7 is able to trigger proliferative defects in p53-deficent breast cancer cells 
when knocked-down [200], and to promote proliferation of some breast cancer cell lines 
[199]. However, other studies demonstrated a proliferation inhibitory effect of BMP7 
showing that the expression is inversely correlated to tumorigenicity and invasiveness in vitro 
[187]. 
 
BMPs in cerebellar development and medulloblastoma onset 
During embryonic development, organogenesis and tissue regeneration, BMPs take part to 
the regulation of the stem cell population, in particular maintaining embryonic stem cell self-
renewal. Alterations of components of the BMP signaling may lead to uncontrolled 
proliferative activity of normal stem cells, breaking the fine balance between quiescence and 
proliferation and leading to accumulation of cells without a fully mature phenotype due to 
failure in the signal that drives differentiation [153]. 
During neural development in different regions of the CNS, BMPs control cell fate, 
proliferation and differentiation of several embryonic cell types to give rise to diverse 
components of the nervous system [201]. The knowledge about the roles of BMPs during 
development comes from observations of gene defects in different organisms and from gene 
knockout experiments in mice. Distinct phenotypes and malformations in different organs are 
associated with alteration of BMP signaling. Compound mutant mice for BMP2 and 4 show 
multiple defects in various organ systems, including skeleton, eye, and heart [202]. 
Homozygous null mutations of BMP7 result in skeletal defects as well as severe defects in 
kidney and eye development [203]. 
As mentioned in the section about normal cerebellum development, BMPs participate by 
regulating proliferation, cell-cycle exit, migration, and differentiation of GNP cells [204]. 
GNPs originate within the rhombic lip and BMP7, BMP6 and Gdf7 are expressed by roof 
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plate cells of the dorsal midline adjacent to the rhombic lip [54]. In particular, in the mouse 
embryo BMP7 is expressed within roof plate cells, whereas BMP6 and Gdf7 are expressed at 
highest levels in cells of the dorsal neuroepithelium adjacent to the roof plate (Fig.11) [54]. 
This region and the secreted signals are implicated in proliferation and migration of GNPs 
[205]. Furthermore, BMPs showed inductive activities on GNP cells, stimulating the generation of 
granule neurons cells in vitro and acting as survival factors for postnatal granule cells [7, 206, 
207]. 
 
 
Figure 11. Expression of BMPs in the mesencephalon/metencephalon (mes/met) region roof plate. (a) 
Schematic diagram of an E9.5 mouse embryo, showing a sagittal section on the left and a transverse section on 
the right. Roof plate is represented in blue (b–d). Transverse sections through the mes/met region of E9.5 mouse 
embryos (boxed in a) showing localization of BMPs by in situ hybridization. Gdf7 (b), BMP6 (c), and BMP7 
(d) are expressed along the dorsal edges of the neural tube. (Adapted from [54]) 
 
Moreover, the choroid plexus is a non-neuronal lobulated structure, composed of blood 
vessels enveloped by a monolayer of epithelial cells, which is located throughout the fourth 
ventricle, bordering the rhombic lip [208, 209]. Besides its secretory and barrier functions, 
the choroid plexus plays a role in early GNP specification maintaining these cells in a 
proliferative state and antagonizing differentiation before their migration towards the external 
and internal granule layer [50, 210]. BMP7 is secreted by cells of the choroid plexus and 
takes part to the inhibition of GNP cells differentiation in the rhombic lip. The mechanism of 
action appears to be related with the ability of BMP7 to increase the expression of MATH1, 
thus maintaining GNP cells in a MATH1 expressing, proliferative state [210]. Differentiation 
of GNPs into the IGL requires decreased levels of BMP7, achieved through MATH1-
mediated induction of the BMP7 antagonist Nbl1 (Fig.12) [50]. 
Thus, BMP7 contributes to determining a correct temporal regulation and spatial organization 
of cerebellar progenitor cells during early development [40]. Along with this role, 
deregulated BMP7 expression in the cerebellum is very likely associated with abnormal cell 
development and MB tumorigenesis. 
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Figure 12. Schematic representation of the regulation of GNP cells development in the rhombic lip. BMP7 
specifies the fate of rhombic lip progenitor cells as future granule neurons, inhibits their differentiation, and 
activates the expression of MATH1. Later, MATH1-mediated expression of Nbl1 antagonizes the effect of 
BMP7 and promotes differentiation. (Adapted from [210]). 
 
Within the IGL, a distinct subgroup of BMPs (BMP2 and BMP4) take part to the cerebellar 
development, counteracting SHH signals and allowing differentiation of GNP cells (Fig.5) 
[62]. These BMPs are capable of inducing differentiation in a gradient-based manner. BMP2 
expression increases in the IGL as it develops, while BMP4 is expressed at a low level and its 
expression and protein level peak during GNP differentiation and migration toward the IGL 
[211]. 
Besides their roles in GNP cells differentiation, several reports suggested that BMPs have an 
anti-apoptotic effect in many cell types [212, 213]. However, the anti-apoptotic effects of 
BMPs in the developing cerebellum and the mechanisms involved remain largely unknown. 
Investigations about treatment of MB cells with BMP2 and BMP4 showed either attenuation 
of intrinsic apoptotic mechanisms and increases in cell count [214] or inhibition of 
proliferation [215]. Murine MB cells overexpressing BMP4 within a nude mouse model 
showed decreases in cellular proliferation. BMP2 and BMP4 also inhibited the rate of gross 
MB tumor growth [215]. 
Although the exact role of BMP7 in MB is not yet well characterized, the available 
information [50], along with our experimental results suggest that the contribution of BMP7 
to MYC-dependent pro-survival mechanisms is important in MB cells. 
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Subject of Investigation 
Identification of MYC target genes in childhood medulloblastoma and 
validation of Bone morphogenetic protein-7 as a direct MYC target with 
pro-survival functions. 
A better knowledge of the MYC effector genes involved in MB neoplastic transformation is 
of great relevance and can suggest novel and suitable therapeutic strategies. To identify MYC 
transcriptional targets and their roles during MB onset and progression we compared the 
cDNA microarray profiles of DAOY-derived cells upon genetic manipulation aiming at 
either overexpressing or downregulating MYC. We identified 209 genes with potential 
relevance to MYC-dependent cellular responses in MB. Among the MYC-responsive genes, 
we found members of the BMP signaling pathway. In particular, we identified the gene 
encoding for the cytokine BMP7 as a direct target of MYC. We confirmed the binding of 
MYC to the promoter of BMP7 by ChIP-on-chip analysis in different MB cell lines. 
Moreover, BMP7 is the only member presenting a positive correlation with MYC in human 
MB patient samples. Next, we evaluated the functional relevance of the BMP pathway in MB 
by employing a small-molecule inhibitor of SMAD1/5/8 activation/phosphorylation (DM). 
DM induces apoptosis and decreases cell viability of MB cells. DAOY cells expressing a 
single MYC copy are significantly less sensitive to DM than cells overexpressing the 
oncogene, indicating that the compound can affect a MYC-driven pro-survival response. 
Similarly to DM, BMP7 silencing by siRNA increased apoptosis and reduced cell viability of 
MB cells. Altogether, our findings indicate that high MYC levels drive BMP7 expression in 
MB to induce pro-survival and pro-proliferative cellular pathways. This observation suggests 
the potential relevance of this growth factor as a MYC effector protein during MYC-driven 
neoplastic transformation of MB precursor cells. This new information also suggests a 
rationale for targeting BMP pathways as a therapeutic intervention strategy for MB patients 
with MYC amplification/overexpression. 
 
 
In this manuscript, I developed the idea behind the investigation. I performed all the experiments 
shown in figure 1, 3e, 4, 5, 6, table 1 and in supplementary figures and tables. Figures 2 and 3 
(a, b, c, d) were obtained through the collaboration with the group of Frank Westermann 
(Dept. Tumor Genetics, German Cancer Research Center (DKFZ) Heidelberg, Germany) and 
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the group of Hiroko Ohgaki (Section of Molecular Pathology, International Agency for 
Research on Cancer (IARC), World Health Organization (WHO), Lyon, France) respectively. 
I wrote the text under the supervision of Michael Grotzer. 
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The quassinoid derivative NBT-272 targets both the mTOR and Erk 
signaling pathways in embryonal tumors 
In the context of MYC-overexpressing embryonal tumors (ET), we wanted to investigate the 
biological responses of a group of ET-derived cell lines to the quassinoid analogue NBT-272, 
a small molecule described as inhibitor of MYC. NBT-272 displayed a strong anti-
proliferative activity and the ability to prevent colony formation in vitro, resulting from the 
combination of diverse biological effects, ranging from G1/S arrest of the cell-cycle to 
apoptosis and autophagy. We investigated the mechanisms of action of NBT-272 and found 
that it is able to prevent full activation of both the eukaryotic initiation factor 4E and its 
binding protein 4EBP-1 that regulate cap-dependent protein translation. Moreover, NBT-272 
significantly interfered with full activation of two key pro-proliferative signaling pathways, 
i.e. the Akt/mammalian target of rapamycin (mTOR) and the Mek/extracellular signal-
regulated kinase (Erk) pathways. It is likely that both these signaling pathways participate in 
orchestrating the cellular responses to NBT-272 and that the depleting effect of NBT-272 on 
MYC protein expression occurred via indirect mechanisms, rather than selective inhibition. 
Further, we checked whether the effects could be reproduced in vivo and found that NBT-272 
treatment arrests tumor growth in a xenograft model of human NB. Moreover, expression of 
MYC and activation of Erk were reduced significantly in the tumors treated with NBT-272. 
In summary, NBT-272 induces a relatively complex pattern of cellular responses. All these 
events could be related functionally to interference with key cell survival pathways playing a 
role in the pathogenesis of several ETs. This study justifies further efforts to define more 
clearly the potential benefits of using NBT-272 in novel therapeutic strategies for pediatric 
tumors. 
 
 
In this manuscript, I contributed to the development of the idea behind the investigation and to the 
writing of the text. I performed the experiments involving the dose-dependent effect of NBT-272 on 
cell viability (Fig. 1B) and the anchorage-independent growth in soft agar (Fig.1C) of ET-derived cell 
lines; I contributed to the creation of table 1; I performed the apoptosis analysis shown in figure 3A; I 
performed the analysis of mRNA levels (qRT-PCR) (Fig. 4A - bottom panel and supplementary Fig. 
1SB) and the RT2 Profiler PCR Array (Fig.4D and supplementary Fig.4S); I performed the 
experiments involving the evaluation of the cell viability in NB-derived cell lines treated with Mycro3 
and 10058-F4 (Fig. 4C); I performed the experiment involving the siRNA-mediated silencing of 
MYC shown in supplementary figure 6S. 
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Disabling c-MYC in Childhood MB and Atypical Teratoid/Rhabdoid 
Tumor Cells by the Potent G-Quadruplex Interactive Agent S2T1-6OTD 
S2T1-6OTD is a novel telomestatin derivative synthesized to target G-quadruplex–forming 
DNA sequences. S2T1-6OTD strongly inhibits c-MYC through its high-affinity physical 
interaction with the G-quadruplex structure in the c-MYC promoter. We investigated the 
efficiency of S2T1-6OTD to stabilize G-quadruplexes in guanine-rich DNA and examined 
the strength of its selectivity for the c-MYC over the telomeric sequences. We found that, 
through its ability to recognize and stabilize the quadruplex structure in the c-MYC promoter 
sequence, S2T1-6OTD is able to reduce the mRNA and protein expressions and decreased 
the activities of c-MYC and its target gene hTERT. Further, we investigated the effects of 
S2T1-6OTD on a representative panel of human MB and atypical teratoid/rhabdoid (AT/RT) 
childhood brain cancer cell lines. Treatment with S2T1-6OTD resulted in a dose and time-
dependent antiproliferative effect in all cell lines tested. Moreover, S2T1-6OTD treatment 
induced cell-cycle arrest and decreased the protein expression of the cell-cycle activator 
cyclin-dependent kinase 2. Long-term treatment with nontoxic concentrations resulted in a 
time-dependent telomere shortening, preceded by a decrease in telomerase activity, and 
followed by cell growth arrest, cell senescence and induction of apoptosis. Altogether our 
findings suggest that S2T1-6OTD may well represent a novel therapeutic strategy for 
childhood brain tumors. 
 
 
My contribution to this manuscript involved the analysis of mRNA levels (RT-PCR measurements) of 
MB cells (Fig.1A – upper panel), the analysis of cell viability (Fig.5A) and the measurement of 
apoptotic cell death (Fig.6C). 
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Bone morphogenetic protein-7 is a MYC target with prosurvival functions
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Medulloblastoma (MB) is the most common malignant brain
tumor in children. It is known that overexpression and/or
ampliﬁcation of the MYC oncogene is associated with poor
clinical outcome, but the molecular mechanisms and the
MYC downstream effectors in MB remain still elusive.
Besides contributing to elucidate how progression of MB
takes place, most importantly, the identiﬁcation of novel
MYC-target genes will suggest novel candidates for targeted
therapy in MB. A group of 209 MYC-responsive genes was
obtained from a complementary DNA microarray analysis of
a MB-derived cell line, following MYC overexpression and
silencing. Among the MYC-responsive genes, we identiﬁed
the members of the bone morphogenetic protein (BMP)
signaling pathway, which have a crucial role during the
development of the cerebellum. In particular, the gene BMP7
was identiﬁed as a direct target of MYC. A positive
correlation between MYC and BMP7 expression was
documented by analyzing two distinct sets of primary MB
samples. Functional studies in vitro using a small-molecule
inhibitor of the BMP/SMAD signaling pathway reproduced
the effect of the small interfering RNA-mediated silencing of
BMP7. Both approaches led to a block of proliferation in a
panel of MB cells and to inhibition of SMAD phosphoryla-
tion. Altogether, our ﬁndings indicate that high MYC levels
drive BMP7 overexpression, promoting cell survival in MB
cells. This observation suggests the potential relevance of
targeting the BMP/SMAD pathway as a novel therapeutic
approach for the treatment of childhood MB.
Oncogene advance online publication, 14 February 2011;
doi:10.1038/onc.2011.10
Keywords: BMP7; MYC; medulloblastoma;
brain tumor; pediatric cancer
Introduction
Medulloblastoma (MB) represents >20% of all pedia-
tric tumors of the central nervous system (Gurney and
Kadan-Lottick, 2001), and is characterized by aggres-
sive clinical behavior and high risk of leptomeningeal
dissemination (Engelhard and Corsten, 2005). Multi-
modal therapy (surgery, radiotherapy and chemother-
apy) has improved the overall survival rate. However,
about 30% of patients are still incurable, and survivors
often suffer from severe tumor- and therapy-related
cognitive and neurological dysfunctions (Mulhern et al.,
2005). MB can be subdivided into different histological
variants (Eberhart et al., 2002; Lamont et al., 2004); the
large-cell/anaplastic MB (20–25% of patients) repre-
sents the most aggressive subtype, and is associated with
a high degree of genomic instability and deregulated
expression of the oncogene MYC (Stearns et al., 2006;
Gilbertson and Ellison, 2008).
MYC represents a family of pleiotropic transcription
factors that activate/repress a large group of target genes
(Grandori et al., 2000; Adhikary and Eilers, 2005) that
are, in turn, the effectors of MYC-dependent biological
responses, ranging from cell growth, proliferation and
migration to programmed cell death and differentiation.
MYC is primarily expressed during development and is
mainly repressed in adult tissues, in which aberrant
expression (upregulation) can drive neoplastic transfor-
mation (Littlewood and Evan, 1990). In MB, MYC
upregulation can originate from genomic ampliﬁcation
(4–10% of MB patients; Neben et al., 2004) or mRNA
overexpression (30–65% of patients; Herms et al., 2000;
Aldosari et al., 2002), and it can occur as a downstream
effect of deregulated signaling pathways (Guessous
et al., 2008) that are involved in the development of
granule neuron precursor cells (GNPs) of the cerebellum
(Gilbertson and Ellison, 2008).
Different approaches have been evaluated to target
MYC in various malignancies, including MB (Vita and
Henriksson, 2006; Grotzer et al., 2009). However, direct
pharmacological targeting of transcription factors has
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proven difﬁcult, thus warranting the effort of investigat-
ing in more detail genes that are downstream of MYC as
novel therapeutic targets. Furthermore, a selective
targeting of downstream effectors would aim at preser-
ving the anti-proliferation (for example pro-apoptotic)
functions of MYC.
In this study, we combined gene expression data from
MB-derived cell lines, which had been engineered to
either overexpress or silence MYC. Among the MYC-
responsive genes, we searched for candidate drivers of
MYC-dependent tumorigenesis in MB. The results
suggested the possible relevance of bone morphogenetic
proteins (BMPs), which are cytokines of the family of
the transforming growth factor-b (Blanco Calvo et al.,
2009). BMPs can be activated, both in a paracrine and
autocrine way, to promote recruitment of cell surface
serine/threonine kinase receptors, thus triggering activa-
tion of SMAD transcription factors (Miyazono et al.,
2005, 2010).
Many studies report on alterations of the BMP
pathway in several tumor systems, including breast,
prostate, lung, and colon cancers, as well as glioblasto-
ma, osteosarcoma and MB (Arihiro and Inai, 2001;
Langenfeld et al., 2003; Miyazaki et al., 2004; Raida
et al., 2005; Piccirillo and Vescovi, 2006; Ye et al., 2007;
Buijs et al., 2007a; Dai et al., 2008). Similar to other
transforming growth factor-b members (Derynck et al.,
2001), BMPs may have a dual role in cancer, both
promoting and repressing tumorigenesis in several
models (Buijs et al., 2007a, b; Ye et al., 2009; Thawani
et al., 2010). BMP7, for instance, was shown to promote
migration and invasion of prostate cancer cells (Feeley
et al., 2005), but also to inhibit prostate tumor cell
growth in vivo (Buijs et al., 2007b). Miyazaki et al.
(2004) showed a dose-dependent effect of BMP7, which
inhibited proliferation of androgen-insensitive prostate
cells at high concentrations, whereas low doses had a
pro-proliferative effect. In breast cancer, the expression
level of BMP7 was found inversely correlated to
tumorigenicity and invasiveness in vitro (Buijs et al.,
2007a), but it was also found to cause abnormal
proliferation in p53-deﬁcient breast cancer cells when
knocked down (Yan and Chen, 2007). Although
apparently contradictory, these data reﬂect the complex-
ity of the BMP/SMAD signaling pathway (Ye et al.,
2009), leading to diverse heterogeneous cellular re-
sponses, which can be tissue- and cell type-speciﬁc and
result from the cross-talk with the microenvironment.
This latter heavily inﬂuences the temporal and spatial
expression of BMPs (Sieber et al., 2009), implying also
that co-expression of antagonists (Walsh et al., 2010;
Yanagita, 2005) or modulators (Balemans and Van Hul,
2002; Yanagita, 2009), as well as the activation status of
other pathways (Miyazono et al., 2005; Guo and Wang,
2009), all contribute signiﬁcantly to the diverse re-
sponses observed.
Finally, because of the relevance of BMPs during
cerebellum development (by regulating proliferation,
cell cycle exit, migration and differentiation of GNPs;
Gilbertson and Ellison, 2008), it is not surprising that
BMPs are likely to have a role in tumorigenesis and at
least in a subset of MB tumors (Thompson et al., 2006;
Grimmer and Weiss, 2008; Behesti and Marino, 2009;
Sutter et al., 2010). In this respect, our experimental
results are consistent with this biological hypothesis and
provide an important contribution by linking, for the
ﬁrst time, a BMP family member to the oncogene MYC,
in the context of MYC-dependent prosurvival mechan-
isms in MB.
Results
Identiﬁcation of MYC-responsive genes in a model of MB
To identify MYC-driven tumorigenic functions in MB,
DAOY and DAOY-derived cells were genetically
manipulated to either enhance or silence MYC expres-
sion (Stearns et al., 2006), and their expression proﬁles
were analyzed by cDNA microarray. In one set of
experiments, we evaluated the transcriptional changes
induced by MYC upregulation in DAOY cells by
comparing the proﬁles of two MYC-overexpressing
clones (DAOY M2.1 and M14) with those of wild-type
DAOY and empty-vector-transfected DAOY V11 cells.
The two clones shared 98% similarity in differentially
expressed genes, they were substantially identical in
terms of transcriptional changes associated with MYC
expression on the genetic background of DAOY cells.
The lists of genes associated with MYC overexpression
in DAOY M2.1 and M14 cells were intersected to select
only common genes and corrected for the contribution
of the empty vector. This analysis enabled us to deﬁne
a list of genes associated with MYC overexpression. In
addition, we analyzed the transcriptome of DAOYM2.1
cells transfected with MYC-speciﬁc small interfering
RNA (siRNA) normalized to control/non-targeting
siRNA and found a group of genes associated with
MYC knockdown. In this latter set of experiments,
the expression analysis was carried out at 48 h post
transfection. This time point was chosen because it
showed the most efﬁcient downregulation of MYC
and of its known direct target telomerase reverse
transcriptase (TERT) (Supplementary Figure S1A).
Figure 1 shows the variation of MYC in all cell lines
in the study, at both the mRNA (Figure 1a) and protein
(Figure 1b) levels.
To select only those entities up/downregulated in
a consistent manner in both sets of experiments,
we intersected the two lists of genes. We obtained a
group of 209 genes that were responsive to MYC
gene modulation with absolute fold change X2.0 and
P-value o0.01 (Figure 1c). Of the 209 genes, 105 were
Figure 1 Gene expression analysis. (a) The mRNA expression levels ofMYC were quantiﬁed by quantitative real-time PCR in DAOY
cells and in DAOY-derived cell clones (empty-vector-transfected DAOY V11, MYC-transfected DAOY M2.1 and M14). Data are
normalized to SDHA and to MYC expression in normal human cerebellum (deﬁned as 1). (b) MYC protein levels were evaluated by
immunoblotting and compared with b-tubulin as the loading control (ctrl). (c) Heat map representing the 209 MYC-responsive genes.
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upregulated and 104 downregulated on ectopic expres-
sion of MYC (Supplementary Table 1). This group of
genes was analyzed by using different bioinformatics
tools, such as GeneGO MetaCore, that allowed us to
draw functional networks between genes based on the
literature.
Our experimental data included several known direct
targets of MYC, such as CCND2 (Adhikary and Eilers,
2005) and TERT (Wu et al., 1999), which overlapped
with the MYC-target gene database (www.myccancer-
gene.org/site/mycTargetDB.asp). In fact, overexpres-
sion of MYC increased the CCND2 level by 3.1- and
2.3-fold in DAOY M2.1 and M14 cells, respectively,
whereas MYC silencing repressed the same gene by 8.4-
fold. In contrast, a gene that is known to be negatively
regulated by MYC, inhibin-b A (INHBA), was sig-
niﬁcantly downregulated in DAOY M2.1 and in DAOY
M14 cells (3.8- and 3.7-fold change, respectively) and
upregulated on MYC silencing (3.9-fold change). The
cDNA microarray data were validated by quantifying
the mRNA expression level of a group of representative
MYC-target genes. The expression changes of TERT
and CCND2 following both upregulation (Supplemen-
tary Figure S1B) and silencing of MYC (Supplementary
Figure S1C) are reported. As a negative control, the
expression of cyclin A2 (CCNA2), which is not a target
of MYC, was analyzed (Supplementary Figure S1A,B).
Effect of MYC modulation on components of the BMP
pathway
Growing evidence suggests the functional relevance of
BMPs in the onset of a subset of MB tumors, which is
currently attributed to abnormal development of GNP
cells of the external granular layer of the cerebellum
(Marino, 2005; Crawford et al., 2007; Gilbertson and
Ellison, 2008; Sutter et al., 2010). Interestingly, several
members of the BMP pathway were differentially
expressed following overexpression or silencing of
MYC (Table 1), suggesting a regulatory effect of
MYC on this pathway in MB.
In particular, a general increase in the mRNA
expression levels of some BMP ligands (BMP2, 6 and
7) in DAOY M2.1 cells hinted at MYC-dependent
activation. Moreover, subtypes of BMP receptors
(BMPRs) type I-II were also represented, although only
a few of them could be validated in our cellular models.
Similar to the majority of BMPs, the mRNA level of
glypican-3 (GPC3), a soluble inhibitor of BMPs
(Grisaru et al., 2001; Filmus et al., 2008), increased
withMYC upregulation, and it may be responsible for a
negative-feedback loop on the pathway. Finally, our
microarray data did not show signiﬁcant alteration of
members of the SMAD family of transcription factors
or of the SMAD-target genes inhibitors of differentia-
tion (ID; Miyazono, 1999). This observation would
imply the involvement of alternative downstream
effectors, not fully characterized yet.
BMP7 as downstream target of MYC in MB
The correlation analysis performed by using GeneGO
set a subgroup of the selected 209 MYC-responsive
genes in direct and functional links with MYC,
according to published data (Supplementary Figure
S2). In particular, several networks revealed a direct
Table 1 Differential expression of BMPs and BMPR-I/II as obtained by the cDNA microarray analysis of DAOY-derived cells
Gene name Description M2-high
MYC versus ctrl
M14-high
MYC versus ctrl
MYC silenced
versus ctrl
FC P-value FC P-value FC P-value
Ligands
BMP2 Bone morphogenetic protein 2 1.99 0.0022 2.78 0.00056 1.42 0.0029
BMP4 Bone morphogenetic protein 4 1.68 0.0035 1.17 0.33 1.61 0.00096
BMP6 Bone morphogenetic protein 6 9.40 0.0002 14.83 0.0000072 1.71 0.00005.8
BMP7 Bone morphogenetic protein 7 (osteogenic protein 1) 2.13 0.00037 8.67 0.00004.6 2.58 0.000001.4
Receptors
BMPR1A Bone morphogenetic protein receptor, type IA 1.16 0.26 1.11 0.72 1.47 0.00047
BMPR2 Bone morphogenetic protein receptor, type II 1.41 0.0006 1.25 0.27 1.22 0.0095
ACVR1 Activin A receptor, type I 1.03 0.25 1.16 0.35 2.26 0.00005.8
ACVR1B Activin A receptor, type 2 B 1.12 0.031 2.28 0.00072 1.61 0.0011
ACVR2A Activin A receptor, type IIA 1.23 0.03 1.29 0.17 1.57 0.00033
ACVR2B Activin A receptor, type IIB 1.04 0.56 1.93 0.0005 2.15 0.00026
Pseudoreceptors
BAMBI BMP and activin membrane-bound inhibitor homolog 1.18 0.52 1.13 0.39 2.91 0.0000004.1
Ligand inhibitors
GPC3 Glypican 3 2.29 0.00075 2.79 0.0042 1.69 0.00023
Secretory antagonist
CRIM1 Cysteine rich transmembrane BMP regulator 1 (chordin-like) 1.21 0.22 1.49 0.017 1.58 0.00086
Abbreviations: BMPs, bone morphogenetic proteins; BMPR, BMP receptor; cDNA, complementary DNA; ctrl, control; FC, fold change.
Ctrl, DAOY/DAOY V11; M2/M14, DAOY M2.1/M14 clones; MYC silenced, DAOY M2.1 transfected with MYC-small inhibitory RNA.
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correlation betweenMYC and BMP7, which we studied
in more detail, trying to elucidate the MYC-dependent
regulation of BMP7 and the relevance of the BMP
pathway in our model of MB. From the gene expression
proﬁling data, BMP7 was upregulated in MYC-over-
expressing DAOYM2.1 and M14 cells (2.1- and 8.7-fold
change, respectively), whereas BMP7 was repressed in
cells silenced for MYC (2.6-fold change; Table 1).
Another BMP member, BMP6, was found strongly
upregulated on MYC overexpression (9.4-fold change).
However, on MYC silencing, the transcriptional level of
BMP6 did not consistently correlate with MYC levels
(1.7-fold-change; Table 1).
To demonstrate that the MYC transcription factor
regulates transcription of BMP7, the ability of MYC to
bind the promoter of BMP7 was evaluated by chroma-
tin immunoprecipitation (ChIP), performed in different
MB cell lines. Genomic DNA was extracted and
precipitated with a MYC-speciﬁc antibody to enrich
for MYC-binding promoter sequences, which were
hybridized to a promoter oligo array (Ma et al., 2010).
We observed an enrichment of DNA fragments sur-
rounding the transcriptional start site of BMP7,
including regions that contain canonical binding sites
for MYC (Figure 2), demonstrating that MYC can
regulate the expression of BMP7 by binding the BMP7
promoter.
BMP7 is expressed in MB tumor samples and correlates
with MYC expression
A total of 66 samples of MB available as a tissue
microarray (TMA) were probed for BMP7 immuno-
reactivity. Cytoplasmic expression of BMP7 was quan-
tiﬁed as positive in 10–50% cells in 17 tumors (26%
MBs), as 51–90% cells in 16 tumors (24% MBs) and as
490% cells in 14 tumors (21% MBs), whereas 19
tumors (29%) expressed no BMP7 (Figure 3a and b).
Notably, BMP7 could not be detected in any of the 16
normal cerebellum cores (Figure 3c). Normal human
renal tubule cells were used as a positive control, as they
express high levels BMP7 in the cytosol (Figure 3d).
To ﬁnd a possible correlation between BMP7 and
MYC in primary MBs, the mRNA expression levels of
both genes were determined in 38 MB samples from the
TMA. The results clearly indicated a positive correlation
between BMP7 and MYC (Pearson’s correlation
value¼ 0.42; P-value¼ 0.0095; Figure 3e). The observa-
tion that BMP7 and MYC positively correlate in
primary tumors was conﬁrmed by the unsupervised
analysis of a different set of gene expression data,
obtained from 46 MBs previously published by Thomp-
son et al. (2006; Supplementary Figure S3). Although
this analysis showed the correlation of BMP7 with
MYC expression in primary tumors, no signiﬁcant
correlation was found between MYC and other BMP
members (from Table 1).
MYC-dependent expression of BMP7 and SMAD1/5/8
activation in MB cells
The MYC-dependent expression of BMP7 was validated
in different cell lines (Figure 4). MYC overexpression
signiﬁcantly increases the mRNA level of BMP7
(Figure 4a). On the other hand, BMP7 was down-
regulated in DAOY M2.1 cells transfected with MYC
siRNA (Figure 4b), similarly to TERT that is a known
MYC direct target gene (see also Supplementary Figure
S1A). Although BMP6 mRNA increased on MYC
overexpression, no effect was observed by silencing the
oncogene. We could not ﬁnd a signiﬁcant correlation
between the expression of BMP6, MYC and TERT
(Supplementary Figure S1A).
To discriminate between the intracellular and the
secreted (active) form of BMP7, both total cell lysates
and supernatants were analyzed for BMP7 expression,
by immunoblotting (Figure 4c) and enzyme-linked
immunosorbent assay (ELISA; Figure 4d), respectively.
The results conﬁrmed that the MYC-dependent expres-
sion of BMP7 induced also an increase of the BMP7
protein, both in the precursor and the mature secreted
form. In fact, BMP7 was detectable in the supernatant
only in MYC-overexpressing cells, whereas it was
undetectable (both in total cell lysates and supernatant)
in cells bearing only one MYC copy (Figure 4c, left
panel). Complementary to this effect, silencing of MYC
Figure 2 Binding of MYC to the BMP7 promoter in MB cells.
ChIP-on-chip data show occupancy of the BMP7 genomic sequence
byMYC in D487 and D283 medulloblastoma cells, respectively. The
genomic positions for probes and their enrichment ratios are given
for MYC at the BMP7 locus in D487 and D283 cells. The horizontal
line indicates the median enrichment ratio for MYC versus input as
calculated from all probes for chromosome 20.
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caused depletion of BMP7 in cell lysates (Figure 4C,
right panel) as well as in the medium (Figure 4e).
Next, we investigated whether MYC-dependent mod-
ulation of BMP7 also affected the downstream SMAD
signaling pathway. Indeed, the levels of phosphorylated
SMAD1/5/8 increased in MYC/BMP7-overexpressing
cells, suggesting an enhanced ligand-dependent engage-
ment of the upstream receptors (Figure 4c, left panel).
On the other hand, we observed a signiﬁcant reduction
of SMAD1/5/8 phosphorylation in cells that were
depleted of MYC (Figure 4c, right panel). As further
evidence, we report on a BMP7-dependent increase of
active SMAD1/5/8 in DAOY V11 and DAOY M2.1
cells, after addition of recombinant BMP7 to the
medium (Figure 4f).
Targeting BMP/SMAD signaling pathway in MB
To investigate the relevance of the BMP/SMAD path-
way in MB cells, we evaluated the effect of interfering
with SMAD activation by using different approaches.
Silencing of BMP7 in DAOY M2.1 cells was evaluated
in a time-course experiment (Figure 5a). Along with the
decreased amount of secreted BMP7 in the medium
(Figure 5b), BMP7 downregulation induced cell death
with concomitant inhibition of cell viability (Figure 5c).
These results indicate the functional relevance of BMP7
as an effector of the prosurvival functions of MYC
in MB. On silencing, BMP7 mRNA level decreased
by B80%, whereas the secreted BMP7 decreased
by B50%, compared with non-targeting-siRNA-
transfected cells. This discrepancy could be explained
Figure 3 MB TMA analysis and BMP7/MYC correlation study in MB patients. (a) BMP7 immunohistochemistry showing
cytoplasmic expression of BMP7 in the majority of neoplastic cells in MB (case number 97), and (b) no expression of BMP7 in a
different MB (case number 38). (c) Normal cerebellum shows no BMP7 immunoreactivity. (d) Renal tubule cells served as a positive
control showing cytoplasmic staining for BMP7. (e) The mRNA expression level of BMP7 and MYC was evaluated by quantitative
real-time PCR in a subset of the MB patient samples present on the TMA. Values were normalized to ribosomal protein 18S and to
BMP7 and MYC expression in normal human cerebellum (deﬁned as 1).
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by the documented stability of the BMP7 mRNA
(Guhaniyogi and Brewer, 2001; Buijs et al., 2010),
which would justify a higher amount of protein detected
than expected. However, we cannot exclude that the
cellular responses we observed are associated not only
with the downregulation of BMP7 but also with a more
general alteration of the entire BMP network following
MYC modulation.
The effect of other BMPs and BMPR isoforms was
evaluated by silencing BMP2, BMP6 and all known
BMPR-I/II receptors, which were found upregulated,
together with BMP7, in MYC-overexpressing cells.
Among the BMPs, downregulation of BMP6 showed an
effect similar to BMP7 silencing (Supplementary Figure
S4A), whereas among the BMPRs only downregulation of
ACVR1 reduced cell viability signiﬁcantly. Although not
considered as direct target of MYC, BMP6 was considered
in double-knockout experiments, to prove whether silen-
cing of both BMP6 and BMP7 had a more pronounced
effect on cell viability than downregulating BMP7 alone.
Single silencing of BMP6 or BMP7 elicited similar effects
on cell viability and on induction of apoptosis, as
Figure 4 MYC-dependent regulation of BMP7 and SMAD activation. (a) BMP7 mRNA was evaluated by quantitative real-time
PCR in the indicated cell lines and reported as relative expression normalized to normal cerebellum (deﬁned as 1). (b)MYC and BMP7
mRNA expression levels in DAOY M2.1 cells transfected with MYC-siRNA are reported as the percentage of the expression in cells
transfected with control/non-targeting siRNA. SDHA expression was used for internal normalization. (c) Protein levels of BMP7,
phospho-SMAD1/5/8, and total SMAD1/5/8 were evaluated by western blot in DAOY cells and DAOY-derived cell clones (left panel)
and in DAOYM2.1 cells withMYC silenced (right panel). Expression of either b-actin or b-tubulin was detected as control. (d, e) The
relative amount of secreted BMP7 in cell supernatants was evaluated by ELISA followingMYC upregulation or silencing, respectively.
Percentages are in comparison to the BMP7 secreted by DAOY cells (d) or by DAOYM2.1 transfected with control siRNA (e). (f) The
activation status of SMAD1/5/8 was also analyzed following cell stimulation with BMP7 100 ng/ml for the indicated durations.
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measured at 24–48h after transfection, whereas silencing
of BMP6 alone was more effective after 72h. Interestingly,
the highest level of cell viability inhibition was achieved by
the double knockdown (Supplementary Figure S4B), thus
highlighting the relevant role of the BMP pathway for
survival of MB cells.
To further study the effect of blocking the BMP/
SMAD signaling pathway in MB cells, we also used
dorsomorphin (DM), a small-molecule inhibitor of the
BMP-dependent phosphorylation of the SMAD1/5/8
complex (Yu et al., 2008). MB cells were assessed for
cell viability in the presence of increasing concentrations
of DM. Interestingly, cells overexpressing MYC were
signiﬁcantly more sensitive to DM than cells bearing
one MYC copy (Figure 6a). In the same cell lines,
phosphorylation of SMAD1/5/8 was prevented by
DM, conﬁrming the inhibitory effect of the compound
on the pathway (Figure 6b). Furthermore, we found a
dose-dependent effect of DM on cell proliferation
(Figure 6c), even though no signiﬁcant difference in
induction of apoptosis was found in cells overexpressing
MYC, if compared with wild type and empty-vector-
transfected cells (Supplementary Figure S5A). On the
contrary, DM induced a signiﬁcantly stronger arrest
of cell proliferation in cells expressing high MYC
(Figure 6c). This observation suggested that DM can
function as a cytotoxic agent inducing block of cell
proliferation in a MYC-dependent way.
A panel of four distinct MB-derived cell lines
expressing different levels of BMP7 was additionally
considered (Supplementary Figure S5B). The results
showed that high BMP7-expressing cells (D425 and
MED1) were more sensitive to DM than cells with lower
BMP7 levels (D341 and PFSK; Figure 6d). This
observation supported the presence of a BMP7-depen-
dent mechanism sustaining cell survival, which DM is
likely to target in MB cells.
Discussion
Owing to the key role in the development of MB, the
oncogene MYC and MYC-target genes have become
attractive therapeutic targets, in particular to treat the
most aggressive MB subtypes (Grotzer et al., 2009).
With the aim of identifying MYC-driven genes or
pathways with potentials as therapeutic target, we
proﬁled MB-derived cells by cDNA microarray, follow-
ing genetic manipulation for either overexpressing or
downregulating MYC. The resulting sets of differen-
tially expressed genes were intersected to narrow down
the great amount of data generated, and thus to deﬁne a
group of MYC-responsive genes. These genes included
known direct targets, as well as novel candidate target
genes of MYC. The gene ontology analysis on the data
obtained, allowed identifying pathways that are known
already to have a role in onset and progression of MB,
but which had not been correlated yet with MYC
expression. In particular, we found several components
of the BMP/SMAD pathway, known to be physiologi-
cally active during embryogenesis, promoting cell
proliferation and differentiation of precursor cells of
the cerebellum, from which MB arises (Thompson et al.,
2006; Gilbertson and Ellison, 2008; Behesti and
Marino, 2009; Sutter et al., 2010). Several in vivo MB
models conﬁrmed that an unbalance of proliferative/
differentiation signals, due to aberrant regulation of
these pathways, can induce MB tumor formation
Figure 5 Effect of BMP7 downregulation. (a) The mRNA expression level of BMP7 in DAOYM2.1 cells is reported as the percentage of
the BMP7 level in control siRNA-transfected cells at the indicated time point. (b) Under the same conditions as in (a), the relative level of
BMP7 secreted into the medium was evaluated by ELISA. (c) Cell viability and cell death induction were evaluated in DAOYM2.1 cells at
the indicated time point after transfection with MYC-siRNA or control siRNA (**Po0.01, ***Po0.001 according to Student’s t-test).
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(Polkinghorn and Tarbell, 2007). In our study, BMP7
was found consistently induced/repressed along with the
up/downregulation of MYC, respectively, and thus
chosen to be investigated in detail
Increasing evidences promote the role of the BMP/
SMAD signaling pathway in determining the fate of the
GNP cells of the cerebellum. In this context, compo-
nents of this pathway and in particular BMP7 emerged
and were further analyzed for a potential involvement in
MYC-driven functions in MB. During the development
of the cerebellum, BMP cytokines, including BMP7, are
expressed by roof plate cells of the dorsal midline, a
region adjacent to the rhombic lip (Alder et al., 1999),
and are known to coordinate proliferation and migra-
tion of GNPs (Chizhikov et al., 2006). Members of the
BMP family can in fact induce maturation of GNPs
(Alder et al., 1999) and survival of postnatal granule
cells (Yabe et al., 2002; Gilbertson and Ellison, 2008).
BMP7 is constitutively expressed by cells of the choroid
plexus of the forth ventricle, anatomically closed to the
cerebellum (Dziegielewska et al., 2001; Redzic and
Segal, 2004), providing a pro-proliferative sustained
signal for the GNP cells (Krizhanovsky and Ben-Arie,
2006; Grimmer and Weiss, 2008). Thus, determining the
correct temporal/spatial organization of cerebellar
progenitor cells during early development seems to be
the main role of BMP7 (Thompson et al., 2006). Along
with this role, deregulated expression of BMP7 in the
cerebellum is very likely associated with abnormal cell
development and MB tumorigenesis.
As a validation of our in vitro results, BMP7 was
analyzed by immunohistochemistry in primary MB
samples. Strikingly, BMP7 was not expressed in normal
cerebellum, indicating that overexpression of BMP7 in
MB may contribute to the increased proliferation and
survival of the tumor cells. Moreover, we found a
signiﬁcant correlation between the gene expression of
MYC and BMP7 in two distinct datasets of MB patient
samples.
Further, we demonstrated that MYC can bind to the
promoter of BMP7 in different MB cell lines by using a
ChIP-on-chip approach. That BMP7 is a direct target of
MYC was previously reported by Zeller et al. (2006)
who performed a global mapping of MYC-binding
genomic regions in a model of human B-lymphoid
tumor. BMP4, another member of the same family, was
described to be a target of MYC in blood cells
(Fernandez et al., 2003). These two reports represent
the only experimental evidences, to our knowledge,
about a transcriptional control of the BMP pathway by
MYC, lacking however of functional information. More
speciﬁcally, no previous studies have mentioned MYC-
driven regulation of this pathway as a signiﬁcant
molecular network in MB.
This investigation, therefore, suggests for the ﬁrst time
the existence of a functional link between the over-
expression of MYC and abnormal regulation of the
BMP pathway in a model of MB. Furthermore,
the functional relevance of the BMP-dependent
signaling pathway in MB was evaluated by using DM,
Figure 6 Inhibition of cell viability of MB cells by the BMP receptor kinase inhibitor dorsomorphin. (a) Cell viability was measured
after 72 h of treatment with DM at the indicated concentrations. Results are expressed as the percentage of the values in vehicle-treated
cells. (b) Phospho-SMAD1/5/8 and total SMAD1/5/8 content was investigated by western blot after treatment for 6 h with DM.
(c) The effect of DM on cell proliferation was evaluated after 48 h. The reference was vehicle-treated cells. (d) The cellular response to
DM was investigated in a panel of different MB-derived cell lines treated as in (a).
MYC targets BMP7 in medulloblastoma
G Fiaschetti et al
9
Oncogene
a small-molecule inhibitor preventing the activation of
SMAD1/5/8 by interfering with the kinase activity of the
receptors BMPR-I/II (Anderson and Darshan, 2008; Yu
et al., 2008). Conversely, DM has no, or very limited,
effect on other components of the transforming growth
factor-b family (fox example, transforming growth
factor-b1 and activin A; Anderson and Darshan,
2008). We reported here the ability of DM to strongly
impair proliferation and cell viability of MB-derived
cells. More interestingly, cells expressing low MYC
levels were signiﬁcantly less sensitive to DM than cells
overexpressing the oncogene, thus indicating that the
compound can affect a MYC-driven pro-survival
response. Moreover, silencing of BMP7 induced cell
death and inhibition of cell viability, although it was
not as efﬁcient as DM. This observation, however, is
reasonable, because of the ability of the compound to
block the pathway by interfering with more components
at the same time.
Our results show the feasibility and potential beneﬁt
of a selective block of the BMP/SMAD pathway, by
either silencing BMP7 or using small-molecule inhibi-
tors. A therapeutic approach interfering with activation
of the BMP pathway was investigated here, for the ﬁrst
time, in MB cells and would represent one attractive
strategy, to be considered in combination with targeting
of sonic hedgehog and Wnt pathways (Chen et al., 2002;
Romer and Curran, 2005; Luo et al., 2007; Rossi et al.,
2008). Additional investigations on the role of other
BMP family members will emphasize the relevance of
the whole pathway in the development of MB. They will
also help to shed lights on the emerging recent data
showing opposite effects of BMPs, such as BMP2 and
BMP4, to whom either anti-apoptotic (Iantosca et al.,
1999) or anti-proliferative properties (Zhao et al., 2008)
were assigned.
In conclusion, our results provide strong evidence of
the induction of BMP7 as a MYC-dependent mechan-
ism and suggest BMP7 as an effector regulatory
molecule, in the context of MYC-driven neoplastic
transformation of MB precursor cells. This study, not
only contributes to a better understanding of the
prosurvival functions of MYC in MB, but it also
suggests a rationale for targeting the BMP pathway in
MB patients with MYC ampliﬁcation/overexpression.
Materials and methods
MB cell lines
The human MB-derived DAOY, D341, D425, MED-1 and
PFSK cell lines used in this study were obtained and
maintained in culture as previously described (von Bueren
et al., 2007). The stable clones DAOY V11 (empty vector
transfected), DAOY M2.1 and DAOY M14 (MYC vector
transfected) were maintained in selective medium in the
presence of 500mg/ml G418 (Stearns et al., 2006).
RNA interference
The cells (70–80% conﬂuent) were transfected using either
SMARTpool siRNA speciﬁc for MYC or siCONTROL
Non-targeting siRNA Pool as a control (Dharmacon, Thermo
Fisher Scientiﬁc, Waltham, MA, USA). Each pool of siRNA
was used at the ﬁnal concentration of 50 nM in combination
with Dharmafect 4 transfection reagent (Dharmacon), accord-
ing to the manufacturer’s instructions. Cells were harvested for
both mRNA and protein extraction, to assess gene expression
by quantitative real-time PCR and protein content by
immunoblotting. To selectively target BMP7 and other
components of the BMP/SMAD pathway (BMP2, BMP6
and BMP receptors BMPR1A, BMPR1B, BMPR2, ACVR1,
ACVR1B, ACVR1C, ACVR2A, ACVR2B and ACVRL1),
Ambion Silencer select predesigned siRNAs (Ambion Diag-
nostics, Applied Biosystems, Foster City, CA, USA) were used
at 20 nM ﬁnal concentration. As control, Silencer Negative
Control siRNA #1 (cat. AM4611; Ambion Diagnostics) was
used under the same conditions.
DNA microarray expression proﬁling and data analysis
The cDNA microarray analysis was performed in collabora-
tion with the Functional Genomic Center of the University
Zurich. Gene expression data were obtained by hybridizing
Human Genome-U133 Plus 2.0 Affymetrix GeneChips
arrays (Affymetrix, Santa Clara, CA, USA), on which
>47 000 transcripts were represented. Raw data generated
by the GCOS Software (Affymetrix) were processed by using
the RMA method (Irizarry et al., 2003) and further statistically
analyzed by using the software R and applying Student’s t-test.
Each experiment represented a group of three independent
biological replicates. A gene was considered expressed only if
the average normalized signal in at least one of the two groups
compared was above 25. Results are expressed as fold change,
and differences in expression were considered signiﬁcant if fold
change X2.0 and P-value o0.01. The expression data were
deposited in NCBI’s Gene Expression Omnibus (Edgar et al.,
2002) and are accessible through GEO series accession number
GSE22139 (http://www.ncbi.nlm.nih.gov/geo). Cluster analy-
sis of the data was performed by using the heatmap.2 method
of the ‘gplots’ package (R Development Core Team, 2008).
The GeneGO MetaCore (GeneGO, St Joseph, MI, USA) was
used to deﬁne functional annotations for the selected genes,
thus assigning them to ontological categories for association
with relevant biological processes and pathways.
MB TMA and BMP7/MYC correlation study in MB patient
samples
The tumor material used to create the MB TMA originates
from three sets of archival MB samples, diagnosed in Zurich,
Switzerland (n¼ 46), Cairo, Egypt (n¼ 14) and Tu¨bingen,
Germany (n¼ 6). All these tumor samples were reviewed
independently by two neuropathologists and diagnosed
as MB.
TMA parafﬁn sections were deparafﬁnized in xylene and
rehydrated stepwise with ethanol. The immunohistochemistry
determination of BMP7 was carried out using the catalyzed
signal ampliﬁcation II system (Dako, Glostrup, Denmark)
according to the manufacturer’s protocol. The endogenous
peroxidase activity was blocked incubating the specimens with
0.3% H2O2 for 5min, followed by 5min with a protein-based
blocking reagent and incubation with a BMP7-speciﬁc anti-
body (Abcam, Cambridge, UK; 1:3000), for 30min at room
temperature. The signal was detected in the presence of
diaminobenzidine. Immunoreactivity was scored as (i) , if
o10%; (ii) þ , if 10–50%; (iii) þ þ , if 51–90%; (iv) þ þ þ ,
if 490% of neoplastic cells with cytoplasmic staining for
BMP7. Human normal kidney tissues on parafﬁn sections
served as a positive control. From a subset of 38 samples from
MYC targets BMP7 in medulloblastoma
G Fiaschetti et al
10
Oncogene
the MB patients diagnosed in Zurich (Switzerland) sufﬁcient
tumor material was available to perform quantitative real-time
PCR for the analysis of BMP7 and MYC mRNA expression.
Total RNA was isolated from formalin-ﬁxed parafﬁn-em-
bedded tumor tissue as described previously (Kunz et al., 2006)
by using the Optimum formalin-ﬁxed parafﬁn-embedded for
parafﬁn block RNA isolation kit (Ambion Diagnostics).
Parafﬁn from 1 20 to 2 20mm slices of formalin-ﬁxed
parafﬁn-embedded MB samples was removed by washing the
samples with xylene for 30min. Samples were collected by
centrifugation, washed with ethanol,and allowed to air dry at
room temperature prior ﬁnal centrifugation. Samples were
then resuspended in 10 ml (60U/ml) proteinase K and 100 ml of
digestion buffer, and incubated at 371C for 3 h and then at
room temperature for further 12 h. After complete digestion,
RNA was extracted according to the manufacturer’s protocol.
To validate our results, expression data obtained from a
different group of primary MB tumors (Thompson et al., 2006)
was used to perform an unsupervised analysis on the mRNA
expression of BMP7 and MYC.
Cell viability, cell proliferation and apoptosis assays
Cell viability was evaluated using the CellTiter 96 AQueous One
Solution Cell Proliferation Assay (Promega Corporation,
Madison, WI, USA) based on the reactivity of (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-
phenyl)-2H-tetrazolium). Alternatively, the number of viable
cells was determined by trypan blue exclusion using a
hemocytometer. Proliferation was quantiﬁed by the chemilumi-
nescence-based Cell Proliferation ELISA BrdU (F Hoffmann-
La Roche AG, Basel Switzerland). Activation of caspases 3 and
7 was detected by using the Caspase-Glo 3/7 Assay (Promega
Corporation); hystone-associated DNA fragments were quanti-
ﬁed by Cell Death Detection ELISAPLUS assay (Roche
Diagnostics). Data are expressed as average values from three
independent experiments.
Gene expression analysis
Total RNA was extracted using the RNeasy Mini Kit (Qiagen,
Basel, Switzerland) following the manufacturer’s instructions.
After enzymatic digestion of DNA with RNase-free DNase
(Qiagen), 0.5–1mg of total RNA was used as template for
reverse transcription, which was triggered by random hexamer
primers and performed by using the High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems). Quantitative
real-time PCR was performed under conditions optimized for
the ABI7900HT instrument, using Gene Expression Master
Mix (Applied Biosystems). Probe-primer speciﬁc for the
following genes (purchased from Applied Biosystems) were
used: MYC (Hs00153408_m1), BMP7 (Hs00233476_m1),
TERT (Hs00162669_m1), CCND2 (Hs00277041_m1) and
CCNA2 (Hs00153138_m1). Normal human cerebellum was
used as a reference (Clontech-Takara Bio Europe, Saint-
Germain-en-Laye, France). The relative gene expression was
calculated for each gene of interest by using the DDCT method,
where cycle threshold (CT) values were normalized to the
housekeeping genes succinate dehydrogenase complex subunit
A (SDHA) (Hs00188166_m1) and b-actin (Hs99999903_m1).
Western blot analysis and ELISA
Total protein extracts were obtained from 0.5–1.5 106 cells
lysed with RIPA buffer (50mM Tris-Cl, pH 6.8, 100mM NaCl,
1% Triton X-100, 0.1% SDS) supplemented with Complete
Mini Protease Inhibitor Cocktail (Roche Applied Sciences) and
with the phosphatase inhibitors b-glycerophosphate (20mM) and
Na3VO4 (200mM). Proteins were resolved by SDS–polyacrylamide
gel electrophoresis and western blotting on polyvinylidene ﬂuoride
membranes (Amersham, GE Healthcare, UK). After binding of
the indicated antibodies, the signal was detected by chemilumi-
nescence using SuperSignal West Femto Maximum Sensitivity
Substrate (Thermo Fisher Scientiﬁc Inc., Rockford, IL, USA).
Antibodies speciﬁc for BMP7 (4E7) and SMAD 1/5/8 (N-18) were
purchased from Santa Cruz Biotechnology Inc., whereas antibodies
against phospho-SMAD1 (Ser463/465), SMAD5 (Ser463/465),
SMAD8 (Ser426/428) and MYC were from Cell Signaling
Technology, Inc. (Danvers, MA, USA). As loading controls,
b-tubulin and b-actin (Sigma-Aldrich Chemie GmbH, Buchs,
Germany) were detected. According to the experimental setting,
cells were incubated in the presence of human recombinant
BMP7 (Calbiochem-Merck, Darmstadt, Germany) for 0.5 or 1h,
and cell lysates were analyzed by western blotting. To quantify
secreted BMP7 in cell supernatants (100ml from each sample),
the human BMP7 ELISA kit (RayBiotech Inc., Norcross, GA,
USA) was used following the manufacturers’ instructions.
ChIP-on-chip
ChIP-on-chip experiments using a MYC antibody were
performed as previously described (Ma et al., 2010). The
MB-derived cell lines D487 and D283 were used in this study.
Statistical analysis
All experiments were performed at least in triplicates. Data
are represented as mean±s.d. For in vitro experiments, the
Student’s t-test was used. P-values of o0.01 were considered
signiﬁcant. Pearson’s correlation test and Fisher’s exact test
were used for in vivo gene correlation.
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The Quassinoid Derivative NBT-272 Targets Both
the AKT and ERK Signaling Pathways in
Embryonal Tumors
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Abstract
The quassinoid analogue NBT-272 has been reported to inhibit MYC, thus warranting a further effort 7to
better understand its preclinical properties in models of embryonal tumors (ET), a family of childhood
malignancies sharing relevant biological and genetic features such as deregulated expression of MYC
oncogenes. In our study, NBT-272 displayed a strong antiproliferative activity in vitro that resulted from
the combination of diverse biological effects, ranging from G1/S arrest of the cell cycle to apoptosis and
autophagy. The compound prevented the full activation of both eukaryotic translation initiation factor 4E
(eIF4E) and its binding protein 4EBP-1, regulating cap-dependent protein translation. Interestingly, all
responses induced by NBT-272 in ET could be attributed to interference with 2 main proproliferative
signaling pathways, that is, the AKT and the MEK/extracellular signal-regulated kinase pathways. These
findings also suggested that the depleting effect of NBT-272 on MYC protein expression occurred via indirect
mechanisms, rather than selective inhibition. Finally, the ability of NBT-272 to arrest tumor growth in a
xenograft model of neuroblastoma plays a role in the strong antitumor activity of this compound, both in vitro
and in vivo, with its potential to target cell-survival pathways that are relevant for the development and
progression of ET. Mol Cancer Ther; 9(12); 3145–57. 2010 AACR.
Introduction
Embryonal tumors (ET) represent an important group
of childhoodmalignancies arising fromdifferent tissues of
fetal origin (1, 2). Medulloblastoma (MB) is a tumor of the
central nervous system, originating from granular pro-
genitor cells of the cerebellum(3) andaccounting for about
20% of all childhood brain tumors (4). Neuroblastoma
(NB) is the most common extracranial solid cancer in
childrenoriginating from the sympathetic nervous system
(5, 6). Constant progress has been achieved in clinical
practice by increasing the overall survival rate of MB
and NB patients, although novel therapeutic strategies
are still needed, particularly to treat the high-risk patients
characterized by a more aggressive disease and poor
prognosis. In both MB and NB, high-grade malignancy
is often associatedwith overexpression or amplification of
MYC oncogenes (7–11) playing a role in embryogenesis
and, if aberrantly expressed, in tumor development as
well (12).
There is a long history of therapeutic benefits produced
by natural compounds and some of these have formed
the backbone for further targeted chemical modifications
improving efficacy and selectivity. Quassinoids have
been investigated for their antineoplastic properties
(13), which has led to the identification of interesting
candidates such as bruceantin, with significant inhibitory
effects on leukemia, lymphoma, and myeloma cell
growth, both in vitro and in vivo (14). Bruceantin was
reported to induce apoptosis and cell differentiation, thus
justifying efforts to develop quassinoid analogues with
improved efficacy.
Among the derivatives of bruceantin, NBT-272 dis-
played a significantly stronger toxicity than the parent
molecule, as tested in different models of hematological
and solid tumors (15, 16). Moreover, NBT-272 was
reported to induce downregulation of c-MYC in MB-
derived cells (16), thus raising the question of the
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mechanisms underlying NBT-272’s cytotoxicity and its
selectivity for MYC in ET.
Besides activating programmed cell death, quassinoids
were shown to arrest cell growth by impairing protein
synthesis mediated by the eukaryotic translation initia-
tion factor 4E (eIF4E; ref. 17). The phosphorylation status
of eIF4E plays an important biological role in modulation
of normal cell growth in response to extracellular stimuli
and during development (18). However, eIF4E was also
reported to be an oncogene (19) and its transformation
properties were attributed, at least in part, to induction of
cell cycle progression through cyclin D1 (CCND1) and
MYC (20). Activation of eIF4E itself is mainly regulated
by 2 pathways, namely the mitogen-activated protein
kinase pathway (21) and the AKT/mammalian target
of rapamycin (mTOR) pathway via the 4E binding pro-
tein (4EBP-1; ref. 22).
In this study,wehave investigated the effect ofNBT-272
in different cellular models of ET, both in vitro and in vivo.
The compound triggered multiple cellular responses,
ranging from cell cycle arrest to induction of autophagy,
which are downstream effector mechanisms of the AKT/
mTOR and extracellular signal-regulated kinase (ERK)
pathways. In turn, interference with these signaling
events could also explain the inhibitory effect of NBT-
272 on protein synthesis and on expression of c-MYC/
MYCN in different ET entities.
Materials and Methods
Cell lines
The followinghumancell lineswereused: theNBSK-N-
BE, SH-SY5Y, and WAC-2 (23; G. M. Brodeur, Children’s
Hospital of Philadelphia, Philadelphia, PA); retinoblas-
toma (RB) Y79 and WERI (A. Eggert, University Chil-
dren’s Hospital, Essen, Germany); Ewing’s sarcoma
family of tumors (ESFT) A673 and TC71 (H. Kovar, St.
Anna Children’s Cancer Research Institute, Vienna, Aus-
tria); andmalignant rhabdoid tumor (MRT) LP andMON
(O. Delattre, Institut Curie, Paris, France). MB DAOY and
D341 were purchased from American Type Culture Col-
lection. Cells that were not purchased from the American
Type Culture Collection were authenticated by compara-
tive genomic hybridization (in the laboratoriesmentioned
above or as described below). The clone DAOYM2 (over-
expressing c-MYC) was kindly provided by D. Stearns
(Johns Hopkins University, Baltimore, MD; ref. 11). NB,
ESFT, and MRT cell lines were grown in RPMI medium
(Life Technologies/Invitrogen) supplemented with 10%
(v/v) fetal calf serum (FCS) and penicillin/streptomycin
(PS)/L-glutamine, whereas RB cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM; Invitro-
gen) supplemented with 15% (v/v) FCS Gold (Invitro-
gen), 10 mg/mL insulin (Sigma-Aldrich), 50 mmol/L 2-
b-mercaptoethanol (Sigma-Aldrich), andPS/L-glutamine.
MB cells were cultured in Richter’s zinc option medium
(Invitrogen) supplementedwith 10% (v/v) FCS and PS/L-
glutamine.
Array CGH
The ET-derived cell lines used in the study were
profiled by array comparative genomic hybridization
(aCGH) using a custom 60K Embryonal Tumor array
CGH-chip (ET-aCGH chip; Agilent Technologies), as
described by Kumps et al. (24).
Cell viability, clonogenic, and apoptosis assays
The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)-based
CellTiter 96 AQueous One assay (Promega) was used
to quantify cell viability. Colony formation in agar was
tested by seeding single cells (4,000 per well) in agar-
containing medium [0.35% (w/v) final concentration]
on top of a 0.5% (w/v) agar layer. Apoptosis was
investigated by quantifying the activation of caspases,
by using the Caspase-Glo 3/7 Assay (Promega) accord-
ing to manufacturer’s instructions. The In Situ Cell
Death Detection Kit (Roche) was also employed to
evaluate the proapoptotic response of ET cells. The
terminal deoxynucleotidyl transferase–mediated dUTP
nick end labeling (TUNEL) reaction was done in the
presence of fluorescein-labeled nucleotides and fol-
lowed by detection under a fluorescent microscope
(Axioskop 2; Zeiss).
Cell cycle analysis
Cells [(5–10) 105] were treated for the indicated time
intervals with different doses of NBT-272 or were mock
treated (control). After washing with PBS, the cells were
washed and harvested in a 2 mmol/L EDTA/PBS solu-
tion. Cell pellets were fixed with ice-cold 70% ethanol
on ice for 40 to 60 minutes and, after centrifugation at
2,500 g for 5 minutes, resuspended with 50 mg/mL
propidium iodide/PBS containing 100 U/mL RNAase
(Sigma-Aldrich). The DNA content was estimated by
using a BD FACS Canto II flow cytometry system for
acquisition and the FlowJo software for the data ana-
lysis.
Gene expression analysis by PCR arrays
Total RNA fromDAOY, D341, SK-N-BE, and SH-SY-5Y
cells, treated with 20 nmol/L NBT-272 for 24 hours or left
untreated, was subjected to reverse transcriptase (RT; RT2
First Strand Kit; SABiosciences). The resulting cDNAwas
used as a template for RT2 Profiler PCR Array (SABios-
ciences) for pathway-focused gene expression analysis
(using sets of arrayed TaqMan probes for cell cycle and
apoptosis genes). Gene expression was expressed as log2
ratio (where ratio is 2DDCt), relative to normalization to
untreated control samples and to the average expression
of five housekeeping genes (B2M, HPRT1, RPL13A,
GAPDH, and ACTB). Only statistically significant gene
expression changes over 3 independent experiments
were considered.
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Western blot analysis
Total cell lysates were prepared in a radioimmunopre-
cipitation assay buffer buffer [50 mmol/L Tris-HCl (pH
7.5), 0.1% sodium laurilsulfate, 0.1% sodium deoxycho-
late, 150 mmol/L NaCl, 1% NP40, 1 mmol/L EDTA, and
1 mmol/L EGTA], supplemented with protease inhibi-
tors (Roche) and phosphatase inhibitors (10 mmol/L
sodium fluoride, 10 mmol/L sodium orthovanadate,
and 10 mmol/L sodium b-glycerophosphate). The
amount of protein was determined by BCA Protein Assay
(Pierce). Cell lysates in SDS-sample buffer were boiled for
8 minutes and equal protein amounts were resolved by
4% to 12% gradient SDS-PAGE and immunoblotting
using polyvinylidene difluoride membranes. The antibo-
dies reacting against the following proteins were
employed: CCND1, caspase-3, AKT, mTOR, phospho-
ERK 1/2(Tyr202/204; Santa Cruz Biotechnology); ERK,
phospho-AKT (Ser473), phospho-MEK1/2 (Ser217/221),
phospho-RB (Ser795), RB, phospho-S6 (Ser235/236), S6,
phospho-mTOR (Ser2248), phospho-MNK1 (Thr197/
202), MNK1, phospho-eIF4E (Ser209), eIF4E, 4EBP-1,
phospho-4EBP-1 (Thr37/46), cyclin E, CDK2, CDK4,
PARP, LC-3, c-MYC, MYCN, and ATG5 (Cell Signaling);
b-tubulin and b-actin antibodies were purchased from
Sigma-Aldrich, whereas the anti-SQSTM1/p62 was pur-
chased from BIOMOL International. To inhibit protea-
some-dependent protein degradation, cells were treated
with 50 mmol/L MG-132 (Sigma-Aldrich). The PI3K/
mTOR inhibitor BEZ-235 was purchased by Axon Med-
chem.
Transmission electron microscopy
After treatment (with NBT-272, rapamycin, or vehi-
cle) for different time intervals, DAOY and SK-N-BE
cells were subjected to fixation at room temperature for
30 minutes with 2% glutaraldehyde and 0.8% formal-
dehyde in 50 mmol/L sodium cacodylate (pH 7.3),
followed by 30-minute exposure to 1% OsO4 and
1.5% K4Fe(CN)6 in 50 mmol/L sodium cacodylate
(pH 7.3). Fixed samples were contrasted using 2% ura-
nyl acetate in water for 2 hours, progressively dehy-
drated in increasing concentrations of ethanol, and
embedded into epon (Catalys). Ultrathin sections of
50 nm were prepared and contrasted with uranyl acet-
ate and lead citrate. Samples were analyzed by using a
CM 100 transmission electron microscope (TEM;
Philips).
In vivo xenograft model
Human NB SH-SY5Y cells were stably transfected with
a pLentiV5-Luciferase-expressing vector (Invitrogen) as
described elsewhere (25). SH-SY5Y-LUC clones were
grown under standard conditions in DMEM containing
10% (v/v) FCS, L-glutamine, and blasticidine for selection.
Eight-week-old female athymic nude mice from
Harlan Laboratories were inoculated subcutaneously in
the right rear flank with 2  106 SHSY5Y-LUC cells,
injected in 100 mL PBS solution. Tumor cell growth
was monitored weekly by measuring luminescence emis-
sion, referred to as bioluminescence imaging (BLI) levels,
using the IVIS 3D Illumina Imaging System (Xenogen
Corp.). A detailed procedure can be obtained from Cali-
per. The BLI/tumor size ratio was quantified by encir-
cling the luciferase-emitting areas using the Living
Images Software 3.2 (Xenogen). Three weeks after
implantation, the mice were divided into 2 homogeneous
groups based on their BLI level (photon/s/cm2). Each
group received either 10 mmol/L per week of NBT-272 or
vehicle (EtOH 0.003%/PBS), administered as 100 mL
solution each time, 3 times a week. The analysis of the
tumor growth was done 3, 4, and 6 weeks after the first
NBT-272 administration. The dose was adjusted by tak-
ing into account preliminary data provided by NaPro
BioTherapeutics, Inc. (maximum tolerated dose ¼
0.9 mg/kg/wk; ref. 15) and the in vitro results. The
treatment was done for 6 weeks before the animals were
sacrificed, and tumor samples were analyzed by immu-
nohistochemistry and Western blotting. Quantitative
data analysis of the tumor size was done by ANOVA
statistical tests, using the Statview program.
All animal experiments were conducted according to
national and international guidelines and following
approval by the Institutional Animal Care and Ethical
Committee of CEINGE-University of Naples Federico II
(Protocol 29, September 30, 2009) and of the Italian Min-
istry of Health (Dipartimento Sanita Pubblica Veterinaria
D.L. 116/92).
Immunohistochemistry
Paraffin-embedded tumor samples were treated with
xylene, heated for 45 minutes (in citrate buffer, pH 6.0),
and finally treated for 15minuteswith1%H2O2 (CarloErba
Reagents). Tissues for immunohistochemistry were
blocked with 3% bovine serum albumin, 5% total goat
serum, and 0.3% Tween 20/PBS (1 hour, room tempera-
ture). Primary antibodies reactive against human Ki67
(M7240; Dako, Glostrup, Denmark) and human cleaved
caspase-3 (9661; Cell Signaling) were used (1 hour, room
temperature, diluted 1:100 in blocking solution). After
incubation with a biotin-conjugated secondary antibody
(1 hour, room temperature), the detection was done in the
presence of 3,30-diaminobenzidin (Dako) according to the
manufacturers’protocol. The sectionswere counterstained
by hematoxylin/eosin (Bio Optica), washing 3 times with
0.2% Triton X-100/PBS after every incubation steps. As
negative control, blocking solutionwas used instead of the
primary antibody.
Results
NBT-272 strongly impaired cell growth in
ET-derived cell lines
NBT-272 (NaPro BioTherapeutics, Inc.; Fig. 1A) is a
semisynthetic analogue of bruceantin (14, 17), with 10-
fold higher toxicity than theparent compound in vitro (15).
Previously published data showed the ability of NBT-272
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to drastically reduce the protein expression level of the
oncogene c-MYC in MB-derived cell lines (16), although
the exact mechanism of action remained unexplored. In
this study, the biological responses induced by NBT-272
were investigated in a panel of 13 cell lines, representative
of 6 different ET entities (Fig. 1). Expression of c-MYC and
MYCN was evaluated in each cell line both at protein
(Supplementary Fig. S1A) andmRNA levels (Supplemen-
tary Fig. S1B); these varied significantly, reflecting the
gene expression ranging from single copy to gene ampli-
fication.
The ET cell lines were profiled for copy number changes
(gain/loss) using aCGH. In Supplementary Fig. S2, the
aCGH data of 8 cell lines are reported. Some cell lines
displayed very few genomic aberrations (1q gain in the
MRTcellsLP,and1qgainand8qgain inMBD341),whereas
othershaveverycomplexprofiles, suchasWERIcellswitha
1q gain region that appeared very discontinuous.
The effect of NBT-272 was first evaluated in terms of
cell viability, clearly showing a very potent effect of the
compound in all selected ET-derived cell lines (Fig. 1B;
Table 1). The IC50 values, calculated from the dose–
response curves, varied in the nmol/L range of con-
centration, that is, about 2 orders of magnitude lower
compared with many small-molecule inhibitors inves-
tigated as anticancer drugs. Additionally, 5 representa-
tive ET cell lines (WAC-2, SK-N-BE, A673, MON, Wit-
49) were tested for anchorage-independent growth in
soft agar in the presence of NBT-272 (Fig. 1C). The
compound reduced colony formation by 50% (com-
pared with mock-treated controls) at doses that were
similar or lower than the IC50 obtained in cell viability
assays (Table 1).
A
B
C
Figure 1. Dose-dependent effect of NBT-272 on cell viability and colony formation in ET-derived cell lines. A, chemical structure of NBT-272. B, MTS
assays were done 72 hours after addition of increasing concentrations of NBT-272 (1–182 nmol/L) in 13 ET-derived cell lines. C, five cell lines were
evaluated for anchorage-independent growth in soft agar. NBT-272 reduced colony formation by 50% relative to monolayer cultures at concentrations
lower than/similar to IC50 values. IC50 (nmol/L): WAC-2, 2.3; SK-N-BE, 4.3; A673, 4.6; MON, < 1; Wit-49, 9.7.
Table 1. The IC50 values relative to NBT-272
toxicity, as calculated from the curves fitting the
data in Figure 1B
ET entity Cell line [NBT-272]
IC50(nmol/L)
Medulloblastoma (MB) DAOY 13.6
DAOY M2 4.9
D341 1.5
Neuroblastoma (NB) WAC-2 4.8
SK-N-BE 1.8
SH-SY5Y 3.5
Retinoblastoma (RB) WERI 4.4
Y79 5.4
Wilms' tumor (WT) Wit-49 4.9
Ewing sarcoma family
of tumors (ESFT)
A673 6.0
TC71 4.6
Malignant rhabdoid
tumor (MRT)
MON 11.8
LP 11.0
Note: DAOY M2 cells (overexpressing c-MYC) are also
reported.
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NBT-272-induced cell cycle arrest at the G1/S
transition
To identify which molecular characteristics were
responsible for NBT-272’s toxicity, we sought to inves-
tigate the diverse biological responses triggered in ET
cell lines by the compound. The effect on cellular
distribution at different stages of the cell cycle was
evaluated by DNA staining in MB and NB cells. In
dose–response experiments at different time points,
5 nmol/L NBT-272 was already sufficient to almost
halve the population of replicating DAOY cells after
24 hours, with a concomitant increase in G1 population
(Supplementary Fig. S3). This observation was found to
extend to NB cell lines (WAC-2, SK-N-BE, and
SH-SY5Y; Fig. 2A). Here, NBT-272 induced a similar
effect after 16-hour treatment, thus suggesting that
blocking the cell cycle progression at the G1 to S transi-
tion occurs as one of the earliest mechanisms leading to
proliferative arrest.
Consistent with the data obtained by cytofluorimetry,
NBT-272 induced loss of CCND1 and of its interacting
partner the cyclin-dependent kinase (CDK)4 (Fig. 2B).
These proteins are both important regulators of the cell
cycle progression through the G1 phase (26), along with
the phosphorylation status of the retinoblastoma protein,
which changes throughout the cell cycle with highest
levels when cells enter the S phase (27). Consistent with
an arrest in the G1/S transition, RB was hypophosphory-
lated on treatment with NBT-272 (Fig. 2B). On the con-
trary, the effect on CCNE1/CDK2 was transient.
Two NB cell lines (SH-SY5Y and SK-N-BE) and the MB
cells DAOY and D341 were treated for 24 hours with 20
nmol/L NBT-272, followed by expression profiling of 84
cell cycle–related genes by qRT-PCR. Supplementary
Fig. S4A illustrates the statistically significant gene
expression changes induced by NBT-272. The 23 tran-
scripts fell into 3 functional categories: (1) G1/S transition
of the cell cycle; (2) DNA damage (e.g., growth arrest and
DNA damage-inducible alpha protein, GADD45A); and
(3) regulation of transcription elongation. The most rele-
vant changes concerned genes involved in the G1 arrest,
in support of the data from our biological assays (Fig. 2).
For instance, consistent with a G1/S block of the cell cycle,
the mRNA level of CDK2 decreased, whereas the inhi-
bitor molecules CDKN1A/p21Cip1 and CDKN1B/p27Kip
were induced on treatment (Supplementary Fig. S4A).
Whereas CCND1 andCCNE1were regulated solely at the
protein level (Fig. 2B), other cyclins and CDK molecules
involved in the RNA polymerase II–mediated gene
transcription (CCNC/CDK8, CCNH/CDK7, and CCNT/
CDK9) were found to be upregulated.
Apoptosis was induced by NBT-272
in a cell type–dependent manner
Induction of apoptosis was assessed by quantifying the
activation of caspase-3/7 induced by NBT-272 (Fig. 3A).
A B
Figure 2. Induction of cell cycle arrest in MB and NB cells. A, WAC-2, SK-N-BE, and SH-SY5Y cells were treated with the indicated amount of
NBT-272 for 16 hours or were left untreated (control). The percentage of cells in different stages of the cell cycle is reported in each diagram. B, WAC-2 and
DAOY cells were subjected to treatment with 20 nmol/L NBT-272 and analyzed for expression of cell cycle–regulatory proteins by immunoblotting at
different time points. The experiment was also confirmed in SH-SY5Y cells treated for 16 hours.
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The proapoptotic response to NBT-272 varied signifi-
cantly in a cell type– and tumor-dependent way. This
observation was also confirmed by Cell Death ELISA
assays (Roche; data not shown). Whereas NBT-272 con-
centrations as small as 10 nmol/L triggered apoptosis in
MB-, ESFT-, and MRT-derived cell lines after 24 hours,
the same doses had a very modest proapoptotic effect in
other cellular models, particularly in NB (Fig. 3A). The
limited proapoptotic effect of NBT-272 in MB and NB
cells was also shown by immunoblotting (Fig. 3B), where
caspase-3 could be only detected as full length protein
and PARP cleavage was only induced in MB cell lines
(e.g., in D341; Fig. 3B). This observationwas confirmed by
TUNEL assay, where NBT-272 was able to induce a
breakage of the genomic DNA in DAOY cells (Supple-
mentary Fig. S5).
Using a similar approach to that employed for cell
cycle–related genes, we investigated the transcriptional
changes related to apoptosis triggered by NBT-272
(Supplementary Fig. S4B). Among the differentially
expressed genes, we found key components of both the
extrinsic and the intrinsic pathways of apoptosis, mainly
upregulated on treatment with the compound. This was
the case with proapoptotic members of the Bcl-2 family
(BIK, BAD, and BAK) and with proteins bearing the
caspase recruitment domain (CARD), such as Bcl-10,
PYCARD and RIPK2, implicated in the recruitment
and binding of caspases. Another major group, namely
A
B
C
D
Figure 3. NBT-272-induced apoptosis and autophagy in ET cell lines. A, induction of apoptosis was quantified by Caspase-Glo 3/7 assay (Promega) in
10 cell lines representative of different ET entities following treatment with 10/20 nmol/L NBT-272 for 24 hours. Luminescence signals were normalized to cell
viability (MTS assay). B, cleavage of PARP/caspase-3 was evaluated by Western blotting in the MB cell lines D341 and DAOY and in 2 NB cell lines (SH-SY5Y
and SK-N-BE), treated as indicated. The apparent molecular weight of full length and cleaved caspase-3 on the blots is indicated (35 kDa, 17–19 kDa).
C, high-resolution electron microscopy was done to analyze the effect of NBT-272 (20 nmol/L, 16 hours) on the ultrastructural organization of DAOY cells
(a, c–e, and h) and of SK-N-BE cells (b, f, and g). Mock-treated cells (a, b) appeared healthy with homogeneous cytoplasm and regular nuclear
envelope. Treated cells displayed a looser cytosol and membrane blebbing at the cell surface (c) and a drastic increase in the amount of vacuoles and
lysosomes (c, d). Numerous autophagosomes containing cellular fragments, ribosomes, and whole mitochondria could be detected (arrow heads). DAOY cells
were treated separately with rapamycin (200 nmol/L, 48 hours) as control (h). Bars, a, h¼ 4 mm; b–d, g¼ 2 mm; and e, f¼ 0.5 mm. D. Change in expression of the
autophagy-related proteins SQSTM1 (p62) and LC-3 and of the Atg 5–12 complex (markers of autophagosome formation) was documented by
immunoblotting in DAOY cells.
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genes encoding for ligands and receptors of the tumor
necrosis factor (TNF) superfamily, was induced (Supple-
mentary Fig. S4B). It included TNF-a, TNF-b/LTA,
TNFSF10/TRAIL, and their corresponding receptors
TNFRSF10A and TNFRSF10B. Also the expression of
TNFRSF5, TNFRSF9, and TNFRSF6/FAS increased on
NBT-272 treatment, altogether indicating enhanced cell
responsiveness to death receptor–mediated signaling.
NBT-272 triggered autophagosome formation
Because NBT-272 induced apoptosis with differing
efficiency in the ET cell lines tested,we sought additional
mechanisms that could lead to cell death. Formation of
the distinctive traits of autophagywas investigated at the
ultrastructure cellular level by TEM, thus revealing
induction of a high number of double-membrane struc-
tures containing cellular material (i.e., cytosolic cargo
molecules and organelles), described as autophago-
somes (28).
In Fig. 3C, TEM images of DAOY (MB) and SK-N-BE
(NB) cells are reproduced. Compared with mock-treated
controls (Fig. 3C, a and b), treated cells (20 nmol/L NBT-
272, 16 hours) displayed all the characteristic signs of
autophagy induction, in particular, formation of large
autophagosomes (arrow heads in Fig. 3C, e, f, and g) and
increased lysosomes and vacuoles. Moreover, the cytosol
appeared looser than in control cells, the nuclear envel-
ope became irregular, the mitochondria acquired swollen
crests indicative of dysfunctional activity, and myelin
figures could be visualized as electron-dense structures.
As positive control, DAOY cells were treated separately
with rapamycin (200 nmol/L, 48 hours; Fig. 3C, h),
inducing autophagy as an event associated with inhibi-
tion of mTOR (29). On comparing the effect of the 2
compounds in DAOY cells, NBT-272 proved to be amuch
stronger inducer of autophagy.
Formation of autophagosomes requires a rather com-
plex rearrangement of Atg proteins, including the protein
conjugation system generating the complex Atg5-Atg12
(30), which was detected by immunoblotting, on treat-
ment of DAOY cells with 20 nmol/L NBT-272 (Fig. 3D).
Concomitantly, we were able to show the degradation of
sequestosome 1 (SQSTM1/p62), that is, a multifunctional
adaptor molecule driving the degradation of polyubiqui-
tinated proteins such as those tagged for autophagic
clearance (31). Further, we documented the conversion
of the microtubule-associated protein light chain 3 (LC3-
I) into its membrane-interacting counterpart (LC3-II),
which is a well-documented marker of autophagy induc-
tion.
MYC depletion resulted as an indirect effect of
NBT-272
Because NBT-272 was originally described as a MYC
inhibitor, we evaluated the correlation of the expression
of c-MYC andMYCN in the ET cell lines (Supplementary
Fig. S1) with cell sensitivity to the compound. However,
only the MB cell line D341 (bearing c-MYC amplification)
was significantly more sensitive to NBT-272 than DAOY
cells expressing c-MYC as single copy gene (Fig. 1; ref. 16),
whereas cells from other ET entities displayed a sensi-
tivity similar to NBT-272 (Fig. 1).
Moreover, again regardless of the MYC isoform
expressed and the gene copy number of c-MYC/MYCN,
NBT-272 induced depletion of MYC in several ET cell
lines, although exclusively at the protein level (Fig. 4A).
In contrast, mRNA expression was either left almost
unchanged (e.g., MYCN in SK-N-BE cells) or was
enhanced (e.g., c-MYC in D341 cells) by NBT-272 in a
dose-dependent manner (Fig. 4A).
The MYC family of transcription factors is known to
have short half-lives (32). Therefore, we researched
whether NBT-272 could have an effect on protein stabi-
lity, thus helping to explain MYC depletion. In fact, by
using the proteasome inhibitor MG132 (33) in combina-
tion with NBT-272, c-MYC was already almost comple-
tely rescued after 4 hours (Fig. 4B).
Additional lines of evidence supported an indirect
effect of NBT-272 on MYC. Two small-molecule inhibi-
tors specifically targeting the MYC/Max interaction (34,
35) did not show the same profile of activity as NBT-272
(Fig. 4C). In fact, significant cell viability could still be
measured at high doses of both Mycro3 and 10058-F4.
In particular, WAC-2 cells were almost unaffected
by either of the compounds, whereas 103 times less
concentrated NBT-272 completely arrested cellular
growth.
Finally, only a limited number of gene expression
changes induced byNBT-272matchedwith the transcrip-
tional effects of siRNA-mediated silencing of c-MYC in
DAOY cells (Supplementary Fig. S6; Fig. 4D). In fact, only
a restricted number of genes were up-/downregulated in
both sets of experiments, that is, 11 apoptosis-related
and 11 cell cycle–related transcripts (out of 84 in each
analysis). Among them, even fewer genes were known
direct targets of c-MYC (i.e., GADD45A, BIRC3, DFFA,
CDK6, CDKN1A/p21, and PCNA). On the other hand,
genes reported to be MYC targets exhibited a different
expression profile, that is, they were mostly downregu-
lated in c-MYC–depleted cells, but induced or left
unchanged in cells treated with NBT-272 (e.g., the cyclins
CCNB1, CCNB2, CCND2, CCNH, and the DNA replica-
tion regulators MCM4 and MCM5).
Altogether, these results led us to conclude that a direct
inhibition of MYC is unlikely to explain the effects trig-
gered by NBT-272 in ET cells, which are more likely to be
the result of more complex mechanisms and of interfer-
ence with upstream pathways.
NBT-272 targeted components of the AKT and ERK
signaling pathways
To improve our understanding of the regulatory
mechanisms leading to arrest of the cell cycle, apoptosis,
and autophagy, we analyzed the activation status of 2
signaling pathways, that is, the AKT/mTOR and the
MEK/ERK pathways, regulating these cellular responses
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(36). Furthermore, both pathways have been documented
to be relevant also in the development of ET.
Figure 5A shows the effect of NBT-272 on the activation
status of AKT varying in different cell lines, with phos-
phorylation at Ser473 significantly decreasing in WAC-2,
SK-N-BE, and SH-SY5Y cell lines, but slightly enhanced in
DAOY cells. On the other hand, the level of phosphory-
latedERK1/2 (p44/p42)diminished inall cell lines tested,
although with different kinetics (Fig. 5A), suggesting a
different sensitivity of the 2 pathways to NBT-272. To test
whether NBT-272 had a direct effect on the enzymatic
activity of either AKT or ERK and could thus be regarded
as a kinase inhibitor, we quantified the in vitro kinase
activity of 271 purified recombinant kinases (Supplemen-
tary Fig. S7A). However, none of them were significantly
impairedbyNBT-272 (20nmol/L).Additionally, different
subunits and isoforms of phosphoinositide-3 kinase
(PI3K)were tested (Supplementary Fig. S7B), again show-
ing no effect from NBT-272 (20 nmol/L).
Although the exact mechanism of action of NBT-272
remained unsolved, the compound clearly affected
AKT- and ERK-dependent cellular functions. The down-
stream target of ERK,MNK1 (37), was also deactivated on
treatment with NBT-272, whereas the upstream kinase
A D
B
C
Figure 4. Indirect effect of NBT-272 on MYC. A, the effect of NBT-272 on either c-MYC or MYCN in different ET cell lines was analyzed at the protein
(Western blotting) and at the mRNA level (qRT-PCR). B, cotreatment of D341 cells with MG132, inhibiting proteasome-mediated protein degradation, rescued
c-MYC from the depleting effect of NBT-272. C, cell viability was evaluated in 3 NB-derived cell lines (SK-N-BE, SH-SY5Y, WAC-2) incubated for 72 hours with
increasing doses of Mycro3 (34) or 10058-F4 (35). D, changes in the expression of apoptosis- (left) and cell cycle–related genes (right) were analyzed
comparing the effect of NBT-272 (1) and of c-MYC downregulation by siRNA (2). For the silencing experiment, DAOY M2 cells were transfected transiently
with c-MYC siRNA and gene expression was analyzed after 48 hours by using the RT2 Profiler PCR Array. The same cell line was treated for 24 hours
with 20 nmol/L NBT-272 and subjected to the same analysis. Results in the hit maps are expressed as the log2 ratio (where ratio is 2
DDCt) obtained from
NBT-272-treated or c-MYC siRNA-transfected cells normalized to the corresponding controls (i.e., mock-treated and control siRNA-transfected cells,
respectively). Values in each analysis represent the average of 3 independent experiments.
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MEK1/2 was only slightly affected (Fig. 5A). MNK1 is
known to phosphorylate both eIF4E and its repressor,
4EBP-1 (38). 4EBP-1 is also a direct target of mTOR,
playing a key role as regulator of protein translation
downstream of AKT (22). Interestingly, regardless of
the AKT activation status, phosphorylation of both eIF4E
and 4EBP-1 was impaired byNBT-272 inMB andNB cells
(Fig. 5B), thus preventing the cap-dependent protein
translation machinery from being completely functional.
Additionally, the phosphorylation status of the ribosomal
S6 protein, target of mTOR via S6 kinase (S6K; ref. 39),
was proven to be unaffected, thus reinforcing the idea of a
4EBP-1–dependent block of protein synthesis.
Moreover, we asked whether the cellular sensitivity to
NBT-272-mediatedG1/S block of the cell cycle, apoptosis,
or autophagy would vary if 1 of the pathways had been
affected by using specific inhibitors. To test the relevance
of the mTOR/AKT pathway, BEZ235 was used (40). A
pretreatment with the PI3K/mTOR inhibitor increased
both depletion of CCND1 and degradation of SQSTM1/
p62when comparedwithNBT-272 alone (Supplementary
Fig. S8A), whereas no significant enhancement of the
proapoptotic functions of NBT-272 was observed (Sup-
plementary Fig. S8B). Although BEZ235 alone had appar-
ently no effect, under these conditions, on the expression
of the cell cycle and autophagy markers in DAOY cells,
the inhibitor was functional, as shown by the strong
deactivation of AKT (Supplementary Fig. S8A) and the
induction of apoptosis (Supplementary Fig. S8B).
NBT-272 blocked tumor progression
in a xenograft model of NB
NB cells bearing a transgene encoding luciferase (SH-
SY5Y-LUC) were injected in the flank of 10 athymic nude
mice and were allowed to develop for 3 weeks. The effect
of the intraperitoneal administration of NBT-272 (10
mmol/L per week) and of the vehicle (0.003% EtOH/
PBS) on the tumor growth was monitored by quantifying
the luminescent signal from engrafted SH-SY5Y-LUC
cells. After 6 weeks of treatment, the tumors almost
A
B
Figure 5. Inhibition of protein translation and of the AKT/mTOR- and ERK-dependent pathways. A, protein expression and activation status of components of
the AKT/mTOR and ERK pathways were investigated by immunoblotting. B, treatment with NBT-272 triggered a depletion of active eIF4E and 4EBP-1
proteins in different cell lines as early as 16 hours.
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stopped growing in the mice receiving NBT-272, whereas
the humanNB SH-SY5Y cells expanded into large tumors
in the control animals (Fig. 6A and B; Supplementary
Fig. S9). In fact, a 6.3-fold increase of tumor size could be
detected in the control group compared with the NBT-
272–treated group (P ¼ 0.037 according to Student’s t
test). The result clearly indicated that NBT-272 has a
significant antiproliferative effect on the tumor develop-
ment in vivo. The hemotoxylin/eosin staining of some
representative tumor samples showed a compact and
rounded shape of the tumors, which were characterized
by a very dense cell distribution with some necrotic areas
(Fig. 6C, a–d). Tumors from NBT-272-treated mice
showed a clear reduction of Ki67-positive cells
(Fig. 6C, f and h), whereas a prominent cellular peri-
nuclear staining in vehicle-treated mice was observed
(Fig. 6C, e and g), thus confirming the significant anti-
proliferative effect of NBT-272 also in vivo. Activation of
caspase-3 was also evaluated (Fig. 6C, i and j), which
shows that the treatment with NBT-272 did not induce a
significantly higher induction of apoptosis than with
control tumors. This result confirmed our findings in
vitro (Fig. 3A and B) by referring to the same cellular
model, that is, SH-SY5Y cells, which were used to induce
the tumors. Finally, NBT-272 treatment had an effect on
MYC stability/expression in the tumors, in which ERK
activation was also impaired (Fig. 6D).
Discussion
A fine regulation of protein turnover by a tunable
modulation of protein stability requires specific post-
A
B C
D
Figure 6. Reduction of tumor growth induced by NBT-272 in a xenograft model. Female athymic nude mice were injected in the right flank with SH-SY5Y-LUC
cells. Three weeks after injection, the mice were divided into 2 homogeneous groups (based on the amount of engrafted human cells). Themice received either
NBT-272 (10 mmol/L per week) or vehicle (0.003% EtOH/PBS), both administered 3 times a week. A, the tumor growth rate was monitored on a weekly
basis by quantifying the luciferase activity of the recombinant tumor cells in vivo (see scale bars) and plotted starting from the first day of
treatment. Blue, vehicle-treated animals. Red, NBT-272-treated animals. BLI data are available as a supplementary figure (see Supplementary Fig. 7S).
B, quantification of the tumor growth rate. C, H&E and immunohistochemistry staining of tumor samples obtained from mice treated either with vehicle
alone (left panels) or with NBT-272 (right panels) according to the described protocol. The panels c and d represent the enlarged view of the selected areas in
panels a and b, respectively. In a and b, the tumors are shown as hyperdense-rounded structures with some necrosis portions (n). In panels e–h, the
tumor sections were stained for Ki67 (proliferation), whereas in panels i and j the staining for cleaved caspase-3 (cl-CASP3, apoptosis) is shown.
Images a and b, 5 magnification; images c–j, 40 magnification. D, Western blotting detection of c-MYC, p-ERK1/2, and p-AKT was done in total protein
extracts from tumors developed by mice 4 (vehicle treated) and 9 (NBT-272 treated).
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translation modifications (such as phosphorylation) of
key molecules. Many of these molecules are significant
components of prosurvival pathways and often play a
crucial role in tumor development and progression, in
conditions of constitutive and growth factor–indepen-
dent activation. In past decades, great efforts have been
made to interfere with those signaling pathways by
employing different strategies of targeted therapy, ran-
ging from antibodies against receptor tyrosine kinases
(RTK) to small-molecule inhibitors blocking downstream
signaling effectors. Downstream of RTK activation, the
induction of MYC transcription factors and of their pleio-
tropic effects on cell growth has been frequently asso-
ciated with neoplastic transformation. Therefore, MYC
itself clearly represents an attractive target for anticancer
therapy (41), also due of its correlation with poor prog-
nosis and high-grade malignancy in many types of
tumors, including pediatric malignancies (10, 11, 42, 43).
In the context of MYC-overexpressing ET tumors, we
wanted to investigate the biological responses of a group
of ET-derived cell lines to NBT-272, a small molecule of
about 550 Da, previously described as inhibitor of MYC
(15, 16). Its toxicity and ability to prevent colony forma-
tion in vitro indicated a very strong effect of NBT-272 at
low concentrations.
In the search for an association between toxicity of
NBT-272 and MYC expression levels in different ET cell
lines, no significant correlation could be found. This
observation led us to question any direct effect of
NBT-272 on the oncogene, which would more likely
be the result of different mechanisms, such as interfer-
ence with protein synthesis and stability, affecting also
theMYC familymembers known to have short half-lives
(32). Indeed, we could observe that inhibition of the
proteasome-dependent protein degradation pathway
restored the depleting effect of NBT-272 and almost
completely stabilized c-MYC. Moreover, the effect
induced by 2 specific MYC/Max inhibitors (34, 35)
and by c-MYC silencing in ET cells did not match the
cellular response to NBT-272, again detrimental to the
hypothesis of a direct effect on MYC. This conclusion,
however, certainly does not exclude thatMYC inhibition
contributed to the panel of cellular responses observed
on NBT-272 treatment.
Even though the compound is not a direct kinase
inhibitor, our study indicated the ability of NBT-272 to
interfere with the activation status of different compo-
nents of the AKT/mTOR and MEK/ERK signaling path-
ways. We therefore attributed the effect of NBT-272 on
apoptosis, cell cycle, and autophagy to its ability to
interfere with these pathways. Indeed, the basal level
phosphorylation of ERK1/2, MNK1, and AKT in MB and
NB cells was impaired by NBT-272, under the same
conditions that induced efficient cell cycle arrest (G1/S)
and autophagosome formation. It is also relevant to
emphasize that the 2 pathways converge to regulate
the activation status of eIF4E and 4EBP-1, both depho-
sphorylated (i.e., inactive) in the presence of NBT-272,
thus leading us to speculate that targeting these pathways
would prevent full activation of the cap-dependent pro-
tein translation machinery. Furthermore, MYC depletion
could possibly be explained, not only as an effect of
protein synthesis inhibition, but also as a consequence
of decreased phosphorylation at its Ser62 residue, which
has a stabilizing effect and is catalyzed by ERK (44).
In total, our observations strongly suggest that both the
AKT and MEK/ERK signaling pathways participate in
orchestrating the cellular responses toNBT-272, at least in
vitro. Moreover, combination of NBT-272 with a specific
inhibitor of PI3K/mTOR, BEZ235 (40), seemed to further
increase the NBT-272–dependent effect on cell cycle and
autophagy, but not apoptosis. Numerous components of
the AKT/mTOR and MEK/ERK pathways have been
found deregulated in cancer, including ET. High basal
activation levels of AKT and of the S6 ribosomal protein
were documented inMB (45, 46) and a relevant role in NB
pathogenesis was attributed to PI3K, found to be over-
expressed in NB tumors (47). Phosphorylation of AKT,
S6, and ERK has also been reported as a frequent event in
NB, in which AKT activation in particular was correlated
with diverse indicators of aggressive disease and poor
prognosis (48). These 2 signaling pathways were also
negatively associated with malignancy in childhood
rhabdomyosarcoma (49) and in Ewing’s sarcoma (50),
thus rendering it certainly worthwhile to promote the
idea of developing common therapeutic strategies effec-
tive in different ET entities.
Finally, NBT-272 arrested tumor growth in a xenograft
model of humanNB, showing that the potent effect of this
compound could also be reproduced in vivo, with con-
comitant reduction of MYC expression and of ERK acti-
vation in the treated tumors. These very encouraging
results warrant the extension of investigations to more
ET models.
In summary, NBT-272 induced a relatively complex
pattern of cellular responses, including inhibition of
crucial regulators of protein synthesis. All these events
could be related functionally to interference with key cell
survival pathways (AKT and MEK/ERK) playing a role
in the pathogenesis of several ETs. Our findings increase
the present level of understanding of the mechanisms of
action of NBT-272, explaining its potent antitumor effect
in in vitro and in vivo models of ET. This study certainly
justifies further efforts to definemore clearly the potential
benefits of using NBT-272 in novel therapeutic strategies
for pediatric tumors.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Acknowledgments
We thank Dr. Brian Carter for his precious contribution in proof-
reading the manuscript and Dr. Beat Bornhauser and Prof. Shida Yousefi
for helpful discussion. We are grateful to Lawrence Helson and James
McChesney for providing NBT-272, developed by Tapestry Pharmaceu-
ticals (Boulder, CO). We also thank Thererse Bruggmann and Gery
Barmettler for their excellent technical support during the preparation
and analysis of samples for electron microscopy.
Effect of the Quassinoid NBT-272 in Embryonal Tumors
www.aacrjournals.org Mol Cancer Ther; 9(12) December 2010 3155
Grant Support
Deborah Castelletti and Giulio Fiaschetti were supported by the European
Community FP6, project STREP (EET-pipeline, number: 037260). Valeria Di
Dato and Daniela De Martino were supported by FP6-EET pipeline LSH-CT-
2006-037260 (M. Zollo), FP7-Tumic HEALTH-F2-2008-201662 (M. Zollo), Asso-
ciazione italiana contro la lotta al Neuroblastoma ''Progetto Pensiero''
(M. Zollo), and AIRC Tumori Pediatrici 2007-2010 (M. Zollo).
Received 06/08/2010; revised 09/17/2010; accepted 09/17/2010;
published OnlineFirst 10/01/2010.
References
1. Scotting PJ, Walker DA, Perilongo G. Childhood solid tumours: a
developmental disorder. Nat Rev Cancer 2005;5:481–8.
2. Grimmer MR, Weiss WA. Childhood tumors of the nervous system as
disorders of normal development. Curr Opin Pediatr 2006;18:
634–8.
3. Guessous F, Li Y, Abounader R. Signaling pathways in medulloblas-
toma. J Cell Physiol 2008;217:577–83.
4. Packer RJ. Childhood brain tumors: accomplishments and ongoing
challenges. J Child Neurol 2008;23:1122–7.
5. Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma:
biology and molecular and chromosomal pathology. Lancet Oncol
2003;4:472–80.
6. Maris JM. The biologic basis for neuroblastoma heterogeneity and risk
stratification. Curr Opin Pediatr 2005;17:7–13.
7. Schwab M, Ellison J, Busch M, Rosenau W, Varmus HE, Bishop JM.
Enhanced expression of the human gene N-myc consequent to
amplification of DNA may contribute to malignant progression of
neuroblastoma. Proc Natl Acad Sci U S A 1984; 81: 4940–4.
8. Bordow SB, Norris MD, Haber PS, Marshall GM, Haber M. Prognostic
significance of MYCN oncogene expression in childhood neuroblas-
toma. J Clin Oncol 1998;16:3286–94.
9. Grotzer MA, Hogarty MD, Janss AJ, et al. MYC messenger RNA
expression predicts survival outcome in childhood primitive neuroec-
todermal tumor/medulloblastoma. Clin Cancer Res 2001;7:2425–33.
10. Pomeroy SL, Tamayo P, Gaasenbeck M, et al. Prediction of central
nervous system embryonal tumour outcome based on gene expres-
sion. Nature 2002;415:436–42.
11. Stearns D, Chaudhry A, Abel TW, Burger PC, Dang CV, Eberhart CG.
c-Myc overexpression causes anaplasia in medulloblastoma. Cancer
Res 2006;66:673–81.
12. Schmidt EV. The role of c-myc in cellular growth control. Oncogene
1999;18:2988–96.
13. Rosati A, Quaranta E, Ammirante M, Turco MC, Leone A, De Feo V.
Quassinoids can induce mitochondrial membrane depolarisation and
caspase 3 activation in human cells. Cell Death Differ 2004;11Suppl 2:
S216–8.
14. Cuendet M, Pezzuto JM. Antitumor activity of bruceantin: an old drug
with new promise. J Nat Prod 2004;67:269–72.
15. Helson L, McChesney J, Bartyzel P. In vitro cytotoxic activity of NBT-
272, a novel quassinoid analog. Geneva: Eur J Cancer 2004;2Suppl;
2004:171.
16. von Bueren AO, Shalaby T, Rajtarova J, et al. Anti-proliferative activity
of the quassinoid NBT-272 in childhood medulloblastoma cells. BMC
Cancer 2007;7:19.
17. Fukamiya N, Lee KH, Muhammad I, et al. Structure-activity relation-
ships of quassinoids for eukaryotic protein synthesis. Cancer Lett
2005;220:37–48.
18. Lachance PE, Miron M, Raught B, Sonenberg N, Lasko P. Phosphor-
ylation of eukaryotic translation initiation factor 4E is critical for
growth. Mol Cell Biol 2002;22:1656–63.
19. De Benedetti A, Harris AL. eIF4E expression in tumors: its possible
role in progression of malignancies. Int J Biochem Cell Biol
1999;31:59–72.
20. Bjornsti MA, Houghton PJ. Lost in translation: dysregulation of cap-
dependent translation and cancer. Cancer Cell 2004;5:519–23.
21. Pyronnet S. Phosphorylation of the cap-binding protein eIF4E by the
MAPK-activated protein kinase MNK1. Biochem Pharmacol
2000;60:1237–43.
22. Sun SY, Rosenberg LM, Wang X, et al. Activation of AKT and eIF4E
survival pathways by rapamycin-mediated mammalian target of rapa-
mycin inhibition. Cancer Res 2005;65:7052–8.
23. Garcia de Veas R, Schweigerer L, Medina MA. Modulation of the
proteolytic balance plasminogen activator/plasminogen activator
inhibitor by enhanced N-myc oncogene expression or application
of genistein. Eur J Cancer 1998;34:1736–40.
24. KumpsC, Van RoyN, Heyrman L, Goossens D, Del-Favero J, Noguera
R, et al. Multiplex Amplicon Quantification (MAQ), a fast and efficient
method for the simultaneous detection of copy number alterations in
neuroblastoma. BMC Genomics 2010;11:298.
25. Garzia L, Andolfo I, Cusanelli E, et al. MicroRNA-199b-5p impairs
cancer stem cells through negative regulation of HES1 in medullo-
blastoma. PLoS One 2009;4:e4998.
26. Van Den Heuvel S, Harlow E. Distinct roles for cyclin-dependent
kinases in cell cycle control. Science 1993;262:2050–4.
27. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk
phosphorylation triggers sequential intramolecular interactions that
progressively block Rb functions as cells move through G1. Cell
1999;98:859–69.
28. Tasdemir E, Galluzzi L, Maiuri MC, et al. Methods for assessing
autophagy and autophagic cell death. Methods Mol Biol 2008;
445:29–76.
29. Faivre S, Kroemer G, Raymond E. Current development of mTOR
inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:
671–88.
30. Ohsumi Y, Mizushima N. Two ubiquitin-like conjugation systems
essential for autophagy. Semin Cell Dev Biol 2004;15:231–6.
31. Pankiv S, Clausen TH, Lamark T, et al. p62/SQSTM1 binds directly to
Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates
by autophagy. J Biol Chem 2007;282:24131–45.
32. Sears RC. The life cycle of c-myc: from synthesis to degradation. Cell
Cycle 2004;3:1133–7.
33. Kim D, Kim SH, Li GC. Proteasome inhibitors MG132 and lactacystin
hyperphosphorylate HSF1 and induce hsp70 and hsp27 expression.
Biochem Biophys Res Commun 1999;254:264–8.
34. Kiessling A, Wiesinger R, Sperl B, Berg T. Selective inhibition of c-
Myc/Max dimerization by a pyrazolo[1,5-a]pyrimidine. Chem Med
Chem 2007;2:627–30.
35. Wang H, Hammoudeh DI, Follis AV, et al. Improved low molecular
weight Myc-Max inhibitors. Mol Cancer Ther 2007;6:2399–408.
36. Song G, Ouyang G, Bao S. The activation of AKT/PKB signaling
pathway and cell survival. J Cell Mol Med 2005;9:59–71.
37. O’Loghlen A, Gonzalez VM, Jurado T, Salinas M, Martin ME. Char-
acterization of the activity of human MAP kinase-interacting kinase
MNK1b. Biochim Biophys Acta 2007;1773:1416–27.
38. Richter JD, Sonenberg N. Regulation of cap-dependent translation by
eIF4E inhibitory proteins. Nature 2005;433:477–80.
39. Ali SM, Sabatini DM. Structure of S6 kinase 1 determines whether
raptor-mTOR or rictor-mTOR phosphorylates its hydrophobic motif
site. J Biol Chem 2005;280:19445–8.
40. Maira SM, Stauffer F, Brueggen J, et al. Identification and character-
ization of NVP-BEZ235, a new orally available dual phosphatidylino-
sitol 3-kinase/mammalian target of rapamycin inhibitor with potent in
vivo antitumor activity. Mol Cancer Ther 2008;7:1851–63.
41. Grotzer MA, Castelletti D, Fiaschetti G, Shalaby T, Arcaro A. Targeting
Myc in pediatric malignancies of the central and peripheral nervous
system. Curr Cancer Drug Targets 2009;9:176–88.
Castelletti et al.
Mol Cancer Ther; 9(12) December 2010 Molecular Cancer Therapeutics3156
42. Rouah E, Wilson DR, Armstrong DL, Darlington GJ. N-myc amplifica-
tion and neuronal differentiation in human primitive neuroectodermal
tumors of the central nervous system. Cancer Res 1989;49:
1797–801.
43. Gilbertson RJ, Wickramasinghe C, Hernan R, et al. Clinical and
molecular stratification of disease risk in medulloblastoma. Br J
Cancer 2001;85:705–12.
44. Lutterbach B, Hann SR. Hierarchical phosphorylation at N-terminal
transformation-sensitive sites in c-Myc protein is regulated by mito-
gens and in mitosis. Mol Cell Biol 1994;14:5510–22.
45. Guerreiro AS, Fattet S, Fischer B, et al. Targeting the PI3K p110alpha
isoform inhibits medulloblastoma proliferation, chemoresistance, and
migration. Clin Cancer Res 2008;14:6761–9.
46. Hartmann W, Digon-Sontgerath B, Koch A, et al. Phosphatidylinositol
30-kinase/AKT signaling is activated in medulloblastoma cell prolif-
eration and is associated with reduced expression of PTEN. Clin
Cancer Res 2006;12:3019–27.
47. Boller D, Schramm A, Doepfner KT, et al. Targeting the phosphoinosi-
tide 3-kinase isoform p110delta impairs growth and survival in neu-
roblastoma cells. Clin Cancer Res 2008;14:1172–81.
48. Opel D, Poremba C, Simon T, Debatin KM, Fulda S. Activation of AKT
predicts poor outcome in neuroblastoma. Cancer Res 2007;67:735–45.
49. Petricoin EF 3rd, Espina V, Araujo RP, et al. Phosphoprotein pathway
mapping: AKT/mammalian target of rapamycin activation is negatively
associated with childhood rhabdomyosarcoma survival. Cancer Res
2007;67:3431–40.
50. Benini S, Manara MC, Cerisano V, et al. Contribution of MEK/MAPK
and PI3-K signaling pathway to the malignant behavior of Ewing's
sarcoma cells: therapeutic prospects. Int J Cancer 2004;108:
358–66.
Effect of the Quassinoid NBT-272 in Embryonal Tumors
www.aacrjournals.org Mol Cancer Ther; 9(12) December 2010 3157
Research Article
Disabling c-Myc in Childhood Medulloblastoma and Atypical
Teratoid/Rhabdoid Tumor Cells by the Potent G-Quadruplex
Interactive Agent S2T1-6OTD
Tarek Shalaby1, André O. von Bueren1, Marie-Louise Hürlimann1, Giulio Fiaschetti1,
Deborah Castelletti1, Tera Masayuki3, Kazuo Nagasawa3, Alexandre Arcaro1,
Ilian Jelesarov2, Kazuo Shin-ya4, and Michael Grotzer1
Abstract
We investigated here the effects of S2T1-6OTD, a novel telomestatin derivative that is synthesized to
target G-quadruplex–forming DNA sequences, on a representative panel of human medulloblastoma (MB)
and atypical teratoid/rhabdoid (AT/RT) childhood brain cancer cell lines. S2T1-6OTD proved to be a
potent c-Myc inhibitor through its high-affinity physical interaction with the G-quadruplex structure in
the c-Myc promoter. Treatment with S2T1-6OTD reduced the mRNA and protein expressions of c-Myc
and hTERT, which is transcriptionally regulated by c-Myc, and decreased the activities of both genes.
In remarkable contrast to control cells, short-term (72-hour) treatment with S2T1-6OTD resulted in a dose-
and time-dependent antiproliferative effect in all MB and AT/RT brain tumor cell lines tested (IC50, 0.25–
0.39 μmol/L). Under conditions where inhibition of both proliferation and c-Myc activity was observed,
S2T1-6OTD treatment decreased the protein expression of the cell cycle activator cyclin-dependent kinase
2 and induced cell cycle arrest. Long-term treatment (5 weeks) with nontoxic concentrations of S2T1-
6OTD resulted in a time-dependent (mainly c-Myc–dependent) telomere shortening. This was accompa-
nied by cell growth arrest starting on day 28 followed by cell senescence and induction of apoptosis on
day 35 in all of the five cell lines investigated. On in vivo animal testing, S2T1-6OTD may well represent a
novel therapeutic strategy for childhood brain tumors. Mol Cancer Ther; 9(1); 167–79. ©2010 AACR.
Introduction
Medulloblastomas (MB) are the most common malig-
nant pediatric neoplasms of the central nervous system
(CNS) and represent >20% of all pediatric brain tumors
(1). With current treatment strategies, nearly half of all
patients will eventually die from progressive tumors.
CNS atypical teratoid/rhabdoid tumors (AT/RT) are rare
but highly malignant embryonal tumors in young chil-
dren (2–5). Experience to date indicates that infants and
children with CNS AT/RT respond very poorly to che-
motherapy and radiotherapy (6–9). Accordingly, the
identification of novel therapeutic strategies for MB and
AT/RT remains a major goal.
Telomestatin is a natural G-quadruplex–intercalating
agent isolated from Streptomyces anulatus 3533-SV4 (10).
Telomestatin is a potent telomere maintenance-disabling
drug in cervical carcinoma, breast cancer, multiple myelo-
ma, leukemia, and neuroblastoma cells (11–14). Telomesta-
tin suppresses cellular proliferation and induces apoptosis
within a few days in various cancer cells but not in normal
cells (15). Telomestatin has a characteristicmacrocyclic ring
system that consists of sequential pentaoxazoles, bis-
methyloxazoles, and a thiazoline. It has been suggested
that these structural features of telomestatin strongly bind
to G-quartets by overlapping, and this interaction is
believed to promote the formation and stabilization of
G-quadruplex structures (16). To increase this interaction,
installation of additional functional groups, such as car-
bonyl, hydroxyl, and/or amino groups, would be re-
quired. Based on this concept, telomestatin derivatives
were designed, and S2T1-6OTD was synthesized as a de-
rivative bearing a macrocyclic bisamide (15). Based on its
three-dimensional structure, it had been speculated that
S2T1-6OTD has a high affinity for G-quadruplex–forming
sequences, including the nuclease hypersensitivity element
III1 (17). This is a major transcriptional control element in
the c-Myc promoter region, and it has been found to con-
trol up to 85% of total c-Myc transcription (17–23).
c-Myc is a pleiotropic transcription factor that has been
linked to diverse cellular functions, such as cell cycle
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regulation (24), proliferation (25), and growth (26), and it
has an important regulatory effect on telomerase activity
(27, 28) that promotes immortalization. Aberrant c-Myc
signaling has been observed in human cancers, and c-
Myc has been shown to promote cell transformation and
tumor progression (29–33). In childhood MB, high c-Myc
mRNA expression and c-Myc gene amplification have
been suggested as indicators of poor prognosis (33–43).
Furthermore, high c-Myc mRNA expression was shown
to be significantly associatedwith tumor anaplasia (44, 45).
In this study, we examined the short- and long-term
effects of S2T1-6OTD in a representative set of childhood
MB and AT/RT cells.
Materials and Methods
Tumor and Control Cells
DAOY human MB cells, CA46 and Ramos human Bur-
kitt's lymphoma cells, PC12 rat pheochromocytoma cells,
and MRC-5 human untransformed fibroblast cells were
purchased from the American Type Culture Collection.
D341 and D425 MB cells were the kind gift of Dr. Henry
Friedman (Duke University, Durham, NC). DAOY M2 (c-
Myc vector–transfected) human MB cells have been de-
scribed previously (45). BT-12 and BT-16 human CNS
AT/RT cells were the kind gift of Dr. Peter Phillips (The
Children's Hospital of Philadelphia, Philadelphia, PA).
Rat fibroblast cells HO15.19 [c-Myc knockout (−/−)]
and TGR-1 c-Myc wild-type (rat fibroblast) were the kind
gift of Prof. B. Amati (European Institute of Oncology,
Milan, Italy). DAOY, D341, and D425 cells were cultured
in Richter's zinc option medium/10% fetal bovine serum
(FBS; 1% nonessential amino acids were added to the me-
dium for D341 and D425 cells and G418 was added to the
medium for DAOYM2 to a concentration of 500 μg/mL).
BT-12 and BT-16 cells were cultured in DMEM (with Glu-
tamax)/10% FBS. CA46 and Ramos cells were grown in
RPMI 1640 supplemented with 10% FBS. MRC-5 cells
were grown in MEM supplemented with 5% FBS. PC12
cells were cultured in complete growth medium with FBS
to a final concentration of 2.5% horse serum. HO15.19
and TGR-1 cells were cultured in DMEM with 8% calf se-
rum. BJ foreskin fibroblasts were cultured in DMEM con-
taining 10% iron-supplemented calf serum. All cell
cultures were maintained at 37°C in a humidified atmo-
sphere with 5% CO2. Cell lines that were not purchased
from the American Type Culture Collection in 2009 were
tested for their authentication by karyotypic analysis us-
ing molecular cytogenetic techniques, such as compara-
tive genomic hybridization.
PCR-Stop Assay
PCR-stop assay was done as previously reported (46).
Oligonucleotides ss-telo24 d[TTAGGGTTAGGGT-
TAGGGTTAGGG] , s s -Pu22 d [GAGGGTGGG-
GAGGGTGGGGAAG], mutated mut-ss-Pu22 d
[GAGGGTAAGGAGGGTGGGGAAG], and the comple-
mentary sequences of telo24 d[TCTCGTCTTCCCTAA]
(telo24 rev) and ss-Pu22 d[ATCGCTTCTCGTCTTCCC-
CA] (ss-Pu22 rev) were used. The chain extension reac-
tion was done in 1× PCR buffer containing 0.2 mmol/L
deoxynucleotide triphosphate, 5 units Taq polymerase,
7.5 pmol oligonucleotides, and various concentrations
of S2T1-6OTD and telomestatin. The mixtures were incu-
bated in a thermocycler under the following conditions:
94°C for 2 min followed by 30 cycles of 94°C for 20 s,
47°C for 20 s, and 72°C for 20 s. Amplified PCR products
were resolved on 12% native polyacrylamide gels in
0.5× Tris-borate EDTA buffer and stained with ethidium
bromide. The IC50 values were calculated based on the
fluorescence intensity scanned with a phosphorimager
(Typhoon 8600, Molecular Dynamics).
Circular Dichroism Spectroscopy
Circular dichroism (CD) experiments were carried out
with a Jasco J-715 instrument equipped with a computer-
controlled water thermostat. Optical path length was
1 mm. The spectra were calculated with J-715 Standard
Analysis software (Japan Spectroscopic Co.). Each spec-
trum was recorded thrice, and the reported spectra rep-
resent the average of three scans at 5 nm/min and data
pitch 0.2 nm. ss-Pu22 (GAGGGTGGGGAGGGTGGG-
GAAG) or ss-Telo24 d[TTAGGG]4 was diluted by
Tris buffer (50 mmol/L, pH 7.0) at a concentration of
10 μmol/L. S2T1-6OTD was dissolved with 10 mmol/L
stock solution and titrated into the DNA samples at
5 mol equivalent (the 10 mmol/L stock solution of
S2T1-6OTD was made up in 10% DMSO–90% water).
The DNA strand concentrations were 10 μmol/L, and
the CD data are a representation of three averaged scans
taken at 25°C. All CD spectra are baseline corrected for
signal contributions due to the buffer and for buffer
and DMSO for the samples containing S2T1-6OTD. Ther-
mal melting experiments were done using 10 μmol/L of
either ss-Pu22–forming or ss-Telo24–forming sequence in
the presence of 50 μmol/L S2T1-6OTD in a Tris-HCl buff-
er (50 mmol/L, pH 7.4), and the ellipticity at 264 nm was
monitored on continuous heating at 2°C/min between
20°C and 95°C.
Real-time Quantitative Reverse Transcription-PCR
Isolation of total RNA, cDNA synthesis, and kinetic
real-time PCR quantification of hTERT and c-Myc mRNA
were done as previously described (47, 48). Experiments
were done in triplicate for each data point. The amount of
hTERT and c-Myc, normalized to the endogenous control
18S rRNA, was related to the commercially available cal-
ibrator human cerebellum (Clontech).
Western Blot Analysis
S2T1-6OTD–treated and control MB and AT/RT cells
were washed twice in medium, centrifuged, and lysed
in buffer [50 mmol/L Tris (pH 8), 150 mmol/L NaCl,
1% Triton X-100, 1% NP40, 0.1% SDS, 5 mmol/L EDTA]
for 20 min on ice followed by centrifugation at 10,000 × g
for 15 min. The crude lysates were heated for 5 min at
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95°C in the presence of 3% mercaptoethanol. Equal
amounts of protein (30 μg/lane) from the homogenates
were separated by 10% (w/v) SDS-PAGE and transferred
onto nitrocellulose membranes (Bio-Rad). Nonspecific
binding sites were blocked with 10 mmol/L TBS contain-
ing 0.1% Tween 20 and 10% nonfat milk. Membranes
were then incubated overnight at 4°C with anti–c-Myc
monoclonal antibody (Cell Signaling Technology, Inc.),
anti–cyclin-dependent kinase 2 (CDK2) monoclonal anti-
body (Santa Cruz Biotechnology), or anti–β-actin mono-
clonal antibody (LS2T1-6OTD; Abcam). Membranes were
then washed thrice at room temperature, and bound im-
munoglobulin was detected with anti-isotype monoclo-
nal antibody coupled to horseradish peroxidase (Santa
Cruz Biotechnology). The signal was visualized by en-
hanced chemiluminescence (Amersham Biosciences) and
autoradiography. Relative band intensities were deter-
mined using Quantity One analysis software (Bio-Rad).
c-Myc Transcription Factor Binding Activation
Assay
Nuclear protein extracts were obtained from S2T1-
6OTD–treated and S2T1-6OTD–untreated MB and AT/
RT cells by using the BD TransFactor Extraction kit (BD
Clontech) as described previously (49). The activation of
c-Myc was measured by using the Mercury TransFactor
assay (BD Clontech), an ELISA-based assay (50), as de-
scribed previously (49).
Cell Cycle Analysis
MB and AT/RT cells were washed with PBS, fixed in
70% ethanol, and kept at −20°C for at least 24 h. Theywere
then washed in PBS and resuspended in 50 mg/mL
propidium iodide and RNase (10 mg/mL) in PBS. The
cell suspension was incubated for 30 min at room tem-
perature, and cell cycle distribution was determined by
flow cytometry (FACSCalibur, Becton Dickinson), with
CellQuest software analysis and quantification using
ModFit software as described previously (49).
Cell Growth Assays
For long-term cell growth studies, cells were seeded at
1 × 104/mL (5 mL) into a 25-cm2 tissue culture flask in
the presence or absence of subtoxic doses of S2T1-
6OTD. Subtoxic dose was defined as the concentration
inhibiting a maximum of 10% human MB cells grown
on a 72-h drug exposure. Cells were then cultured for 4
d and then trypsinized and counted. At each passage, 1 ×
104 cells/mL were replated into a new culture flask with
fresh medium containing drug solution. Results were ex-
pressed as the cumulated population doublings as a
function of the time of culture, as described by Binz et
al. (14) and Riou et al. (51). For cytotoxicity assay, cell vi-
ability was quantified using a colorimetric MTS assay
(Promega) as previously described (47, 52). Each condi-
tion was done in triplicate.
Telomerase Activity
Telomerase activity in human MB and AT/RT cell lines
was measured by using the TeloTAGGG Telomerase PCR
ELISA kit (Roche Diagnostics) as previously described
(14, 47). All samples were assayed in triplicate.
Telomere Length
Telomere length in MB and AT/RT cells was deter-
mined by using the TeloTAGGG Telomere Length Assay
(Roche Diagnostics) for measuring the length of telomere
restriction fragments as previously described (47).
Apoptosis Assay
A photometric enzyme immunoassay (Cell Death De-
tection ELISA, Roche Diagnostics) was used for the
Figure 1. PCR-stop assay
products in the presence of
increasing concentrations
of S2T1-6OTD and either
G-quadruplex–forming
single-stranded c-Myc promoter
sequence ss-Pu22 (A) or telomeric
ssDNA sequence ss-Telo24
oligomer (B). C, quantification
of the band absorbance
(fluorescence intensity) by using
phosphorimager. Points, mean of
three independent experiments;
bars, SD. PCR-inhibitory activities
were calculated by the following
equation: (intensity of the band
in the presence of S2T1-6OTD)/
(intensity of positive control band).
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quantitative determination of cytoplasmic histone-
associated DNA fragments, as described previously (53).
Statistical Analysis
All data are expressed as mean ± SD. Student's t test
was used to test statistical significance. P < 0.05 was con-
sidered to be significant. GraphPad Prism 4 (GraphPad
Software) software was used to calculate IC50 values
and their 95% confidence intervals and to statistically
compare the fitted midpoints (log IC50) of the two
curves.
Results
S2T1-6OTD Structure
Supplementary Fig. S1A shows the chemical structure
of S2T1-6OTD compared with the well-characterized tel-
omestatin. The structure of S2T1-6OTD was confirmed by
1H nuclear magnetic resonance (Supplementary Fig. S1B)
and high-resolution mass spectrometry (Supplementary
Fig. S1C).
Stabilization of c-Myc G-Quadruplex Structures by
S2T1-6OTD
To test whether S2T1-6OTD is able to stabilize the c-
Myc G-quadruplex in the guanine-rich sequence of the
c-Myc promoter, we used PCR-stop assay (54). In the
presence of increasing concentrations of S2T1-6OTD,
the 5′ to 3′ DNA extension of the ssDNA of the c-Myc
promoter sequence ss-Pu22 oligomer was inhibited in a
dose-dependent manner, indicating the stabilization of
the G-quadruplex structure by S2T1-6OTD with a low
IC50 value of 0.70 ± 0.02 μmol/L (Fig. 1A). No significant
inhibition was observed when ss-Pu22 mutant (contain-
ing a mutation in two guanine repeats into aniline) was
used (data not shown).
Because potential G-quadruplex–forming sequences
exist not only in the c-Myc promoter region but also in
the telomeric ssDNA that proved to be recognized and
specifically stabilized by telomestatin, the parental com-
pound of S2T1-6OTD (10), we investigated the selectivity
of S2T1-6OTD to stabilize the G-quadruplex in the c-Myc
promoter ss-Pu22 over the telomeric ssDNA sequence
ss-Telo24 by the PCR-stop assay. The results showed
that inhibition of ss-Telo24 fragment extension needed a
35-fold higher concentration of S2T1-6OTD (IC50, 24.9 ±
3.1 μmol/L) compared with ss-Pu22 (IC50, 0.70 ±
0.02 μmol/L; Fig. 1B and C), indicating much weaker
binding and stabilization ability to G-quadruplex in ss-
Telo24 than in ss-Pu22. This result was supported by CD
spectroscopy, which showed that S2T1-6OTD failed to
stabilize the conformation of ss-Telo24 to a G-quadruplex
(Supplementary Fig. S2). Together, these results show a
higher selectivity of S2T1-6OTD for the c-Myc promoter
sequence compared with telomere DNA.
The binding affinity of S2T1-6OTD and stabilization of
the G-quadruplex in the c-Myc promoter (c-MycQ) were
further investigated by CD spectroscopy. Figure 2A
shows that, under our experimental conditions, the
c-Myc G-quadruplex–forming sequence exhibited the typ-
ical spectral signature of a G-quadruplex with a character-
istic maximum at 264 nm (55, 56). In the presence of a
five-times molar excess of S2T1-6OTD, the peak centered
at 264 nm was significantly broader, with lower ellipticity
Figure 2. A, CD spectra of c-MycQ in
the presence or absence of S2T1-6OTD
(50 μmol/L). The c-MycQ–forming
oligonucleotide concentration was
10 μmol/L. Spectra were recorded in
50 mmol/L Tris (pH 7.2) and 100 mmol/L
KCl at 25°C. B, CD melting curves of
ss-Pu22 (10 μmol/L) at 265 nm in the
presence of S2T1-6OTD (50 μmol/L).
C, CD melting curves of ss-Telo24
(10 μmol/L) at 265 nm in the presence of
S2T1-6OTD (50 μmol/L).
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Figure 3. A, treatment with
S2T1-6OTD results in a reduction
of c-Myc mRNA as measured by
quantitative real-time PCR (n = 3)
and in a reduction of c-Myc protein
expression (representative of two
independent experiments) in D341,
D425, BT-12, and BT-16 cells but
not in DAOY cells. Bars, SD. B,
treatment with S2T1-6OTD results
in a significant reduction of c-Myc
activity (measured by c-Myc
binding capacity to its consensus
sequence “CACGTG” of the E-box
element) as determined by the
ELISA-based TransAM c-Myc
activity assay. Columns, mean
absorbance (n = 3); bars, SD.
*, P < 0.05; ***, P < 0.001.
Treatment of MB and AT/RT
cells with S2T1-6OTD resulted
in a significant decrease of
hTERT mRNA expression (C) and
telomerase activity (D) as
determined by quantitative
real-time PCR and the Telomerase
PCR ELISA kit. Columns, mean
percentage decrease compared
with untreated control cells (n = 3);
bars, SD.
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at the maximum. This indicates a physical interaction be-
tween S2T1-6OTD and the ssDNA of the c-Myc promoter
sequence. However, the spectral differences were not
large enough to permit titration experiments to calculate
the binding constant.
Thermodynamic stability profiling provides informa-
tion about the relative stability of DNA structures on li-
gand binding (57). Therefore, the stabilization effect of
S2T1-6OTD on the G-quadruplex structure in the c-Myc
promoter sequence was further studied by CD spectros-
copy by measuring the thermodynamic stability profile
of the ss-Pu22 oligomer and the change in absorption at
264 nm. The results in Fig. 2B show that the normalized
CD intensity of ss-Pu22 at 264 nm with 50 μmol/L S2T1-
6OTD in a Tris-HCl buffer (50 mmol/L, pH 7.4) had a Tm
value of 46.7°C calculated from the CD melting curves at
264 nm using a sigmoidal fitting. Under the same condi-
tions, the Tm value of S2T1-6OTD-Telo24 complex was
Figure 4. S2T1-6OTD reduces the
protein expression of CDK2 and
induces cell cycle arrest and
apoptotic cell death in human MB
and AT/RT cells. A, S2T1-6OTD
decreased the cell cycle activator
CDK2 protein expression in D341,
D425, BT-12, and BT-16 but not in
DAOY cells as determined by Western
blotting. B, effects of S2T1-6OTD
on cell cycle in human brain
tumor cells as determined by
fluorescence-activated cell sorting
analysis. Cells were treated with
S2T1-6OTD (0.4 μmol/L) or left
untreated for 72 h and then fixed
and stained as described in
Materials and Methods. At least
20,000 cells were counted. Results
are presented as percentages of cells
in G1, S, G2-M, and sub-G1 phases
in two independent experiments. The
subdiploid peak represents the
apoptotic fraction. S2T1-6OTD
treatment resulted in a decrease
in the percentage of cells in the
S phase and an increase in the cells
in the G0-G1 and sub-G1 phases
in all cell lines tested. *, P < 0.05;
***, P < 0.001.
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only 30.7°C (Fig. 2C), indicating a strong stabilizing effect
of S2T1-6OTD on G-quadruplex in NHE III1 DNA and a
weaker effect on G-quadruplex in telomere sequence.
Because indiscriminate binding of a compound to
nonspecific DNA can result in significant loss of the com-
pound and may have unintentional effects on the regula-
tion of nontargeted genes, we investigated the binding
ability of S2T1-6OTD to duplex DNA. A CD melting
curve was done for the duplex ds-Pu22 in the presence
or absence of 50 μmol/L S2T1-6OTD. The results showed
no detectable change in melting temperature of the ds-
Pu22 DNA in the presence or absence of S2T1-6OTD
(Supplementary Fig. S3A), indicating the inability of
S2T1-6OTD to bind to duplex DNAs. This result was con-
firmed by the electrophoretic mobility shift assay, which
excluded the ability of S2T1-6OTD to interact with
dsDNA sequences (Supplementary Fig. S3B).
S2T1-6OTD Treatment Down-Regulates c-Myc
Expression and c-Myc Binding Activity
To test whether treatment with S2T1-6OTD alters c-
Myc expression, we incubated a panel of MB and AT/
RT cells with 0.4 μmol/L S2T1-6OTD for 72 hours and
measured c-MycmRNA expression by real-time quantita-
tive reverse transcription-PCR and c-Myc protein by
Western blotting. With the exception of DAOY cells
(low basal c-Myc expression), treatment with S2T1-
6OTD resulted in significant reductions of c-Myc mRNA
and protein expression in all other MB and AT/RT cell
lines tested (Fig. 3A). To examine whether treatment
with S2T1-6OTD alters c-Myc binding activity, we incu-
bated the five cell lines under study with S2T1-6OTD
(0.4 μmol/L for 72 hours) and measured binding activity.
S2T1-6OTD treatment reduced c-Myc binding activity
significantly in all MB and AT/RT cells (Fig. 3B).
S2T1-6OTD Reduces Telomerase mRNA Expression
and Activity
Because hTERT, the catalytic subunit of telomerase, is
transcriptionally under the control of c-Myc (27, 28) and
having shown an inhibitory effect of S2T1-6OTD on
c-Myc expression in MB and AT/RT cells, we were inter-
ested in the effects that this interaction might have on
telomerase activity. MB and AT/RT cells were treated
with 0.4 μmol/L S2T1-6OTD for 72 hours, total RNA
was isolated for reverse transcription-PCR, and total pro-
tein was extracted. Using real-time quantitative reverse
transcription-PCR to measure hTERT mRNA and the Tel-
omerase PCR ELISA kit to measure telomere repeat am-
plification protocol (TRAP) activity, it was found that
S2T1-6OTD could indeed reduce hTERT mRNA expres-
sion in BT-12, BT-16, DAOY, and D341 cells. No effect
was observed on hTERT mRNA in the mainly ALT (Al-
ternative Lengthening of Telomeres)-dependent D425 cell
line (Fig. 3C; ref. 47). Moreover, S2T1-6OTD reduced tel-
omerase activity in all cell lines tested, with maximum
inhibition in D341 (64%) and a minimum 17% in D425
(Fig. 3D).
The direct effect of S2T1-6OTD on telomerase activity
was examined in a cell-free system. In this experiment, in-
creasing concentrations of S2T1-6OTD (0.005–5 μmol/L)
were added to the telomerase reaction mixture contain-
ing extract from D341 cells. The results showed that
S2T1-6OTD inhibited in vitro the process of telomerase
activity; the concentration that resulted in 50% decrease
in telomerase inhibition (EC50) was 0.1651 μmol/L
when measured by TRAP and was 0.3577 μmol/L when
measured by the TRAP-LIG assay (58), which was used
to eliminate drug contamination of the PCR reaction.
The results of these two experiments not only indicates
that S2T1-6OTD by itself has no significant inhibitory
effect on the PCR but also confirms that S2T1-6OTD
possesses a direct effect on telomerase activity when
examined in cell-free system (data not shown).
NHE III1 Sequence in the Promoter Region of c-Myc
Is Needed for S2T1-6OTD to Exert Its Effect on
c-Myc
To further confirm the requirement of the G-quadruplex–
forming NHE III1 sequence in the promoter region of
c-Myc for the exertion of downregulation of c-Myc ex-
pression by S2T1-6OTD, two Burkitt's lymphoma cell
lines with different translocation break points within
the c-Myc promoter (17, 59, 60) were investigated (Sup-
plementary Fig. S4A). In the CA46 cells where the NHE
III1 is deleted, S2T1-6OTD treatment (0.4 and 0.8 μmol/L
for 72 hours) had no effect on c-Myc mRNA and protein
expression, whereas in the Ramos cells, in which the
NHE III1 is present, treatment with S2T1-6OTD signifi-
cantly reduced c-Myc mRNA and protein expression
(Supplementary Fig. S4B and C). In DAOY M2 MB cells
where c-Myc is mainly under the control of a cytomega-
lovirus promoter (45), treatment with S2T1-6OTD did
not decrease but rather slightly increased c-Myc expres-
sion (Supplementary Fig. S4D), also indicating a high af-
finity of S2T1-6OTD for NHE III1.
Effects of S2T1-6OTD on the Cell Cycle of MB and
AT/RT Cells
To determine the possible effects of S2T1-6OTD on cell
cycle regulation, we assessed the cellular DNA content
by using flow cytometry (fluorescence-activated cell sort-
ing) and determined CDK2 protein expression. With the
exception of DAOY cells, S2T1-6OTD (0.4 μmol/L) treat-
ment for 72 hours resulted in a significant decrease in the
cell cycle activator CDK2 (Fig. 4A). Moreover, treatment
with S2T1-6OTD resulted in a significant decrease in the
percentage of cells that were able to enter the S phase and
in an increase of the cells in the G0-G1 and sub-G1 phases
(Fig. 4B), indicating that S2T1-6OTD mediates cell cycle
arrest and induction of apoptotic cell death.
S2T1-6OTD Treatment Results in Suppression of
MB and AT/RT Cell Proliferation
To test whether treatment with S2T1-6OTD alters cellu-
lar proliferation, MB and AT/RT cells were incubated
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Figure 5. A, dose- and time-dependent inhibition of cell viability inMB and AT/RT cells by S2T1-6OTD as determined byMTS assay.B, S2T1-6OTD treatment
had no antiproliferative effect on HO15.19 [c-Myc knockout (−/−)] rat fibroblast cells when compared with the parental TGR-1 c-Myc wild-type (rat fibroblast)
cells. C, S2T1-6OTD treatment also had no major antiproliferative effect on PC12 cells (that do not depend on c-Myc in their proliferation) or MRC-5
normal fetal lung fibroblast cells when compared with MB and AT/RT cells. D, S2T1-6OTD exhibits much less cell toxicity than telomestatin on MRC-5.
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with various concentrations of S2T1-6OTD for 72 or
96 hours and cell viability was assessed by using the
MTS assay (Fig. 5A). Treatment with S2T1-6OTD resulted
in a dose- and time-dependent cytotoxic response in all
cell lines tested, with IC50 concentrations between
0.14 and 0.33 μmol/L (72-hour treatment time). However,
S2T1-6OTD had no antiproliferative effect on c-Myc
knockout (−/−) HO15.19 rat fibroblast cells when com-
pared with the parental TGR-1 c-Mycwild-type (rat fibro-
blast) cells (Fig. 5B; ref. 61). Moreover, S2T1-6OTD also
had no antiproliferative effect on PC12 cells. These cells
do not depend on c-Myc to proliferate due to the absence
of Max, the partner protein to which c-Myc dimerizes to
be activated (Fig. 5C; ref. 62). When compared with brain
tumor cells, S2T1-6OTD showed significantly less cyto-
toxic effects (IC50, 3.44 μmol/L) on normal (not trans-
formed) fetal lung fibroblast MRC-5 cells (63, 64),
indicating some tumor specificity. Interestingly, when
compared with the parental compound telomestatin,
S2T1-6OTD showed much less cell toxicity on MRC-5
cells (Fig. 5D). Because S2T1-6OTD also causes a decrease
in hTERT expression and activity, we investigated wheth-
er it was the c-Myc downregulation or the reduction in
telomerase that exerted the antiproliferative effect of
S2T1-6OTD on MB cell culture. To that end, we tested
the effect of S2T1-6OTD on cell viability of telomerase-
negative cells (e.g., the human foreskin fibroblasts BJ;
ref. 65). Treatment with S2T1-6OTD resulted in a clear
concentration- and time-dependent cytotoxic response
in the telomerase-negative BJ cells (data not shown), indi-
cating that telomerase is most likely not responsible for
the effect of S2T1-6OTD on MB and AT/RT cell growth.
Effects of Long-term Treatment with Nontoxic
Concentration of S2T1-6OTD
To examine the long-term effects of S2T1-6OTD on
MB and AT/RT cells, cells were treated with nontoxic
concentrations of S2T1-6OTD (0.04 or 0.004 μmol/L)
for 5 weeks. We then characterized the growth proper-
ties of the treated cells during the long-term cultivation
experiments. Treatment with S2T1-6OTD at 0.04 μmol/L
resulted in telomere shortening in all MB and AT/RT
cells tested (Fig. 6A). The shortening observed after
3 weeks of S2T1-6OTD treatment was 2.0 kbp in DAOY
cells, 1.5 kbp in D341 cells, 2.6 kbp in BT-12 cells, 2.0
kbp in BT-16 cells, but only 0.8 kbp in D425 cells. The
growth kinetics of S2T1-6OTD–treated MB and AT/RT
cells did not differ significantly from those of untreated
control cells in the first week. After 2 to 3 weeks, cell
growth of S2T1-6OTD–treated cells decreased (Fig. 6B).
Cells treated with S2T1-6OTD at 0.004 μmol/L were
able to grow better as compared with cells treated with
S2T1-6OTD at 0.04 μmol/L, but a decrease in cell
growth was also observed with the very low concentra-
tion. The morphologic examination of the 0.04 μmol/L
S2T1-6OTD–treated cells at the plateau phase showed
an increased proportion of flat and giant cells with phe-
notypic characteristics of senescence and positive for
senescence-associated β-galactosidase (data not shown).
Finally, the cells underwent delayed apoptosis when
examined morphologically (data not shown) and were
characterized by an increase in apoptotic cell death, as
measured by Cell Death Detection ELISA (Fig. 6C).
Discussion
In this study, we investigated the efficiency of S2T1-
6OTD to stabilize G-quadruplexes in guanine-rich DNA
and examined the strength of its selectivity for the c-Myc
over the telomeric sequences. We then examined the
S2T1-6OTD–mediated cellular effects in a representative
set of childhood MB and AT/RT cells.
We have shown here that S2T1-6OTD binds more se-
lectively with higher affinity to the G-quadruplex–form-
ing sequence in the major transcription control element in
the c-Myc promoter than to the telomeric DNA sequence.
This high-affinity physical interaction was established by
the results obtained from the PCR-stop assay, which
showed that a 35-fold higher concentration of S2T1-
6OTD is needed to stabilize a G-quadruplex structure
in ss-Telo24 compared with ss-Pu22 sequence. This result
was further confirmed by the CD spectroscopy experi-
ments, which showed that the G-quadruplex structure
stabilization by S2T1-6OTD in the c-Myc promoter toler-
ated a higher thermal melting point compared with the
telomeric DNA sequence.
The preference of a compound for quadruplexes over
duplex DNA is of great importance. This is because indis-
criminate binding to a duplex DNA can result in a signif-
icant loss of the compound and might lead to unexpected
cytotoxicity. Our results illustrated that S2T1-6OTD is un-
able to bind DNA duplexes, as shown by the absence of
any changes in the thermal melting curve in the presence
of S2T1-6OTD, compared with Tm of naked duplex DNA,
rendering it suitable for further studies as a highly selec-
tive G-quadruplex–interacting molecule.
Through its ability to recognize and stabilize the quadru-
plex structure in the c-Mycpromoter sequence, S2T1-6OTD
was able to suppress both c-Myc mRNA and protein ex-
pression and reduce c-Myc activity in MB and AT/RT cell
lines after 72-hour incubation; however, the ability to re-
press c-Myc expression was found to be cell type specific.
Interestingly, whenwe treatedMBDAOYM2 cells overex-
pressing c-Myc under a different promoter, S2T1-6OTD
failed to downregulate c-Myc, indicating specific affinity
to the transcriptional control element sequence NHE III1
in the c-Myc promoter. In agreement with this was our
finding that S2T1-6OTD had no effect on c-Myc expression
in Burkitt's lymphoma cell line CA46 with the deleted
NHE III1 element due to its chromosomal aberration.
These results therefore provided convincing evidence that
the effect of S2T1-6OTD on c-Myc is indeed mediated
through the interaction with the c-Myc promoter and fur-
ther implicated effects on c-Myc–dependent downstream
pathways. However, it has to be said that mechanisms reg-
ulating c-Myc transcription are multifaceted and involve
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Figure 6. Effects of long-term treatments
with nontoxic concentrations of S2T1-6OTD.
Every 5 d, the cells were trypsinized and
living cells were reseeded at the same
number. A, effect of 0.04 μmol/L S2T1-6OTD
on telomere length as determined by the
TeloTAGGG Telomere Length Assay. All cell
lines tested showed time-dependent
telomere shortening. B, effect of 0.04 or
0.004 μmol/L S2T1-6OTD on cell growth as
determined by MTS assay. All cell lines
tested showed time-dependent decrease in
cell growth. C, apoptotic cell death was
quantified using Cell Death Detection ELISA
measuring DNA fragmentation in S2T1-
6OTD–treated cells (0.04 μmol/L, for 5 wk).
Columns, mean absorbance of cytoplasmic
histone-associated DNA fragments (n = 3;
representative of two independent
experiments); bars, SD. **, P < 0.005;
***, P < 0.001.
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not only the regulatory DNA sequence in c-Myc promoter
but also several DNA binding proteins that have been
shown to preferentially bind to, stabilize, unwind, or
cleave the c-Myc G-quadruplex structure (66–68). In addi-
tion, recent reports have shown that putative G-quadru-
plex sequences are widespread in >40% of human gene
promoters (66, 67). Hence, it could be speculated that
any mutation in the regulatory motifs, differences in
DNA binding protein expression patterns, or off-target li-
gand interactionmight be critical for the sensitivity toward
G-quadruplex–based c-Myc inhibitor, such as S2T1-6OTD,
in some cell lines, and their effect might present a different
profile of biological activity than initially expected.
Based on previously published work, it is well estab-
lished that the suppression of c-Myc expression is closely
linked to the specific arrest in the G0-G1 cell cycle phase
(69–72) and downregulation of c-Myc inhibits both cyclins
and CDK2 expression in rhabdomyosarcoma (73), in
T lymphocytes (74), and in colorectal cancer cells (75).
Our results show that under the conditions where inhibi-
tion of both proliferation and c-Myc activitywas observed,
S2T1-6OTD treatment resulted in a decrease in the protein
expression of the cell cycle activator CDK2 and in a clear
G0-G1 cell cycle arrest in all brain tumor cell lines tested
and decreased the percentage of the cells that were able
to enter the S phase. This providedadditional evidence that
c-Mycmust be a direct target for S2T1-6OTD action. How-
ever, it is noteworthy that S2T1-6OTD was able to induce
cell cycle arrest despite no measurable decrease in the
mRNA/protein level of c-Mycwasobserved inDAOYcells
after 72-hour treatment. These results suggest that inhibi-
tion of c-Myc expression by S2T1-6OTDmay not be the on-
ly mechanism explaining the G0-G1 arrest of the cell cycle
and the cell growth inhibition, but the expression level of
other oncogenes may be affected with an effect on down-
stream signaling pathways governing cell proliferation.
Many experimental lines of evidence from different
groups have shown the association of c-Myc and cell pro-
liferation (69, 76). We therefore expected that S2T1-6OTD
treatments would induce a c-Myc–dependent cell growth
arrest. Indeed, short-term treatments with S2T1-6OTD in-
duced a dose- and time-dependent negative effect on cell
viability of all the MB- and AT/RT-derived cell lines test-
ed already at concentrations lower than 1 μmol/L. Of
considerable interest was the finding that S2T1-6OTD
showed a significantly lower antiproliferative effect
when applied to normal human fibroblast cells MRC-5
(77). Ideally, a c-Myc–targeted therapy should be active
on cells with deregulated c-Myc and should not affect
the majority of the normal cells in vivo. Here, we showed
a more prominent effect of S2T1-6OTD on cellular
growth of MB- and AT/RT-derived cells compared with
its weaker effects on normal cells, which would be sup-
portive of a selective activity on neoplastic cells.
Treatment with S2T1-6OTD resulted not only in c-Myc
downregulation but also in a decrease in hTERT mRNA
and reduction of telomerase activity in most of the cell
lines tested. This is of particular interest considering that
the catalytic subunit of telomerase hTERT is transcrip-
tionally regulated by c-Myc (27, 78) and that activation
or repression of c-Myc can alter hTERT activity in nor-
mal or tumor cells both in vitro and in vivo (22, 28,
79–82). However, on the other hand, our finding that
S2T1-6OTD binds more potently to the c-Myc promoter
sequence did not exclude a weaker binding to telomeric
DNA (with 35-fold less efficiency). Together with our
discovery that S2T1-6OTD exerted a direct inhibitory ef-
fect on TRAP activity in a cell-free system, this result
suggests a possible direct inhibition of the telomerase
enzyme by S2T1-6OTD and could provide an explana-
tion for the differences between the levels of c-Myc activ-
ity inhibition and the degree of hTERT activity reduction
we observed in Fig. 4. Nevertheless, one should remember
that S2T1-6OTD showed a dose- and time-dependent
antiproliferative effect on the telomerase-negative human
foreskin fibroblast cells (BJ) and on the ALT-dependent
D425 while having no antiproliferative effect on c-Myc
knockout (−/−) HO15.19 rat fibroblast cells or PC12
cells, which do not depend on c-Myc in their proliferation.
Together, these data confirm that a functional c-Myc
pathway, and not telomerase, is needed for S2T1-6OTD
to exert its antiproliferative effect. This observation coun-
ters the concern about the specificity of S2T1-6OTD
toward c-Myc and reveals that it is c-Myc inhibition
rather than telomerase downregulation that is responsi-
ble for the proliferation arrest exerted by S2T1-6OTD in
our experiments.
To extend our findings beyond the outcome of 72-hour
treatment, we studied the effects of long-term treatment of
MB andAT/RTcellswith nontoxic concentrations of S2T1-
6OTD, compatible with long-term drug dosage, and ob-
served the effect of telomerase inhibition on the children's
brain cancer cells. The desired effect of telomerase inhibi-
tionwould be to shorten telomeres to critical lengths, caus-
ing replicative senescence and preferably cell death. The
data obtained from our experiments showed that pro-
longed treatment did indeed result in a time-dependent
telomere shortening that was preceded by a decrease in
telomerase activity and accompanied by cell growth arrest
and senescence-associated morphologic changes in MB
and AT/RT cells, which also showed positive expression
of senescence-associated markers. This finding was fol-
lowed by apoptosis at day 35 in all cells treated.
In conclusion, we have shown the preferential recogni-
tion of the G-rich sequence in the c-Myc promoter over
the telomere sequence by a novel small-molecule S2T1-
6OTD. Through its ability to recognize and stabilize a
G-quadruplex structure in the c-Myc promoter sequence,
S2T1-6OTD was able to inhibit c-Myc and decrease telo-
merase activities, to disrupt telomere maintenance, to
force cells into senescence, and to induce growth arrest
and apoptosis in childhood brain tumor cell lines. A bet-
ter knowledge about the in vivo pharmacokinetics and ef-
ficacy of S2T1-6OTD is mandatory. However, S2T1-6OTD
may well represent a potential effective and innovative
therapeutic strategy for childhood brain tumors.
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Conclusions 
Targeting MYC and its target genes as therapeutic strategy 
MYC and its target genes have become attractive targets for cancer therapy, also due to 
MYC’s correlation with poor prognosis and high-grade malignancy in different types of adult 
and pediatric tumors [37, 216-219]. Many attempts have been made so far to target MYC at 
different biological levels (discussed in appendix section, Review 1). Down-regulation of 
MYC may be achieved already at the transcriptional level, by either preventing the activation 
of the promoter [220] or destabilizing the specific transcript by antisense strategies. Small 
interference RNA (siRNA) molecules gave remarkable results in different tumor models, 
both in vitro and in vivo, and by this approach, MYC depletion led to a decrease of cell 
proliferation and inhibition of colony formation in soft agar assays, as well as a reduction in 
tumor growth in nude mice [221]. 
Although different therapeutic approaches have been evaluated to target MYC in various 
malignancies, such as MB [105, 216], direct pharmacological targeting of transcription 
factors has proven difficult. Moreover, designing MYC-selective therapeutic strategies must 
take into account the complexity of downstream signaling pathways, directly or indirectly 
depending on MYC, which can eventually lead to cellular responses with opposite effects. In 
fact, inhibiting MYC could affect its pro-apoptotic functions, which would be sensible to 
preserve in the context of anti-cancer therapies. 
One of the major goals of our research was to investigate novel strategies to target the 
oncogene MYC and/or its target genes (cellular effectors) in the context of MYC-
overexpressing ET and, in particular, in MB. 
 
Quassinoids and NBT-272 
While searching for molecules potentially useful as MYC inhibitors, we studied a group of 
compounds called quassinoids, historically known in folk medicine for their wide spectrum 
of activities (discussed in appendix section, Review 2). Quassinoids are heterogeneous 
molecules isolated from plants belonging to the Simaroubaceae family. Many members of 
this family are able to target the multiple signaling pathways and cellular processes that are 
necessary for a cancer cell to live. Together with cytotoxicity, protein synthesis inhibition, 
and induction of apoptosis, the capacity to down-regulate the oncogene MYC is a common 
feature among a subset of quassinoids [8, 16, 25, 27, 45]. We focused our research on a 
lipophilic semi-synthetic quassinoid analog named NBT-272. This compound showed the 
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ability to inhibit cellular proliferation of a variety of cancer cell lines and to trigger down-
regulation of the MYC oncogene [222, 223]. The effects of NBT-272 have been investigated 
on different types of tumors where MYC plays an important role. In particular, it 
demonstrated a highly potent anti-proliferative effect when tested on in vitro models of NB 
and MB. Interestingly, cells with MYC amplification or over-expression appeared to be more 
sensitive and prone to apoptosis upon treatment. However, all cell lines tested were strongly 
affected, suggesting that MYC expression is not the only factor regulating cellular sensitivity 
to NBT-272 [222]. 
We deeply investigated the wide range of biological activities exerted by the quassinoid 
derivative NBT-272 on a panel of ET cell lines (discussed in result section, manuscript 2). 
Indeed, we were able to show that NBT-272 induces in vitro a complex pattern of cellular 
responses functionally related to interference with key cell survival pathways playing a role 
in the pathogenesis of several ETs (e.g., Akt/mTOR and Mek/Erk). Furthermore, by testing 
the compound in a xenograft model of human NB, we could confirm also in vivo that NBT-
272 triggers down-regulation of the expression levels of MYC and reduction of the activation 
levels of Erk, causing an arrest of tumor growth. 
In the search for an association between toxicity of NBT-272 and MYC expression levels 
in different ET cell lines, no significant correlation could be found. This observation led us to 
question any direct effect of NBT-272 on the oncogene, which would more likely be the 
result of different mechanisms, such as interference with protein synthesis and stability, also 
affecting the MYC family members, which are known to have short half-lives [224]. Indeed, 
we could observe that inhibition of the proteasome-dependent protein degradation pathway 
restored the depleting effect of NBT-272 and almost completely stabilized MYC. Moreover, 
depletion of MYC protein was associated with cell-cycle arrest and occurred via an indirect 
mechanism involving inhibition of two pro-proliferative pathways, i.e., the AKT and 
MEK/extracellular signal-regulated kinase (ERK) pathways. These two pathways converge to 
regulate the activation status of eIF4E and 4E-BP1, both dephosphorylated (i.e., inactive) in 
the presence of NBT-272, thus leading us to speculate that targeting these pathways would 
prevent full activation of the cap-dependent protein translation machinery. 
Moreover, the effect induced by two specific MYC/MAX inhibitors [225, 226] and by 
MYC silencing in ET cells did not match the cellular response to NBT-272, again detrimental 
to the hypothesis of a direct effect on MYC. However, this conclusion does not exclude that 
MYC inhibition contributed to the cellular responses caused by NBT-272 treatment. 
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Our findings increase the present level of understanding of the mechanisms of action as anti-
tumor agents of the quassinoids, and in particular of the lipophilic derivative NBT-272. 
However, the broad spectrum of biological effects exerted by the quassinoid compounds 
highlights a need for more accurate and systematic screening of these molecules as well as 
for a rational drug design-based study to identify leads for the synthesis or semi-synthesis of 
new analogs with increased activity, decreased toxicity and/or improved pharmacological 
profiles for the development of future cancer therapeutics. 
 
Disabling MYC by a G-quadruplex interactive agent 
Our research investigation focused on a different approach for targeting MYC acting through 
the stabilization of the quadruplex structure in the promoter sequence of the oncogene by the 
compound S2T1-6OTD (discussed in result section, manuscript 3). S2T1-6OTD is a 
molecule able to suppress both mRNA and protein expression of MYC. We examined the 
efficiency of this compound to stabilize G-quadruplexes in guanine-rich DNA and the 
strength of its selectivity for MYC over the telomeric sequences. 
Moreover, we studied the S2T1-6OTD-mediated cellular effects in a representative set of 
childhood MB and atypical teratoid/rhabdoid tumor (AT/RT) cells. S2T1-6OTD induced a 
dose- and time-dependent negative effect on cell viability of all tumor cell lines tested and it 
reduced the activity of MYC in a cell-type specific manner. Recent reports have shown that 
putative G-quadruplex sequences are widespread in >40% of human gene promoters (66, 67). 
Hence, it could be speculated that any mutation in regulatory motifs, differences in DNA-
binding protein expression patterns, or off-target ligand interaction might be critical for 
sensitivity to G-quadruplex-based MYC inhibitors, such as S2T1-6OTD, in some cell lines. 
Furthermore, their effect might present a different profile of biological activity than initially 
expected. 
Our results show that in parallel to the inhibition of both proliferation and MYC activity, 
S2T1-6OTD treatment provoked a decrease in the protein expression of the cell-cycle 
activator CDK2 and a G0-G1 cell-cycle arrest in all brain tumor cell lines tested. This 
provided additional evidence that MYC must be a direct target for S2T1-6OTD action. 
However, it is noteworthy that S2T1-6OTD was able to induce cell-cycle arrest despite no 
measurable decrease in the mRNA/protein level of MYC was observed. These results suggest 
that inhibition of the oncogene expression may not be the only mechanism explaining the G0-
G1 cell-cycle arrest and cell growth inhibition. 
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Moreover, through its ability to recognize and stabilize a G-quadruplex structure in the 
promoter sequence of MYC, S2T1-6OTD was also able to decrease telomerase activities, to 
disrupt telomere maintenance, to force cells into senescence, and to induce growth arrest and 
apoptosis in childhood brain tumor cell lines. Thus, S2T1-6OTD may represent a potential 
effective and innovative therapeutic strategy for childhood brain tumors. However, better 
knowledge of in vivo pharmacokinetics and efficacy of this compound is still needed. 
 
MYC target genes candidates in MB 
There is growing evidence that a subset of MB tumors derives from an aberrant development 
of GNP cells triggered and sustained by a deregulated expression of the cellular pathways 
physiologically active during embryogenesis. Although MYC does not represent a pathway 
“per se”, the oncogene is a central mediator of virtually all the pathways known to take part 
in cerebellum development and found altered in MB, including the BMP/SMAD pathway. 
Better knowledge of the MYC effector genes involved in MB neoplastic transformation is of 
great relevance in order to find novel and suitable therapeutic strategies. We defined a list of 
candidate MYC target genes with potential roles in MB onset and/or progression. Our 
instrumental approach to investigate MYC-regulated genes consisted of using a model of 
MB-derived cells and profiling them by cDNA microarray upon genetic manipulation aiming 
at either overexpressing [37] or down-regulating MYC. The resulting sets of differentially 
expressed genes were then intersected to narrow down the great amount of data generated and 
to finally define a group of MYC-responsive genes. The list of 209 candidates comprises 105 
genes up-regulated and 104 genes down-regulated by MYC overexpression, and consistently 
following the levels of the oncogene upon MYC silencing. These genes included known direct 
targets such as CCND2 [112] and TERT [227]. In fact, over-expression of MYC increased the 
CCND2 level by 3.1- and 2.3-fold in DAOY M2.1 and M14 cells, respectively, whereas MYC 
silencing repressed the same gene by 8.4-fold. In contrast, a gene that is known to be 
negatively regulated by MYC, inhibin-beta A (INHBA), was significantly downregulated in 
DAOY M2.1 and DAOY M14 cells (3.8- and 3.7-fold change, respectively) and upregulated 
upon MYC silencing (3.9-fold change). 
Novel candidate target genes of potential interest have been evaluated. In particular, gene 
ontology analysis led us to identify components of pathways which were already known to 
play a role in the onset and progression of MB but had not been correlated with MYC and 
which may play a relevant role in MYC-driven cellular responses (discussed in result section, 
manuscript 1). 
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BMP7 is a MYC target with pro-survival functions in MB 
The gene expression analysis we performed brought to our attention components of the BMP 
pathway that are responsive to MYC modulation in MB cells (discussed in result section, 
manuscript 1). In particular, a general increase in the mRNA expression levels of BMP 
ligands (BMP2, 6, 7) in DAOY M2.1 cells hinted at MYC-dependent activation. Many 
subtypes of BMP receptors (BMPR) type I-II were also represented. However, only few of 
them could be correlated in expression with MYC in our cellular models. Similar to the 
majority of BMPs, the mRNA level of glypican-3 (GPC3), a soluble inhibitor of BMPs [228, 
229], increased with MYC up-regulation, and it may be responsible for a negative-feedback 
loop on the pathway. Our microarray data did not show significant alteration of members of 
the SMAD family of transcription factors or of the SMAD target genes inhibitors of 
differentiation (ID) [230]. This observation would imply the involvement of alternative 
downstream effectors, which are yet to be fully characterized. 
Among the BMP members modulated by MYC, BMP7 was the only one presenting 
consistently induced/repressed high fold-change values along with MYC up-/down-
regulation, respectively. 
In this context, recent evidences suggest that BMP7 contributes to determining a correct 
temporal regulation and spatial organization of cerebellar progenitor cells during 
development [40, 69]. Along with this role, deregulated BMP7 expression in the cerebellum 
is very likely to trigger abnormal cell development and tumorigenesis. 
Our investigation shows for the first time the existence of a functional link between MYC 
over-expression and abnormal BMP pathway regulation in a model of MB. 
That BMP7 is a direct target of MYC was previously reported by Zeller et al. [113], who 
performed a global mapping of MYC-binding genomic regions in a model of human B 
lymphoid tumor. BMP4, another BMP family member, was described to be a target of MYC 
in blood cells [231]. However, these reports represent the only experimental evidence, to our 
knowledge, of a transcriptional control of the BMP pathway by the MYC oncoprotein. More 
specifically, no previous studies have mentioned MYC-driven regulation of this pathway as a 
significant molecular network in MB. We proved that BMP7 is a direct MYC target showing 
the binding of MYC to the promoter of BMP7 by ChIP-on-chip analysis in different MB cell 
lines. 
Furthermore, BMP7 was analyzed by IHC in primary MB samples. Strikingly, BMP7 was 
not expressed in normal cerebellum, indicating that BMP7 over-expression in MB may 
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contribute to the increased proliferation and survival of tumor cells. Moreover, we found a 
significant correlation between the gene expression of MYC and BMP7 in two distinct 
datasets of MB patient samples. 
The functional relevance of the BMP-dependent signaling pathway in MB was evaluated by 
targeting the BMP pathway via specific siRNA-mediated silencing of BMP7 expression and 
employing a small-molecule inhibitor (Dorsomorphin) able to prevent the activation of 
SMAD1/5/8 by interfering with the kinase activity of the receptors BMPR-I/II [232, 233]. 
Conversely, DM has no, or very limited, effect on other components of the TGF-β family 
(e.g., TGF-β1 and activin A) [233]. DM strongly impaired cell proliferation and viability, and 
interestingly, cells expressing a single copy, or low levels, of MYC were significantly less 
sensitive to DM than cells overexpressing the oncogene, indicating that the compound can 
affect a MYC-driven pro-survival response. Similarly, the silencing of BMP7 alone induced 
cell death and inhibition of cell viability, even though it had a less prominent effect compared 
to the toxicity of DM. This observation is reasonable because the compound can block the 
pathway more efficiently by acting on more components than single siRNAs. 
Therefore, our results show the feasibility and potential benefit of selectively blocking the 
BMP/SMAD pathway by either gene silencing or small-molecule inhibitors – strategies that 
were investigated here for the first time in MB cells. A therapeutic approach preventing 
deregulated activation of this pathway in MB would certainly represent one additional 
attractive strategy to be considered, together with the interference of SHH and WNT 
pathways, for which therapeutic targets have been already described [234-237]. However, as 
a novel therapeutic approach for pediatric malignancies, this strategy should be carefully 
evaluated for its efficacy and safety. Additional investigations about the other members of the 
BMP family with potential roles in MB are needed, since the available studies are often 
controversial (i.e., treatment of MB cells with BMP2 and BMP4 showed either attenuation of 
intrinsic apoptotic mechanisms and increase in cell count [214] or inhibition of proliferation 
[215]). 
In conclusion, our results provide evidence of the induction of BMP7 as a MYC-dependent 
mechanism and indicate this growth factor as a direct target of MYC and a potential effector 
protein during MYC-driven neoplastic transformation of MB precursor cells. This new 
information not only contributes to a better understanding of the pro-survival functions of 
MYC during MB development, but it also suggests a rationale for targeting BMP pathways as 
a therapeutic intervention strategy for MB patients with MYC amplification/overexpression. 
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An extensive in vivo analysis is required to significantly demonstrate the correlation between 
MYC and BMP7 and to have a better insight about their actual roles in MB tumorigenicity. 
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Abstract: Myc family genes are often deregulated in embryonal tumors of childhood including medulloblastoma and neu-
roblastoma and are frequently associated with aggressive, poorly differentiated tumors. The Myc protein is a transcription 
factor that regulates a variety of cellular processes including cell growth and proliferation, cell cycle progression, tran-
scription, differentiation, apoptosis, and cell motility. Potential strategies that either inhibit the proliferation-promoting ef-
fect of Myc and/or activate its pro-apoptotic function are presently being explored. In this review, we will give an over-
view of Myc activation in embryonal tumors and discuss current strategies aimed at targeting Myc for cancer treatment.  
Keywords: Cancer, child, brain tumor, neuroblastoma, targeted therapies, Myc. 
INTRODUCTION  
Embryonal Tumors of the Central and Peripheral Nerv-
ous System 
Embryonal tumors of the central and peripheral nervous 
system including medulloblastoma (MB), atypical tera-
toid/rhabdoid tumors (AT/RT), and neuroblastoma (NB) 
occur most commonly in the first few years of life and ac-
count for approximately 20% of childhood malignancies [1]. 
This broad group of childhood tumors originates from imma-
ture tissue as a result of the aberrant proliferation of early 
precursor cells and their morphological appearance resem-
bles that of tissues in the developing embryo and fetus [2, 3]. 
Tumors of the central nervous system have been repetitively 
re-classified by the World Health Organization (WHO) [4, 
5], along with the acquisition of further knowledge about 
their biology. One of the biggest controversies was how to 
describe the four MB variants, discriminating them from 
other types of primitive neuroectodermal tumors (PNET) [6-
8]. The continuous nomenclature changes also reflect the 
improved understanding of the signaling pathways and mo-
lecular processes involved in tumorigenesis at different lev-
els (i.e. genetic, transcriptional, and protein level), leading to 
definite steps forward towards a more accurate patients 
stratification and the development of novel therapeutic 
strategies.  
During embryonal development, tissue growth and dif-
ferentiation are regulated by complex cellular processes that 
involve precise control of both cell division and apoptosis. 
Defects in any of the pathways controlling these events can 
promote transformation, making these developing cells par-
ticularly prone to tumorigenesis [9]. Since its identification 
as the cellular homologue of the avian myelocytomatosis 
virus oncogene (v-myc), the human myc family of genes (c-
myc, MYCN, L-myc) has emerged as a critical regulator of 
embryonal cell growth and one of the most frequently altered 
in cancer [10-13].  
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Myc in Normal and Cancer Cells 
Myc is broadly expressed during mammalian develop-
ment and is detectable at the RNA level in various embryo-
nal tissues [14, 15]. In mouse, the expression of the myc 
genes is differentially regulated during embryogenesis, with 
tissue- and cell-specific patterns of expression unique to 
MYCN as compared to the related c-myc gene [16]. In par-
ticular, MYCN shows the highest mRNA expression in em-
bryonal brain, kidney, and lung [17, 18], whereas c-myc lev-
els are comparatively constant in these organs throughout 
development [19, 20]. Knockout of either of these two myc 
genes resulted to be lethal. The mouse embryos died in the 
earliest developmental phases [21-23], confirming the essen-
tial role of the proto-oncogene in the proliferation control 
during mammalian embryogenesis. On the other hand how-
ever, the other family member L-myc seems to be dispensa-
ble, since L-myc -/- mouse embryos were fully viable and 
had a normal appearance [24]. 
Myc proteins are transcription factors with a basic-helix-
loop-helix-leucine zipper (B-HLH-LZ) motif, responsible for 
binding to DNA and for dimerization with the partner pro-
tein Max, following upstream activating signals [25]. 
Myc/Max heterodimers can bind to the consensus sequence 
CACGTG of E-box promoter elements and recruit elongation 
factors, ATPases, histone acetyltransferases, and the E3 
ubiquitin ligase Skp2, in order to promote gene transcription 
[26]. Alternatively, gene expression can also be repressed by 
the involvement of additional Myc-interacting factors, such 
as Miz1 [26], Sp1 [27], and YY1 [28]. Many Myc target 
genes have been already identified by using different ex-
perimental approaches, including cDNA microarray analysis 
and chromatin immunoprecipitation [25, 29-33]. These stud-
ies revealed that Myc is a multifunctional transcription fac-
tor, determining the expression of a large number of down-
stream target genes that are the actual effectors of the diverse 
Myc-dependent cellular responses. The same cellular func-
tions can be deregulated during tumorigenesis and play a 
role in cancer development: cell cycle progression [34-37], 
cell proliferation [26, 38-40], apoptosis [41-45], immortali-
zation [46, 47], angiogenesis [22, 48], and cellular differen-
tiation [49, 50].  
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In quiescent adult cells, Myc is almost undetectable [51]. 
Activation of Myc can be driven by growth factors, mito-
gens, and other transcription factors like -catenin, enhanc-
ing the transcription rate of the myc gene [52]. Alternatively, 
Myc expression can be suppressed by transforming growth 
factor- (TGF-) and by an auto-regulatory mechanism [53, 
54]. Upon mitogenic stimulation, the mRNA and protein 
levels of Myc increase rapidly and determine the beginning 
of the G1 phase of the cell cycle. This event is transient and 
followed by a gradual decline of Myc expression to low, but 
still detectable, steady-state levels in proliferating cells [51, 
55, 56]. 
In contrast to the strictly regulated expression of the myc 
genes during normal cellular proliferation, cancer cells may 
activate myc in an uncontrolled fashion, as a result of genetic 
aberrations, therefore no longer requiring exogenous stimuli 
from the microenvironment to proliferate [57]. Myc can be 
abnormally activated by gene amplification [12, 58, 59], 
chromosomal translocation and DNA rearrangement [60-62], 
upregulation of transcription [52], and point mutation [63, 
64], all leading to a constitutive overexpression of the onco-
gene. Sustained high levels of Myc seem to be required for 
cell survival and acquisition of a malignant phenotype by 
cells of different origin, e.g. hematopoietic cells [65], mam-
mary glands [66], hepatic [67] and epithelial cells [68], as 
well as pancreatic islets [69]. However, besides the Burkitt’s 
lymphoma [70] and the myeloid and plasma cell leukemia 
[71], deregulation of Myc represents a malignant signature 
for many more types of cancer, such as breast carcinoma [72, 
73], ovarian carcinoma [74, 75], colon carcinoma [76], small 
cell lung carcinoma [77], and neuroectodermal tumors [2, 3]. 
In many of these neoplasias the overexpression of Myc has 
been associated with tumor aggressiveness and low cellular 
differentiation, although the molecular mechanisms underly-
ing Myc-induced tumorigenesis are not completely under-
stood yet [78].  
Transgenic Mouse Models 
The ability of Myc to transform cells in vitro and to pro-
mote cell proliferation and arrest of cellular differentiation 
represent strong evidences supporting the role of Myc in 
tumorigenesis [79]. Additionally, the development of trans-
genic animals with inducible and tunable expression of the 
oncogene further proved the transforming potential of Myc 
in vivo. Transgenic mice expressing MYCN under the control 
of the rat tyrosine hydroxylase (TH) promoter [80] have 
been proven to be a good model of NB, because of tumor 
formation in peripheral neural crest-derived structures show-
ing histological features that resemble the human disease 
[80, 81].  
B-cell lymphoma was induced in a different mouse 
model by overexpressing c-myc under the control of the im-
munoglobulin heavy chain enhancer (Eμ) [82], unrevealing 
important c-Myc-mediated mechanisms of tumorigenesis 
that involve downstream regulators of apoptosis. The authors 
showed that Myc overexpression in Eμ-myc mice (model for 
the human non-Hodgkin’s lymphoma) selects for loss of 
p19(ARF) and/or p53 function and therefore inactivates the 
ARF-MDM2-p53 pro-apoptotic pathway in vivo [82]. Alter-
natively, the anti-apoptotic proteins Bcl-2 and Bcl-XL can be 
overexpressed as a result of Myc upregulation, representing 
an additional distinct mechanism of resistance to apoptosis 
triggered by the oncogene [83, 84]. The same mouse model 
also allowed further studies on the effect of upregulation of 
MDM2 in B cells. It has been shown that MDM2 can medi-
ate genomic instability and prevent p53-dependent apoptosis 
[85, 86], suggesting MDM2 as a tumor target. 
Taken together, the clinical and experimental observa-
tions collected so far warrant further efforts aimed at better 
understanding the biological role of Myc in tumorigenesis 
with the perspective of developing effective Myc-targeted 
therapeutic strategies for cancer treatment [87-89]. The ulti-
mate goal is the development of more efficacious and less 
toxic treatment schedules, used alone or combined with con-
ventional cytotoxic drugs. 
TARGETING MYC FOR CANCER THERAPY 
Due to the great variety of genes and cellular responses 
under the control of Myc, targeting Myc itself will eventu-
ally influence many downstream regulatory pathways, cru-
cial in both the induction and progression of cancer. Wang et 
al. recently showed that a sustain expression of c-Myc is 
required in a large number of tumor cell lines to maintain 
proliferation and that c-Myc depletion negatively affects cell 
survival by inducing arrest of the cell cycle at various stages 
[90]. Further evidence supporting the potential benefits of 
targeting Myc came from the work of Felsher et al., who 
used a tetracycline-regulated system to modulate Myc levels 
in hematopoietic cells of transgenic mice [65]. Suppression 
of Myc induced tumor regression associated with a rapid 
proliferative arrest, differentiation and apoptosis of tumor 
cells, therefore indicating that the functional rescue of even a 
single genetic lesion may be sufficient to reverse tumori-
genesis. Nevertheless, Myc can also activate apoptosis, a 
cellular response that would be rather preserved than lost in 
the context of therapeutic anti-tumor approaches [26, 91]. 
Jain et al. have addressed this issue using the same trans-
genic model mentioned above [65], where a fraction of ani-
mals developed osteogenic sarcomas expressing high levels 
of Myc and sharing some features with the human disease 
[92]. A brief inactivation of Myc was able to promote tumor 
regression and cellular differentiation into mature bone, 
while Myc re-expression resulted in activation of apoptosis 
instead of restoring cell proliferation [92]. This observation 
greatly supports the feasibility of Myc-targeting strategies, 
where a transient suppression of Myc may be sufficient to 
achieve a therapeutic effect. 
Many attempts have been made so far to target Myc at 
different biological levels, as schematically described in Fig. 
(1). Down-regulation of Myc may be achieved at the tran-
scriptional level, by either preventing the activation of the 
myc promoter [93] or destabilizing the myc-specific tran-
script by antisense strategies, which can be based on oli-
gonucleotides [94] or on the more stable peptide nucleic ac-
ids [95]. Although they are rather susceptible to degradation 
by nucleases, small interference RNA (siRNA) molecules 
gave remarkable results in different tumor models, both in 
vitro and in vivo. By this approach, c-Myc depletion led to a 
decrease in cell proliferation and to inhibition of colony for-
mation in soft agar assays, as well as a reduction in tumor 
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growth in nude mice [96]. Moreover, the silencing of Myc 
represents an experimental approach that is instrumental to 
the identification of new Myc target genes [97]. 
Interfering with Myc stability at the protein level, by 
stimulating the cytosolic proteasome-mediated degradation 
machinery, may represent a further strategy of intervention 
(Fig. (1)). A contribution in this direction has been provided 
by the identification of the ubiquitin-specific protease 
USP28, which stabilizes Myc in proliferating tumor cells 
[98]. This enzyme and other members of Myc-stabilizing 
complexes might be targeted in order to ultimately promote a 
more rapid turnover of the active form of Myc. Finally also, 
preventing the association of Myc to its partner Max would 
in turn affect the Myc-dependent regulation of transcription 
[99]. Antagonists of the Myc/Max dimerization represent a 
novel category of small-molecule Myc-specific inhibitors 
that are currently under investigation [100, 101]. 
Because of the multiple downstream signaling pathways 
directly or indirectly regulated by Myc, it is clear that target-
ing this oncogene represents a very powerful but, at the same 
time, a very complex strategy for therapeutic purposes. As 
mentioned already, Myc exhibits a dual function by promot-
ing both proliferation and apoptosis [26], also implying that 
apoptosis can be prevented, eventually, upon Myc inhibition. 
This aspect should always be taken into consideration during 
optimization of therapeutic protocols, in particular when 
different approaches are combined, such as Myc-inhibitory 
agents and chemotherapeutic drugs. In fact, some anti-tumor 
compounds (e.g. cisplatin) can induce apoptosis in a way 
dependent on Myc expression level [102], and tumor cells 
may become therefore drug resistant upon Myc down-
regulation [103].  
A better elucidation of the Myc-dependent mechanisms 
inducing programmed cell death (i.e. identification of apop-
tosis-related Myc target genes) will help developing more 
efficient clinical strategies. Concomitantly, other therapeutic 
targets (downstream of Myc) should be also considered, in 
order to selectively activate Myc-dependent pathways not 
influencing apoptosis or, alternatively, to functionally reacti-
vate pro-apoptotic signals. One relevant apoptotic pathway 
involves, for instance, the transcription factor MIZ-1 and the 
anti-apoptotic protein Bcl-2, whose encoding genes are both 
repressed by Myc [104]. A direct targeting of either of these 
genes would therefore rescue the pro-apoptotic functions of 
Myc also in a setup of Myc down-regulation [105].  
Some of the strategies mentioned here have been investi-
gated by in vitro and in vivo models of embryonal tumors, 
aiming at reducing the transforming potential of Myc. In the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Myc targeting at different levels. Either at the genetic level or at the protein level, Myc can be a suitable target to design new 
therapeutic strategies, aiming at eventually modulating Myc-dependent cellular events involved in tumorigenesis. Small interference RNA 
molecules, DNA-based oligonucleotides, and peptide nucleic acids represent diverse forms to deliver sequence-specific oligonucleotides, 
preventing translation or promoting degradation of myc-mRNA in the nucleus (1). In the cytosol, the protein can be destabilized or blocked 
by small-molecule inhibitors of different kind, usually chemically synthesized derivatives of natural toxic compounds (2). The stability of 
Myc can be also altered via indirect mechanisms, like by promoting the ubiquitin-dependent degradation of Myc (3). Moreover, the function-
ality of Myc can be affected by preventing the protein from interacting productively with the transcription partner Max, in the nucleus (4). 
Consequently, transcription not only of Myc target genes but also of myc itself, which is determined by auto-regulatory feedback mecha-
nisms, is impaired. In turn, the downstream cellular responses normally elicited (e.g. cell proliferation, differentiation, and apoptosis) can be 
very significantly altered. 
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next sections, we will review the existing data on the in-
volvement of Myc in the development of embryonal tumors 
of the central and peripheral nervous system, and on the 
main experimental studies currently on-going to selectively 
regulate Myc expression and function in these tumors. The 
major work so far has been done in NB, whereas only a few 
examples of translational research are available in the field 
of MB and AT/RT. 
Myc IN NEUROBLASTOMA 
Neuroblastoma (NB) is a tumor derived from primitive 
cells of the sympathetic nervous system and is the most 
common extra-cranial solid tumor in childhood [106]. The 
clinical outcome of NB can range from complete regression 
(mainly in infants) to rapid tumor progression and metastasis 
with poor prognosis [107]. Identification of the most com-
mon genomic alterations associated with the disease has al-
lowed the classification of NB into low-, intermediate- and 
high-risk groups [108, 109]. Unfavorable tumors are charac-
terized by deletions of 1p or 11q, unbalanced gain of 17q 
and/or amplification of MYCN [110]. Amplified MYCN has 
been proposed as an example of the first clinical application 
of cellular oncogenes, and is now established as a powerful 
molecular parameter to determine patient prognosis, as well 
as a basis for patient stratification [109, 111, 112] (Table 1). 
MYCN is localized at 2p23-24 [113] and it is found in 
double minutes (DM) and homogeneously staining chromo-
somal regions (HSR) when amplified [114]. MYCN can be 
amplified up to 50- or 100-fold, although duplications at 
2p24 were also found in NB, maybe as precursors of further 
amplification [115]. Amplified MYCN was shown to be sen-
sitive to differentiation-inducing signals (e.g. retinoic acid) 
that evoke a drastic decrease in the mRNA level of MYCN in 
NB cells [116]. This observation is in line with previous 
findings in undifferentiated neuroblasts that differentiate into 
ganglion cells by losing expression of MYCN [117]. 
The development of an effective therapy for NB has 
proved to be one of the major frustrations in pediatric oncol-
ogy [118]. Over time, the favorable outcome of patients with 
stage I and II disease was recognized and such children re-
ceived less treatment [118]. Those with stage III and IV were 
treated with increasingly aggressive regimens. The survival 
time improved a little, but not the survival rate. Until re-
cently, the survival of stage IV-patients over one year of age 
has remained only about 10%. The development of more 
effective and also less toxic therapeutic schedules is, there-
fore, of great importance. An overview of some of the ex-
perimental approaches aimed at selectively interfering with 
Myc or Myc-dependent pathways in NB will be given here 
(Table 2). Each study has put forward new interesting find-
ings of therapeutic relevance that have the potential to be 
further developed into clinical approaches. 
MYCN expression was silenced by using siRNA oligonu-
cleotides, alone or cloned into expression vectors, with the 
result of inducing differentiation and apoptosis in NB cells 
[119]. A decrease in MYCN mRNA level was also achieved 
upon treatment with retinoic acid, which concomitantly in-
duced neuronal differentiation and a reduction in cell prolif-
eration due to cell cycle arrest in G1 [120]. Synthetic deriva-
Table 1. Myc Expression and Clinical Outcome 
 
 Myc status Clinical outcome 
Amplification of MYCN  Poor prognosis [92-94] 
Rapid tumor progression [92-94] 
 Neuroblastoma 
High MYCN mRNA expression without gene amplification Uncertain prognostic significance [95, 96] 
Amplification of c-myc Poor prognosis, anaplasia [144, 154, 164] 
High c-Myc mRNA expression Poor prognosis [147, 158] 
 Medulloblastoma 
Low c-Myc mRNA expression Favorable-risk prognosis [147, 158] 
The change in expression of MYCN and c-myc are reported here in relation to the prognostic value, as emerged from the clinical data of neuroblastoma and medulloblastoma patients. 
Table 2. Myc Targeting 
 
 Level  Strategy Effect 
Small interfering RNA [103] Differentiation, apoptosis 
DNA antisense oligos [106] Differentiation, decrease in cell proliferation 
Peptide nucleic acids [107, 108] Decrease in cell proliferation, cell cycle (G1) arrest 
mRNA 
Retinoic acid/derivatives [104, 105] Cell growth and cell cycle (G1) arrest, differentiation 
 Neuroblastoma 
Protein  CR-UK compound collection [111] Inhibition of Myc transcriptional activity 
mRNA Small interfering RNA [167] Cell proliferation and cell cycle (S) arrest 
Quassinoid derivatives (NBT-272) [169] Cell proliferation, cell cycle (G1) arrest and apoptosis 
 Medulloblastoma 
Protein 
Resveratrol [167] Cell proliferation arrest, apoptosis 
The experimental strategies aiming at downregulating Myc in neuroblastoma and medulloblastoma are here summarized, divided into approaches targeting MYCN/c-myc at the 
mRNA or protein level.  
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tives of retinoic acid have also been screened for anti-
proliferative potential in NB. Ponthan et al. reported about 
one particular derivative inducing apoptosis in SK-N-BE(2) 
and SH-SY5Y cells [121]. In addition, MYCN-specific an-
tisense DNA oligonucleotides have been successfully tested 
for their capacity to decrease the proliferation rate and to 
induce cellular differentiation in the LAN-5 cell line [122]. 
The same antisense oligonucleotides were validated in a 
transgenic mouse model of human MYCN-induced NB, in 
which tumor incidence and progression could be decreased 
[122]. Another strategy employed the more stable peptide 
nucleic acids to target MYCN in NB cells with Myc overex-
pression. These molecules were used alone [123] or in com-
bination with a somatostatin analogue for a better cellular 
uptake in the IMR32 cell line, thus eliciting an inhibition of 
cell proliferation and/or arrest of the cell cycle in phase G1 
[124]. 
At a further biosynthetic level, proteins can also be tar-
geted, by affecting for instance protein stability and ulti-
mately preventing their function, such as the Myc transcrip-
tional activity on its downstream targets. Recently, it has 
been shown that the stability of MYCN depends on Akt 
phosphorylation and inhibition of glycogen synthase kinase-
3 (GSK3-) [125]. Inhibition of phosphoinositide 3-kinase 
(PI3K), upstream of Akt, led to a rapid decrease in MYCN 
protein levels, resulting in inhibition of tumor growth [125]. 
Inhibitors of PI3K, of Akt, and of GSK3 have been evalu-
ated for the development of clinical treatments of tumors 
bearing MYCN amplification [126]. Although possible side 
effects of inhibitors of the PI3K/Akt pathway include diabe-
tes, targeting specific PI3K isoforms was shown to be a fea-
sible approach in vivo [127, 128]. Another class of inhibitors 
was designed to block the activity of MYCN. As an exam-
ple, Lu et al. reported on a library of chemical compounds, 
screened by using a cell-based reporter gene assay [129]. 
Eight substances (out of 2800) induced a reduction in lu-
ciferase activity greater than 50% and were selected for fur-
ther investigation. 
Sarkar and Nuchtern evaluated the potential of MYCN in 
cell-mediated immunotherapy [130]. They designed a 
MYCN-derived peptide containing a binding motif for the 
HLA-A1 allele of the Major Histocompatibility Complex-
class I. Cytotoxic T lymphocytes responsive to this specific 
MYCN-epitope were able to selectively lyse NB cells from a 
HLA-A1-positive patient [130], suggesting that vaccine-
based strategies could represent one possible approach to 
treat MYCN-amplified NB, provided that further experimen-
tal evidences will be given.  
As an alternative to target MYCN itself, small-molecule 
inhibitors could be used against effector molecules down-
stream/upstream of Myc in Myc-related signaling pathways. 
The nucleoside analogue transcriptional inhibitor ARC has 
been recently identified and proposed as a pro-apoptotic 
compound, acting via a mechanism that involves the protein 
kinase Akt and triggers MYCN down-regulation [131]. 
Other signaling pathways have been also considered as 
therapeutic targets, such as the wingless (Wnt)/-catenin 
pathway. Its alteration in the pathological onset is responsi-
ble, at least in part, for deregulating Myc and altering the 
expression profile of other oncogenes in high-risk NB with 
no MYCN amplification [132].  
MDM2, a direct transcriptional target of MYCN and ac-
tivated in NB [133], has been reported as a necessary and 
sufficient mediator of MYCN-dependent centrosome ampli-
fication by exerting a central inhibitory effect on p53 [134]. 
To functionally inactivate MDM2, the small-molecule in-
hibitor of the MDM2-p53 interaction nutlin-3 [135] was 
used. Nutlin-3, in fact, has shown a therapeutic potential for 
treatment of NB with wild type p53, by selectively activating 
p53-dependent apoptosis and inducing a block of the cell 
cycle in NB cells, regardless of the activation status of 
MYCN [136].  
Not only conventional protein-coding genes may have an 
oncogenic function in NB, as well as in cancer development 
in general. MicroRNAs (miRNA) are non-translated RNA 
sequences that map to regions of genomic imbalance and can 
regulate the gene expression at a post-transcriptional level 
[137]. These molecules can either degrade or prevent the 
translation of a target mRNA, with consequences on gene 
expression. So far, two independent studies reported the dif-
ferential expression of miRNA in primary NB samples with 
favorable and unfavorable clinical outcome [138, 139]. Al-
though the predictive clinical value of miRNA expression 
was difficult to address, four miRNA sequences were identi-
fied in both studies to positively correlate with MYCN ampli-
fication. Recently, Schulte et al. [140] reviewed the in-
volvement of miRNA in the pathogenesis of NB, underlining 
the relevance of two miRNA clusters in particular, which 
have been identified as tumor suppressor (miR-34a) and as 
oncogene (miR-17-92), respectively. Whereas the miR-17-
92 cluster is a direct target of MYCN [139], the MYCN gene 
was found to be a target of miR-34a that induces cell cycle 
arrest and apoptosis [141, 142]. Even though investigating 
the role of miRNA in tumorigenesis is a relatively new field, 
the possibility to manipulate miRNA-mediated functions 
already represents a promising approach of anti-tumor gene 
therapy [137]. Inhibitors of miRNA have been administered 
in vivo [143, 144], and other chemically modified nucleic 
acids are predicted to be useful in the future to functionally 
replace tumor suppressor miRNA that are down-regulated in 
cancer.  
In summary, different approaches can be suggested as 
potential novel therapies for the treatment of NB. In particu-
lar, we have mentioned strategies that aim at targeting the 
oncogene MYCN, which is overexpressed in many NB tu-
mors with poor clinical outcome (Table 1). So far, MYCN 
has been targeted at both the mRNA and protein levels in 
preclinical studies (mainly in vitro), which lead to very inter-
esting preliminary findings and surely warrant further inves-
tigations in vivo (Table 2). 
Myc IN MEDULLOBLASTOMA  
Medulloblastoma (MB) is the most common malignant 
tumor of the central nervous system in childhood and repre-
sents more than 20% of all pediatric brain tumors [145]. MB 
is characterized by aggressive clinical behavior and high-risk 
of leptomeningeal dissemination. Most metastatic and recur-
rent MB tumors are resistant to current therapeutic ap-
proaches, including high-dose chemotherapy with autolo-
gous hematopoietic stem cell rescue [146-148]. It is there-
fore of particular relevance to achieve a better understanding 
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of the molecular basis of MB pathogenesis, also in the view 
of discovering new therapeutic targets. 
A better knowledge of the biology of MB has allowed the 
identification of some crucial signaling pathways involved in 
development and progression of MB. Sonic hedgehog (Shh) 
is a mitogenic glycoprotein secreted by cerebellar Purkinje 
cells, which provides a signal for the granule cell progenitor 
(GCP, the most abundant neuron in the cerebellum) to initi-
ate cell proliferation [149]. The Shh and the Wnt signaling 
pathways [150-152] were found to be implicated in MB de-
velopment [153-157], by inducing an upregulation of MYCN 
and consequently an increase of the cell proliferation rate 
[158-162]. High levels of MYCN in turn activate the cyclin 
D family (cell cycle-activators) and repress the expression of 
some cyclin-dependent kinase inhibitors eliciting the oppo-
site effect (cell cycle-inhibitors) [163]. Increased expression 
and stability of MYCN have a synergistic effect, together 
with the activation of the Shh signaling pathway, in the in-
duction of MB [164, 165]. 
Although the involvement of MYCN has come histori-
cally together with the first evidences of deregulation of sig-
naling pathways in MB, another gene of the Myc family, c-
Myc, has been found to be very relevant in the development 
of this pathology [166-176]. Both MYCN and c-Myc are 
amplified in 5 to 10% of MB patients [169, 177-180], with 
this rate increasing to 17% in the clinical subgroup of high-
risk patients [171, 181]. Amplification of the c-myc gene and 
high level of the c-Myc gene product have both been used as 
clinical indicators of poor prognosis [173, 174, 182, 183] 
(Table 1). Another complementary histopathological prog-
nostic factor is the large cell/anaplastic (LC/A) phenotype, 
indicative of a very aggressive clinical behavior and outcome 
[169, 175, 180, 181, 184-189]. In contrast, low expression of 
c-Myc, alone or in combination with high TrkC-mRNA lev-
els, has been proved to be strong predictors of a favorable 
outcome in MB [174, 190, 191]. 
Contrary to the substantial amount of preclinical studies 
in NB, the investigation of Myc-specific therapeutic ap-
proaches in MB is still in its infancy (Table 2). To date, there 
are only two in vitro studies published. Zhang et al. used an 
antisense approach to silence c-Myc [192], which led to an 
inhibition of cell proliferation and to an arrest of the cell 
cycle in the S phase. In the same report, it was also sug-
gested that Myc down-regulation is likely to represent the 
critical intermediate event responsible for the anti-
proliferative effect of resveratrol in MB cells [193]. Another 
compound, the synthetic quassinoid derivative NBT-272, is 
currently under investigation in our group, on the basis of 
previous findings obtained in a panel of MB-derived cell 
lines [194]. In this report, NBT-272 was able to reduce cell 
proliferation and to block cell cycle progression. Although 
still preliminary, these studies may open the way to the use 
of small-molecule inhibitors in the treatment of Myc-
overexpressing MB tumors. 
Myc IN RHABDOID TUMORS  
Rhabdoid tumors are rare but highly aggressive tumors 
that typically occur in infancy or early childhood [195, 196]. 
Rhabdoid tumors predominantly arise in the kidney and 
brain (atypical teratoid/rhabdoid tumors, AT/RT), but they 
can also be found in a deep axial location, such as the neck 
or the paraspinal region [197]. Different forms of rhabdoid 
tumors can be similar in their aggressiveness, histological 
features, and loss of function of INI1/hSNF5 mapping on 
chromosome 22 [198, 199]. From the clinical experience, 
infants and children with rhabdoid tumors respond very 
poorly to chemotherapy and radiotherapy [200-202], al-
though this remarkable resistance to both cytostatic drugs 
and radiotherapy has found no convincing explanation at the 
molecular level, to date. 
INI1/hSNF5, initially identified as a host protein interact-
ing with the human immunodeficiency virus type 1-integrase 
[203, 204], contributes to the functional core of the ATP-
dependent chromatin-remodeling SWI/SNF complex [205]. 
The components of this complex have been shown to play a 
role in both activation and repression of gene transcription. 
In particular, INI1/hSNF5 has been described as a tumor 
suppressor and its loss results in various aggressive cancers 
[206]. Point mutations or deletion of both copies of 
INI1/hSNF5 are observed in approximately 70% of primary 
AT/RT, whereas an additional 20-25% of tumors have a re-
duced expression of INI1/hSNF5 at either the mRNA or pro-
tein level [207]. 
Ectopic expression of INI1/hSNF5 leads to cell cycle ar-
rest in G1 and consequently prevents cell entry into phase S. 
This event is associated to down-regulation of a subset of 
E2F target genes, including cyclin A, E2F1 and CDC6 [208]. 
Notably, some genes of the E2F and cyclin family have also 
been identified as c-Myc targets [209]. Similarly to the other 
embryonal tumor entities discussed above, c-Myc is often 
up-regulated in rhabdoid tumors [210-213], even though no 
solid evidence of correlation with clinical parameters has 
been defined at present. 
By using the yeast two-hybrid system approach [49, 
214], c-Myc was identified as a component of the SWI/SNF 
macromolecular complex and as an interacting partner of 
INI1 [206]. The DNA-binding B-HLH-LZ motif at the 
COOH-terminus of Myc is responsible for recognition and 
binding to the conserved repeat-1 region of INI1. This inter-
action seems to have not only a structural, but also a func-
tional relevance [206], by mediating the recruitment of the 
chromatin-remodeling complex SWI/SNF to the E-box of 
genes that are repressed upon chromatin condensation [215, 
216]. The same SWI/SNF complex, however, can also acti-
vate transcription of c-Myc target genes that are involved in 
apoptosis [206, 217]. This evidence would therefore support 
the existence of a common SWI/SNF-dependent mechanism 
of chromatin remodeling, able to regulate both repression of 
pro-survival genes and activation of pro-apoptotic genes, 
eventually eliciting a tumor-suppression signal. Either ef-
fects on gene expression are probably dictated by a distinct 
combination of transcription elements of the Myc family [26, 
38-40]. 
To investigate the mechanism of INI1/hSNF5-dependent 
tumor-suppression, Zhang et al. reintroduced the gene in the 
MON cell line carrying biallelic deletions at the INI1/hSNF5 
locus. As a consequence, cells were prevented from entering 
the S phase of the cell cycle [218], cell proliferation was 
inhibited, cell morphology changed, and the expression of 
cyclin D1 was repressed [219]. Because of the critical role of 
Targeting myc Oncogenes in Pediatric Solid Tumors Current Cancer Drug Targets, 2009, Vol. 9, No. 1      7 
cyclin D1 in cell proliferation [220-222], it is not surprising 
that cyclin D1 and other cell cycle-regulators are also often 
overexpressed in rhabdoid tumors [223]. 
Chromatin immunoprecipitation studies showed that cy-
clin D1 is a direct target of INI1/hSNF5, as well as of c-Myc 
[30]. In fact, cyclin D1 belongs to the group of genes, whose 
expression can be either activated or repressed, depending on 
the chromatin status and on the transcription factors that are 
engaged. Whereas Myc/Max dimers promote transcription of 
cyclin D1 [224], Myc can silence the same gene by a mecha-
nism independent of Max, which does not interact with INI1 
[199]. 
Taken together, these findings also suggest possible new 
targets along the Myc-dependent cell proliferation pathways, 
alternative to target Myc itself. Repression of cyclin D1 rep-
resents one attractive approach [225]. Possible ways of in-
tervention are treatment with retinoic acid or siRNA mole-
cules specific for cyclin D1, which are under investigation in 
other tumor models [226]. Furthermore, gene therapy aiming 
at reintroducing INI1/hSNF5, which is able to arrest cell 
growth in AT/RT, could also be considered in order to re-
store the defective copies of this gene in patients.  
CONCLUSIONS AND FUTURE PERSPECTIVES 
We have summarized here the current progresses in the 
design of novel therapeutic strategies for the treatment of 
embryonal tumors based on targeting Myc, with a particular 
emphasis on NB, MB, and AT/RT. Deregulation of the myc 
proto-oncogene is often linked to the development of a more 
aggressive disease and to poor prognosis in patients. Myc is 
a family of multifunctional transcription factors that, directly 
or indirectly, determine a multitude of cellular events re-
sponsible for tumorigenesis. Therefore, the possibility to 
target Myc or Myc target genes in order to eventually ma-
nipulate Myc-dependent signaling pathways, like those lead-
ing to cell proliferation and apoptosis, is particularly attrac-
tive. The Myc targeting approaches under investigation, al-
though still at the preclinical stage, range from RNA/DNA-
based oligonucleotides to small-molecule inhibitors. These 
strategies could complement the administration of more con-
ventional drugs to patients, aiming at less toxic and more 
selective treatment schedules. Among all, the RNA interfer-
ence (RNAi) approach seems to be particularly promising to 
silence disease-causing or disease-promoting genes [227, 
228]. Although some aspects (i.e. drug delivery, possible 
immunoreactivity, off-target effects) have still to be better 
understood and optimized, the recent fast progress in the 
field has triggered some optimism about the development of 
RNAi-based therapeutic tools for translational research in 
the clinic [229]. Finally, the increased knowledge about dif-
ferent tumor entities similarly characterized by Myc deregu-
lation, and the preliminary results obtained by employing 
RNAi or other approaches, will certainly contribute to make 
important steps forward in developing novel therapies for 
embryonal tumors. 
ACKNOWLEDGEMENTS 
The work in the authors’ laboratory is supported by the 
EU Sixth Framework Program (E.E.T.-Pipeline).  
REFERENCES 
[1] Legler, J. M.; Ries, L. A.; Smith, M. A.; Warren, J. L.; Heineman, 
E. F.; Kaplan, R. S.; Linet, M. S. Cancer surveillance series [cor-
rected]: brain and other central nervous system cancers: recent 
trends in incidence and mortality. J. Natl. Cancer Inst. 1999, 91, 
1382-1390. 
[2] Scotting, P. J.; Walker, D. A.; Perilongo, G. Childhood solid tu-
mours: a developmental disorder. Nat. Rev. Cancer 2005, 5, 481-
488. 
[3] Grimmer, M. R.; Weiss, W. A. Childhood tumors of the nervous 
system as disorders of normal development. Curr. Opin. Pediatr. 
2006, 18, 634-638. 
[4] Kleihues, P.; Burger, P. C.; Scheithauer, B. W. The new WHO 
classification of brain tumours. Brain Pathol. 1993, 3, 255-268. 
[5] Kleihues, P.; Sobin, L. H. World Health Organization classification 
of tumors. Cancer 2000, 88, 2887. 
[6] Hart, M. N.; Earle, K. M. Primitive neuroectodermal tumors of the 
brain in children. Cancer 1973, 32, 890-897. 
[7] Rorke, L. B. The cerebellar medulloblastoma and its relationship to 
primitive neuroectodermal tumors. J. Neuropathol. Exp. Neurol. 
1983, 42, 1-15. 
[8] Gilbertson, R. J.; Ellison, D. W. The origins of medulloblastoma 
subtypes. Annu Rev Pathol. 2008, 3, 341-365. 
[9] Knoepfler, P. S. Myc goes global: new tricks for an old oncogene. 
Cancer Res. 2007, 67, 5061-5063. 
[10] Sheiness, D.; Fanshier, L.; Bishop, J. M. Identification of nucleo-
tide sequences which may encode the oncogenic capacity of avian 
retrovirus MC29. J. Virol. 1978, 28, 600-610. 
[11] Sheiness, D.; Bishop, J. M. DNA and RNA from uninfected verte-
brate cells contain nucleotide sequences related to the putative 
transforming gene of avian myelocytomatosis virus. J. Virol. 1979, 
31, 514-521. 
[12] Nesbit, C. E.; Tersak, J. M.; Prochownik, E. V. MYC oncogenes 
and human neoplastic disease. Oncogene 1999, 18, 3004-3016. 
[13] DePinho, R. A. The age of cancer. Nature 2000, 408, 248-254. 
[14] Hurlin, P. J. N-Myc functions in transcription and development. 
Birth Defects Res. C Embryo Today 2005, 75, 340-352. 
[15] Pavelic, K.; Slaus, N. P.; Spaventi, R. Growth factors and proto-
oncogenes in early mouse embryogenesis and tumorigenesis. Int. J. 
Dev. Biol. 1991, 35, 209-214. 
[16] Stanton, B. R.; Perkins, A. S.; Tessarollo, L.; Sassoon, D. A.; 
Parada, L. F. Loss of N-myc function results in embryonic lethality 
and failure of the epithelial component of the embryo to develop. 
Genes Dev. 1992, 6, 2235-2247. 
[17] Zimmerman, K. A.; Yancopoulos, G. D.; Collum, R. G.; Smith, R. 
K.; Kohl, N. E.; Denis, K. A.; Nau, M. M.; Witte, O. N.; Toran-
Allerand, D.; Gee, C. E.; et al. Differential expression of myc fam-
ily genes during murine development. Nature 1986, 319, 780-783. 
[18] Strieder, V.; Lutz, W. Regulation of N-myc expression in devel-
opment and disease. Cancer Lett. 2002, 180, 107-119. 
[19] Muller, R.; Tremblay, J. M.; Adamson, E. D.; Verma, I. M. Tissue 
and cell type-specific expression of two human c-onc genes. Na-
ture. 1983, 304, 454-456. 
[20] Cole, M. D. The myc oncogene: its role in transformation and 
differentiation. Annu. Rev. Genet. 1986, 20, 361-384. 
[21] Davis, A. C.; Wims, M.; Spotts, G. D.; Hann, S. R.; Bradley, A. A 
null c-myc mutation causes lethality before 10.5 days of gestation 
in homozygotes and reduced fertility in heterozygous female mice. 
Genes Dev. 1993, 7, 671-682. 
[22] Baudino, T. A.; McKay, C.; Pendeville-Samain, H.; Nilsson, J. A.; 
Maclean, K. H.; White, E. L.; Davis, A. C.; Ihle, J. N.; Cleveland, 
J. L. c-Myc is essential for vasculogenesis and angiogenesis during 
development and tumor progression. Genes Dev. 2002, 16, 2530-
2543. 
[23] Bates, C. M.; Kharzai, S.; Erwin, T.; Rossant, J.; Parada, L. F. Role 
of N-myc in the developing mouse kidney. Dev. Biol. 2000, 222, 
317-325. 
[24] Hatton, K. S.; Mahon, K.; Chin, L.; Chiu, F. C.; Lee, H. W.; Peng, 
D.; Morgenbesser, S. D.; Horner, J.; DePinho, R. A. Expression 
and activity of L-Myc in normal mouse development. Mol. Cell 
Biol. 1996, 16, 1794-1804. 
[25] Schuhmacher, M.; Kohlhuber, F.; Holzel, M.; Kaiser, C.; 
Burtscher, H.; Jarsch, M.; Bornkamm, G. W.; Laux, G.; Polack, A.; 
8    Current Cancer Drug Targets, 2009, Vol. 9, No. 1 Grotzer et al. 
Weidle, U. H.; Eick, D. The transcriptional program of a human B 
cell line in response to Myc. Nucleic Acids Res. 2001, 29, 397-406. 
[26] Adhikary, S.; Eilers, M. Transcriptional regulation and transforma-
tion by Myc proteins. Nat. Rev. Mol. Cell. Biol. 2005, 6, 635-645. 
[27] Gartel, A. L.; Ye, X.; Goufman, E.; Shianov, P.; Hay, N.; Najma-
badi, F.; Tyner, A. L. Myc represses the p21(WAF1/CIP1) pro-
moter and interacts with Sp1/Sp3. Proc. Natl. Acad. Sci. USA 2001, 
98, 4510-4515. 
[28] de Nigris, F.; Botti, C.; Rossiello, R.; Crimi, E.; Sica, V.; Napoli, 
C. Cooperation between Myc and YY1 provides novel silencing 
transcriptional targets of alpha3beta1-integrin in tumour cells. On-
cogene 2007, 26, 382-394. 
[29] Coller, H. A.; Grandori, C.; Tamayo, P.; Colbert, T.; Lander, E. S.; 
Eisenman, R. N.; Golub, T. R. Expression analysis with oligonu-
cleotide microarrays reveals that MYC regulates genes involved in 
growth, cell cycle, signaling, and adhesion. Proc. Natl. Acad. Sci. 
USA 2000, 97, 3260-3265. 
[30] Guo, Q. M.; Malek, R. L.; Kim, S.; Chiao, C.; He, M.; Ruffy, M.; 
Sanka, K.; Lee, N. H.; Dang, C. V.; Liu, E. T. Identification of c-
myc responsive genes using rat cDNA microarray. Cancer Res. 
2000, 60, 5922-5928. 
[31] O'Hagan, R. C.; Ohh, M.; David, G.; de Alboran, I. M.; Alt, F. W.; 
Kaelin, W. G., Jr.; DePinho, R. A. Myc-enhanced expression of 
Cul1 promotes ubiquitin-dependent proteolysis and cell cycle pro-
gression. Genes Dev. 2000, 14, 2185-2191. 
[32] Bouchard, C.; Dittrich, O.; Kiermaier, A.; Dohmann, K.; Menkel, 
A.; Eilers, M.; Luscher, B. Regulation of cyclin D2 gene expres-
sion by the Myc/Max/Mad network: Myc-dependent TRRAP re-
cruitment and histone acetylation at the cyclin D2 promoter. Genes 
Dev. 2001, 15, 2042-2047. 
[33] Frank, S. R.; Schroeder, M.; Fernandez, P.; Taubert, S.; Amati, B. 
Binding of c-Myc to chromatin mediates mitogen-induced acetyla-
tion of histone H4 and gene activation. Genes Dev. 2001, 15, 2069-
2082. 
[34] Obaya, A. J.; Mateyak, M. K.; Sedivy, J. M. Mysterious liaisons: 
the relationship between c-Myc and the cell cycle. Oncogene 1999, 
18, 2934-2941. 
[35] Pelengaris, S.; Rudolph, B.; Littlewood, T. Action of Myc in vivo - 
proliferation and apoptosis. Curr. Opin. Genet. Dev. 2000, 10, 100-
105. 
[36] Pelengaris, S.; Khan, M.; Evan, G. c-MYC: more than just a matter 
of life and death. Nat. Rev. Cancer 2002, 2, 764-776. 
[37] Schorl, C.; Sedivy, J. M. Loss of protooncogene c-Myc function 
impedes G1 phase progression both before and after the restriction 
point. Mol. Biol. Cell. 2003, 14, 823-835. 
[38] Schmidt, E. V. The role of c-myc in cellular growth control. Onco-
gene 1999, 18, 2988-2996. 
[39] Dang, C. V.; Resar, L. M.; Emison, E.; Kim, Q.; Prescott, J. E.; 
Wonsey, D.; Zeller, K. Function of the c-Myc oncogene transcrip-
tion factor. Experimental Cell Res. 1999, 253, 63-77. 
[40] Trumpp, A.; Refaeli, Y.; Oskarsson, T.; Gasser, S.; Murphy, M.; 
Martin, G. R.; Bishop, J. M. c-Myc regulates mammalian body size 
by controlling cell number but not cell size. Nature 2001, 414, 768-
773. 
[41] Evan, G. I.; Wyllie, A. H.; Gilbert, C. S.; Littlewood, T. D.; Land, 
H.; Brooks, M.; Waters, C. M.; Penn, L. Z.; Hancock, D. C. Induc-
tion of apoptosis in fibroblasts by c-myc protein. Cell. 1992, 69, 
119-128. 
[42] Prendergast, G. C. Mechanisms of apoptosis by c-Myc. Oncogene. 
1999, 18, 2967-2987. 
[43] Nilsson, J. A.; Cleveland, J. L. Myc pathways provoking cell sui-
cide and cancer. Oncogene 2003, 22, 9007-9021. 
[44] Meyer, N.; Kim, S. S.; Penn, L. Z. The Oscar-worthy role of Myc 
in apoptosis. Semin. Cancer Biol. 2006, 16, 275-287. 
[45] Nesbit, C. E.; Grove, L. E.; Yin, X.; Prochownik, E. V. Differential 
apoptotic behaviors of c-myc, N-myc, and L-myc oncoproteins. 
Cell Growth Differ. 1998, 9, 731-741. 
[46] Wu, K. J.; Grandori, C.; Amacker, M.; Simon-Vermot, N.; Polack, 
A.; Lingner, J.; Dalla-Favera, R. Direct activation of TERT tran-
scription by c-MYC. Nat. Genet. 1999, 21, 220-224. 
[47] Greenberg, R. A.; O'Hagan, R. C.; Deng, H.; Xiao, Q.; Hann, S. R.; 
Adams, R. R.; Lichtsteiner, S.; Chin, L.; Morin, G. B.; DePinho, R. 
A. Telomerase reverse transcriptase gene is a direct target of c-Myc 
but is not functionally equivalent in cellular transformation. Onco-
gene 1999, 18, 1219-1226. 
[48] Dews, M.; Homayouni, A.; Yu, D.; Murphy, D.; Sevignani, C.; 
Wentzel, E.; Furth, E. E.; Lee, W. M.; Enders, G. H.; Mendell, J. 
T.; Thomas-Tikhonenko, A. Augmentation of tumor angiogenesis 
by a Myc-activated microRNA cluster. Nat. Genet. 2006, 38, 1060-
1065. 
[49] Henriksson, M.; Luscher, B. Proteins of the Myc network: essential 
regulators of cell growth and differentiation. Adv. Cancer Res. 
1996, 68, 109-182. 
[50] Grandori, C.; Cowley, S. M.; James, L. P.; Eisenman, R. N. The 
Myc/Max/Mad network and the transcriptional control of cell be-
havior. Annu. Rev. Cell Dev. Biol. 2000, 16, 653-699. 
[51] Kelly, K.; Cochran, B. H.; Stiles, C. D.; Leder, P. Cell-specific 
regulation of the c-myc gene by lymphocyte mitogens and platelet-
derived growth factor. Cell. 1983, 35, 603-610. 
[52] Henderson, B. R.; Fagotto, F. The ins and outs of APC and beta-
catenin nuclear transport. EMBO Rep. 2002, 3, 834-839. 
[53] Lombardi, L.; Grignani, F.; Sternas, L.; Cechova, K.; Inghirami, 
G.; Dalla-Favera, R. Mechanism of negative feed-back regulation 
of c-myc gene expression in B-cells and its inactivation in tumor 
cells. Curr. Top. Microbiol. Immunol. 1990, 166, 293-301. 
[54] Penn, L. J.; Brooks, M. W.; Laufer, E. M.; Land, H. Negative 
autoregulation of c-myc transcription. EMBO J. 1990, 9, 1113-
1121. 
[55] Campisi, J.; Gray, H. E.; Pardee, A. B.; Dean, M.; Sonenshein, G. 
E. Cell-cycle control of c-myc but not c-ras expression is lost fol-
lowing chemical transformation. Cell. 1984, 36, 241-247. 
[56] Moore, J. P.; Hancock, D. C.; Littlewood, T. D.; Evan, G. I. A 
sensitive and quantitative enzyme-linked immunosorbence assay 
for the c-myc and N-myc oncoproteins. Oncogene Res. 1987, 2, 65-
80. 
[57] DePinho, R. A.; Schreiber-Agus, N.; Alt, F. W. myc family onco-
genes in the development of normal and neoplastic cells. Adv. Can-
cer Res. 1991, 57, 1-46. 
[58] Dalla-Favera, R.; Wong-Staal, F.; Gallo, R. C. Onc gene amplifica-
tion in promyelocytic leukaemia cell line HL-60 and primary leu-
kaemic cells of the same patient. Nature 1982, 299, 61-63. 
[59] Fuller, G. N.; Bigner, S. H. Amplified cellular oncogenes in neo-
plasms of the human central nervous system. Mutat. Res. 1992, 
276, 299-306. 
[60] Dalla-Favera, R.; Bregni, M.; Erikson, J.; Patterson, D.; Gallo, R. 
C.; Croce, C. M. Human c-myc onc gene is located on the region of 
chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. 
Natl. Acad. Sci. USA 1982, 79, 7824-7827. 
[61] Magrath, I. The pathogenesis of Burkitt's lymphoma. Adv. Cancer 
Res. 1990, 55, 133-270. 
[62] Janz, S. Myc translocations in B cell and plasma cell neoplasms. 
DNA Repair (Amst). 2006, 5, 1213-1224. 
[63] Hoang, A. T.; Lutterbach, B.; Lewis, B. C.; Yano, T.; Chou, T. Y.; 
Barrett, J. F.; Raffeld, M.; Hann, S. R.; Dang, C. V. A link between 
increased transforming activity of lymphoma-derived MYC mutant 
alleles, their defective regulation by p107, and altered phosphoryla-
tion of the c-Myc transactivation domain. Mol. Cell Biol. 1995, 15, 
4031-4042. 
[64] Pasqualucci, L.; Neumeister, P.; Goossens, T.; Nanjangud, G.; 
Chaganti, R. S.; Kuppers, R.; Dalla-Favera, R. Hypermutation of 
multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. 
Nature 2001, 412, 341-346. 
[65] Felsher, D. W.; Bishop, J. M. Reversible tumorigenesis by MYC in 
hematopoietic lineages. Mol. Cell. 1999, 4, 199-207. 
[66] D'Cruz, C. M.; Gunther, E. J.; Boxer, R. B.; Hartman, J. L.; Sinta-
sath, L.; Moody, S. E.; Cox, J. D.; Ha, S. I.; Belka, G. K.; Golant, 
A.; Cardiff, R. D.; Chodosh, L. A. c-MYC induces mammary tu-
morigenesis by means of a preferred pathway involving spontane-
ous Kras2 mutations. Nat. Med. 2001, 7, 235-239. 
[67] Shachaf, C. M.; Kopelman, A. M.; Arvanitis, C.; Karlsson, A.; 
Beer, S.; Mandl, S.; Bachmann, M. H.; Borowsky, A. D.; Ruebner, 
B.; Cardiff, R. D.; Yang, Q.; Bishop, J. M.; Contag, C. H.; Felsher, 
D. W. MYC inactivation uncovers pluripotent differentiation and 
tumour dormancy in hepatocellular cancer. Nature 2004, 431, 
1112-1117. 
Targeting myc Oncogenes in Pediatric Solid Tumors Current Cancer Drug Targets, 2009, Vol. 9, No. 1      9 
[68] Arnold, I.; Watt, F. M. c-Myc activation in transgenic mouse epi-
dermis results in mobilization of stem cells and differentiation of 
their progeny. Curr. Biol. 2001, 11, 558-568. 
[69] Pelengaris, S.; Khan, M.; Evan, G. I. Suppression of Myc-induced 
apoptosis in beta cells exposes multiple oncogenic properties of 
Myc and triggers carcinogenic progression. Cell. 2002, 109, 321-
334. 
[70] Dang, C. V.; O'Donnell K, A.; Juopperi, T. The great MYC escape 
in tumorigenesis. Cancer Cell. 2005, 8, 177-178. 
[71] Jennings, B. A.; Mills, K. I. c-myc locus amplification and the 
acquisition of trisomy 8 in the evolution of chronic myeloid leu-
kaemia. Leuk. Res. 1998, 22, 899-903. 
[72] Pavelic, Z. P.; Steele, P.; Preisler, H. D. Evaluation of c-myc proto-
oncogene in primary human breast carcinomas. Anticancer Res. 
1991, 11, 1421-1427. 
[73] Liao, D. J.; Dickson, R. B. c-Myc in breast cancer. Endocr. Relat. 
Cancer 2000, 7, 143-164. 
[74] Baker, V. V.; Borst, M. P.; Dixon, D.; Hatch, K. D.; Shingleton, H. 
M.; Miller, D. c-myc amplification in ovarian cancer. Gynecol. On-
col. 1990, 38, 340-342. 
[75] Wu, R.; Lin, L.; Beer, D. G.; Ellenson, L. H.; Lamb, B. J.; Rouil-
lard, J. M.; Kuick, R.; Hanash, S.; Schwartz, D. R.; Fearon, E. R.; 
Cho, K. R. Amplification and overexpression of the L-MYC proto-
oncogene in ovarian carcinomas. Am. J. Pathol. 2003, 162, 1603-
1610. 
[76] Heerdt, B. G.; Molinas, S.; Deitch, D.; Augenlicht, L. H. Aggres-
sive subtypes of human colorectal tumors frequently exhibit ampli-
fication of the c-myc gene. Oncogene 1991, 6, 125-129. 
[77] Makela, T. P.; Saksela, K.; Alitalo, K. Amplification and rear-
rangement of L-myc in human small-cell lung cancer. Mutat. Res. 
1992, 276, 307-315. 
[78] Wade, M.; Wahl, G. M. c-Myc, genome instability, and tumori-
genesis: the devil is in the details. Curr. Top. Microbiol. Immunol. 
2006, 302, 169-203. 
[79] Lutz, W.; Leon, J.; Eilers, M. Contributions of Myc to tumorigene-
sis. Biochim. Biophys. Acta. 2002, 1602, 61-71. 
[80] Weiss, W. A.; Aldape, K.; Mohapatra, G.; Feuerstein, B. G.; 
Bishop, J. M. Targeted expression of MYCN causes neuroblastoma 
in transgenic mice. EMBO J. 1997, 16, 2985-2995. 
[81] Chesler, L.; Goldenberg, D. D.; Seales, I. T.; Satchi-Fainaro, R.; 
Grimmer, M.; Collins, R.; Struett, C.; Nguyen, K. N.; Kim, G.; Ti-
han, T.; Bao, Y.; Brekken, R. A.; Bergers, G.; Folkman, J.; Weiss, 
W. A. Malignant progression and blockade of angiogenesis in a 
murine transgenic model of neuroblastoma. Cancer Res. 2007, 67, 
9435-9442. 
[82] Eischen, C. M.; Weber, J. D.; Roussel, M. F.; Sherr, C. J.; Cleve-
land, J. L. Disruption of the ARF-Mdm2-p53 tumor suppressor 
pathway in Myc-induced lymphomagenesis. Genes Dev. 1999, 13, 
2658-2669. 
[83] Eischen, C. M.; Woo, D.; Roussel, M. F.; Cleveland, J. L. Apopto-
sis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is 
bypassed during lymphomagenesis. Mol. Cell Biol. 2001, 21, 5063-
5070. 
[84] Eischen, C. M.; Packham, G.; Nip, J.; Fee, B. E.; Hiebert, S. W.; 
Zambetti, G. P.; Cleveland, J. L. Bcl-2 is an apoptotic target sup-
pressed by both c-Myc and E2F-1. Oncogene 2001, 20, 6983-6993. 
[85] Alt, J. R.; Greiner, T. C.; Cleveland, J. L.; Eischen, C. M. Mdm2 
haplo-insufficiency profoundly inhibits Myc-induced lymphoma-
genesis. EMBO J. 2003, 22, 1442-1450. 
[86] Wang, P.; Lushnikova, T.; Odvody, J.; Greiner, T. C.; Jones, S. N.; 
Eischen, C. M. Elevated Mdm2 expression induces chromosomal 
instability and confers a survival and growth advantage to B cells. 
Oncogene 2008, 27, 1590-1598. 
[87] Prochownik, E. V. c-Myc as a therapeutic target in cancer. Expert 
Rev. Anticancer Ther. 2004, 4, 289-302. 
[88] Ponzielli, R.; Katz, S.; Barsyte-Lovejoy, D.; Penn, L. Z. Cancer 
therapeutics: targeting the dark side of Myc. Eur. J. Cancer 2005, 
41, 2485-2501. 
[89] Vita, M.; Henriksson, M. The Myc oncoprotein as a therapeutic 
target for human cancer. Semin. Cancer Biol. 2006, 16, 318-330. 
[90] Wang, H.; Mannava, S.; Grachtchouk, V.; Zhuang, D.; Soengas, M. 
S.; Gudkov, A. V.; Prochownik, E. V.; Nikiforov, M. A. c-Myc de-
pletion inhibits proliferation of human tumor cells at various stages 
of the cell cycle. Oncogene 2008, 27, 1905-1915. 
[91] Maddika, S.; Ande, S. R.; Panigrahi, S.; Paranjothy, T.; Weglar-
czyk, K.; Zuse, A.; Eshraghi, M.; Manda, K. D.; Wiechec, E.; Los, 
M. Cell survival, cell death and cell cycle pathways are intercon-
nected: implications for cancer therapy. Drug Resist. Updat. 2007, 
10, 13-29. 
[92] Jain, M.; Arvanitis, C.; Chu, K.; Dewey, W.; Leonhardt, E.; Trinh, 
M.; Sundberg, C. D.; Bishop, J. M.; Felsher, D. W. Sustained loss 
of a neoplastic phenotype by brief inactivation of MYC. Science 
2002, 297, 102-104. 
[93] Grand, C. L.; Han, H.; Munoz, R. M.; Weitman, S.; Von Hoff, D. 
D.; Hurley, L. H.; Bearss, D. J. The cationic porphyrin TMPyP4 
down-regulates c-MYC and human telomerase reverse transcriptase 
expression and inhibits tumor growth in vivo. Mol. Cancer Ther. 
2002, 1, 565-573. 
[94] Smith, J. B.; Wickstrom, E. Inhibition of tumorigenesis in a murine 
B-cell lymphoma transplant model by c-Myc complementary oli-
gonucleotides. Adv. Exp. Med. Biol. 1998, 451, 17-22. 
[95] Pooga, M.; Kut, C.; Kihlmark, M.; Hallbrink, M.; Fernaeus, S.; 
Raid, R.; Land, T.; Hallberg, E.; Bartfai, T.; Langel, U. Cellular 
translocation of proteins by transportan. FASEB J. 2001, 15, 1451-
1453. 
[96] Wang, Y. H.; Liu, S.; Zhang, G.; Zhou, C. Q.; Zhu, H. X.; Zhou, X. 
B.; Quan, L. P.; Bai, J. F.; Xu, N. Z. Knockdown of c-Myc expres-
sion by RNAi inhibits MCF-7 breast tumor cells growth in vitro 
and in vivo. Breast Cancer Res. 2005, 7, R220-228. 
[97] Li, C. M.; Margolin, A. A.; Salas, M.; Memeo, L.; Mansukhani, 
M.; Hibshoosh, H.; Szabolcs, M.; Klinakis, A.; Tycko, B. PEG10 is 
a c-MYC target gene in cancer cells. Cancer Res. 2006, 66, 665-
672. 
[98] Popov, N.; Wanzel, M.; Madiredjo, M.; Zhang, D.; Beijersbergen, 
R.; Bernards, R.; Moll, R.; Elledge, S. J.; Eilers, M. The ubiquitin-
specific protease USP28 is required for MYC stability. Nat. Cell 
Biol. 2007, 9, 765-774. 
[99] Berg, T.; Cohen, S. B.; Desharnais, J.; Sonderegger, C.; Maslyar, 
D. J.; Goldberg, J.; Boger, D. L.; Vogt, P. K. Small-molecule an-
tagonists of Myc/Max dimerization inhibit Myc-induced transfor-
mation of chicken embryo fibroblasts. Proc. Natl. Acad. Sci. USA 
2002, 99, 3830-3835. 
[100] Wang, H.; Hammoudeh, D. I.; Follis, A. V.; Reese, B. E.; Lazo, J. 
S.; Metallo, S. J.; Prochownik, E. V. Improved low molecular 
weight Myc-Max inhibitors. Mol. Cancer Ther. 2007, 6, 2399-
2408. 
[101] Kiessling, A.; Sperl, B.; Hollis, A.; Eick, D.; Berg, T. Selective 
inhibition of c-Myc/Max dimerization and DNA binding by small 
molecules. Chem. Biol. 2006, 13, 745-751. 
[102] Fulda, S.; Lutz, W.; Schwab, M.; Debatin, K. M. MycN sensitizes 
neuroblastoma cells for drug-induced apoptosis. Oncogene 1999, 
18, 1479-1486. 
[103] Biliran, H., Jr.; Banerjee, S.; Thakur, A.; Sarkar, F. H.; Bollig, A.; 
Ahmed, F.; Wu, J.; Sun, Y.; Liao, J. D. c-Myc-induced chemosen-
sitization is mediated by suppression of cyclin D1 expression and 
nuclear factor-kappa B activity in pancreatic cancer cells. Clin. 
Cancer Res. 2007, 13, 2811-2821. 
[104] Patel, J. H.; McMahon, S. B. BCL2 is a downstream effector of 
MIZ-1 essential for blocking c-MYC-induced apoptosis. J. Biol. 
Chem. 2007, 282, 5-13. 
[105] Hemann, M. T.; Bric, A.; Teruya-Feldstein, J.; Herbst, A.; Nilsson, 
J. A.; Cordon-Cardo, C.; Cleveland, J. L.; Tansey, W. P.; Lowe, S. 
W. Evasion of the p53 tumour surveillance network by tumour-
derived MYC mutants. Nature 2005, 436, 807-811. 
[106] Schwab, M.; Westermann, F.; Hero, B.; Berthold, F. Neuroblas-
toma: biology and molecular and chromosomal pathology. Lancet 
Oncol. 2003, 4, 472-480. 
[107] Maris, J. M. The biologic basis for neuroblastoma heterogeneity 
and risk stratification. Curr. Opin. Pediatr. 2005, 17, 7-13. 
[108] Westermann, F.; Schwab, M. Genetic parameters of neuroblas-
tomas. Cancer Lett. 2002, 184, 127-147. 
[109] Brodeur, G. M. Neuroblastoma: biological insights into a clinical 
enigma. Nat. Rev. Cancer 2003, 3, 203-216. 
[110] Riley, R. D.; Heney, D.; Jones, D. R.; Sutton, A. J.; Lambert, P. C.; 
Abrams, K. R.; Young, B.; Wailoo, A. J.; Burchill, S. A. A system-
atic review of molecular and biological tumor markers in neuro-
blastoma. Clin. Cancer Res. 2004, 10, 4-12. 
10    Current Cancer Drug Targets, 2009, Vol. 9, No. 1 Grotzer et al. 
[111] Bordow, S. B.; Norris, M. D.; Haber, P. S.; Marshall, G. M.; Haber, 
M. Prognostic significance of MYCN oncogene expression in 
childhood neuroblastoma. J. Clin. Oncol. 1998, 16, 3286-3294. 
[112] Cohn, S. L.; London, W. B.; Huang, D.; Katzenstein, H. M.; Sal-
wen, H. R.; Reinhart, T.; Madafiglio, J.; Marshall, G. M.; Norris, 
M. D.; Haber, M. MYCN expression is not prognostic of adverse 
outcome in advanced-stage neuroblastoma with nonamplified 
MYCN. J. Clin. Oncol. 2000, 18, 3604-3613. 
[113] Schwab, M.; Varmus, H. E.; Bishop, J. M.; Grzeschik, K. H.; Nay-
lor, S. L.; Sakaguchi, A. Y.; Brodeur, G.; Trent, J. Chromosome lo-
calization in normal human cells and neuroblastomas of a gene re-
lated to c-myc. Nature 1984, 308, 288-291. 
[114] Schwab, M.; Varmus, H. E.; Bishop, J. M. Human N-myc gene 
contributes to neoplastic transformation of mammalian cells in cul-
ture. Nature 1985, 316, 160-162. 
[115] Corvi, R.; Savelyeva, L.; Schwab, M. Duplication of N-MYC at its 
resident site 2p24 may be a mechanism of activation alternative to 
amplification in human neuroblastoma cells. Cancer Res. 1995, 55, 
3471-3474. 
[116] Thiele, C. J.; Reynolds, C. P.; Israel, M. A. Decreased expression 
of N-myc precedes retinoic acid-induced morphological differentia-
tion of human neuroblastoma. Nature 1985, 313, 404-406. 
[117] Schwab, M.; Ellison, J.; Busch, M.; Rosenau, W.; Varmus, H. E.; 
Bishop, J. M. Enhanced expression of the human gene N-myc con-
sequent to amplification of DNA may contribute to malignant pro-
gression of neuroblastoma. Proc. Natl. Acad. Sci. USA 1984, 81, 
4940-4944. 
[118] Evans, A. E. In Neuroblastoma; (Ed: S. T. Brodeur G.M., Tsuchida 
Y., Voute P.A., Elsevier), Amsterdam 2000, 1-7. 
[119] Kang, J. H.; Rychahou, P. G.; Ishola, T. A.; Qiao, J.; Evers, B. M.; 
Chung, D. H. MYCN silencing induces differentiation and apopto-
sis in human neuroblastoma cells. Biochem. Biophys. Res. Com-
mun. 2006, 351, 192-197. 
[120] Matsuo, T.; Thiele, C. J. p27Kip1: a key mediator of retinoic acid 
induced growth arrest in the SMS-KCNR human neuroblastoma 
cell line. Oncogene 1998, 16, 3337-3343. 
[121] Ponthan, F.; Johnsen, J. I.; Klevenvall, L.; Castro, J.; Kogner, P. 
The synthetic retinoid RO 13-6307 induces neuroblastoma differ-
entiation in vitro and inhibits neuroblastoma tumour growth in vivo. 
Int. J. Cancer 2003, 104, 418-424. 
[122] Negroni, A.; Scarpa, S.; Romeo, A.; Ferrari, S.; Modesti, A.; Ra-
schella, G. Decrease of proliferation rate and induction of differen-
tiation by a MYCN antisense DNA oligomer in a human neuroblas-
toma cell line. Cell Growth Differ. 1991, 2, 511-518. 
[123] Pession, A.; Tonelli, R.; Fronza, R.; Sciamanna, E.; Corradini, R.; 
Sforza, S.; Tedeschi, T.; Marchelli, R.; Montanaro, L.; Camerin, 
C.; Franzoni, M.; Paolucci, G. Targeted inhibition of NMYC by 
peptide nucleic acid in N-myc amplified human neuroblastoma 
cells: cell-cycle inhibition with induction of neuronal cell differen-
tiation and apoptosis. Int. J. Oncol. 2004, 24, 265-272. 
[124] Sun, L.; Fuselier, J. A.; Murphy, W. A.; Coy, D. H. Antisense 
peptide nucleic acids conjugated to somatostatin analogs and tar-
geted at the n-myc oncogene display enhanced cytotoxity to human 
neuroblastoma IMR32 cells expressing somatostatin receptors. 
Peptides 2002, 23, 1557-1565. 
[125] Chesler, L.; Schlieve, C.; Goldenberg, D. D.; Kenney, A.; Kim, G.; 
McMillan, A.; Matthay, K. K.; Rowitch, D.; Weiss, W. A. Inhibi-
tion of phosphatidylinositol 3-kinase destabilizes Mycn protein and 
blocks malignant progression in neuroblastoma. Cancer Res. 2006, 
66, 8139-8146. 
[126] Kurmasheva, R. T.; Houghton, P. J. Pediatric oncology. Curr. 
Opin. Chem. Biol. 2007, 11, 424-432. 
[127] Foukas, L. C.; Claret, M.; Pearce, W.; Okkenhaug, K.; Meek, S.; 
Peskett, E.; Sancho, S.; Smith, A. J.; Withers, D. J.; Vanhaesebro-
eck, B. Critical role for the p110alpha phosphoinositide-3-OH 
kinase in growth and metabolic regulation. Nature 2006, 441, 366-
370. 
[128] Jia, S.; Liu, Z.; Zhang, S.; Liu, P.; Zhang, L.; Lee, S. H.; Zhang, J.; 
Signoretti, S.; Loda, M.; Roberts, T. M.; Zhao, J. J. Essential roles 
of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. 
Nature 2008, 454, 776-779. 
[129] Lu, X.; Pearson, A.; Lunec, J. The MYCN oncoprotein as a drug 
development target. Cancer Lett. 2003, 197, 125-130. 
[130] Sarkar, A. K.; Nuchtern, J. G. Lysis of MYCN-amplified neuro-
blastoma cells by MYCN peptide-specific cytotoxic T lympho-
cytes. Cancer Res. 2000, 60, 1908-1913. 
[131] Radhakrishnan, S. K.; Halasi, M.; Bhat, U. G.; Kurmasheva, R. T.; 
Houghton, P. J.; Gartel, A. L. Proapoptotic compound ARC targets 
Akt and N-myc in neuroblastoma cells. Oncogene 2008, 27, 694-
699. 
[132] Liu, X.; Mazanek, P.; Dam, V.; Wang, Q.; Zhao, H.; Guo, R.; Ja-
gannathan, J.; Cnaan, A.; Maris, J. M.; Hogarty, M. D. Deregulated 
Wnt/beta-catenin program in high-risk neuroblastomas without 
MYCN amplification. Oncogene 2008, 27, 1478-1488. 
[133] Slack, A.; Chen, Z.; Tonelli, R.; Pule, M.; Hunt, L.; Pession, A.; 
Shohet, J. M. The p53 regulatory gene MDM2 is a direct transcrip-
tional target of MYCN in neuroblastoma. Proc. Natl. Acad. Sci. 
USA 2005, 102, 731-736. 
[134] Slack, A. D.; Chen, Z.; Ludwig, A. D.; Hicks, J.; Shohet, J. M. 
MYCN-directed centrosome amplification requires MDM2-
mediated suppression of p53 activity in neuroblastoma cells. Can-
cer Res. 2007, 67, 2448-2455. 
[135] Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; 
Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; 
Fotouhi, N.; Liu, E. A. In vivo activation of the p53 pathway by 
small-molecule antagonists of MDM2. Science 2004, 303, 844-848. 
[136] Van Maerken, T.; Speleman, F.; Vermeulen, J.; Lambertz, I.; De 
Clercq, S.; De Smet, E.; Yigit, N.; Coppens, V.; Philippe, J.; De 
Paepe, A.; Marine, J. C.; Vandesompele, J. Small-molecule MDM2 
antagonists as a new therapy concept for neuroblastoma. Cancer 
Res. 2006, 66, 9646-9655. 
[137] Calin, G. A.; Croce, C. M. Chromosomal rearrangements and mi-
croRNAs: a new cancer link with clinical implications. J. Clin. In-
vest. 2007, 117, 2059-2066. 
[138] Chen, Y.; Stallings, R. L. Differential patterns of microRNA ex-
pression in neuroblastoma are correlated with prognosis, differen-
tiation, and apoptosis. Cancer Res. 2007, 67, 976-983. 
[139] Schulte, J. H.; Horn, S.; Otto, T.; Samans, B.; Heukamp, L. C.; 
Eilers, U. C.; Krause, M.; Astrahantseff, K.; Klein-Hitpass, L.; 
Buettner, R.; Schramm, A.; Christiansen, H.; Eilers, M.; Eggert, A.; 
Berwanger, B. MYCN regulates oncogenic MicroRNAs in neuro-
blastoma. Int. J. Cancer 2008, 122, 699-704. 
[140] Schulte, J. H.; Horn, S.; Schlierf, S.; Schramm, A.; Heukamp, L. 
C.; Christiansen, H.; Buettner, R.; Berwanger, B.; Eggert, A. Mi-
croRNAs in the pathogenesis of neuroblastoma. Cancer Lett. 2008. 
[141] Welch, C.; Chen, Y.; Stallings, R. L. MicroRNA-34a functions as a 
potential tumor suppressor by inducing apoptosis in neuroblastoma 
cells. Oncogene 2007, 26, 5017-5022. 
[142] Wei, J. S.; Song, Y. K.; Durinck, S.; Chen, Q. R.; Cheuk, A. T.; 
Tsang, P.; Zhang, Q.; Thiele, C. J.; Slack, A.; Shohet, J.; Khan, J. 
The MYCN oncogene is a direct target of miR-34a. Oncogene 
2008. 
[143] Krutzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K. G.; Tuschl, T.; 
Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivo with 
'antagomirs'. Nature 2005, 438, 685-689. 
[144] Esau, C. C.; Monia, B. P. Therapeutic potential for microRNAs. 
Adv. Drug Deliv. Rev. 2007, 59, 101-114. 
[145] Gurney, J. G.; Smith, M. A.; Bunin, G. R. In Cancer Incidence and 
Survival Among Children and Adolescents: United States SEER 
Program, 1975-1995; (Ed: S. M. A. Ries G., Gurney J.G. et al., El-
sevier), National Cancer Institute, Bethesda, MD 1999, 51-63. 
[146] Graham, M. L.; Herndon, J. E., 2nd; Casey, J. R.; Chaffee, S.; 
Ciocci, G. H.; Krischer, J. P.; Kurtzberg, J.; Laughlin, M. J.; Lon-
gee, D. C.; Olson, J. F.; Paleologus, N.; Pennington, C. N.; Fried-
man, H. S. High-dose chemotherapy with autologous stem-cell res-
cue in patients with recurrent and high-risk pediatric brain tumors. 
J. Clin. Oncol. 1997, 15, 1814-1823. 
[147] Dunkel, I. J.; Boyett, J. M.; Yates, A.; Rosenblum, M.; Garvin, J. 
H., Jr.; Bostrom, B. C.; Goldman, S.; Sender, L. S.; Gardner, S. L.; 
Li, H.; Allen, J. C.; Finlay, J. L. High-dose carboplatin, thiotepa, 
and etoposide with autologous stem-cell rescue for patients with 
recurrent medulloblastoma. Children's Cancer Group. J. Clin. On-
col. 1998, 16, 222-228. 
[148] Zeltzer, P. M.; Boyett, J. M.; Finlay, J. L.; Albright, A. L.; Rorke, 
L. B.; Milstein, J. M.; Allen, J. C.; Stevens, K. R.; Stanley, P.; Li, 
H.; Wisoff, J. H.; Geyer, J. R.; McGuire-Cullen, P.; Stehbens, J. A.; 
Shurin, S. B.; Packer, R. J. Metastasis stage, adjuvant treatment, 
Targeting myc Oncogenes in Pediatric Solid Tumors Current Cancer Drug Targets, 2009, Vol. 9, No. 1      11 
and residual tumor are prognostic factors for medulloblastoma in 
children: conclusions from the Children's Cancer Group 921 ran-
domized phase III study. J. Clin. Oncol. 1999, 17, 832-845. 
[149] Ye, P.; Xing, Y.; Dai, Z.; D'Ercole, A. J. In vivo actions of insulin-
like growth factor-I (IGF-I) on cerebellum development in trans-
genic mice: evidence that IGF-I increases proliferation of granule 
cell progenitors. Brain Res. Developmental Brain Res. 1996, 95, 
44-54. 
[150] Scotting, P. J.; Thompson, S. L.; Punt, J. A.; Walker, D. A. Paediat-
ric brain tumours: an embryological perspective. Childs Nerv Syst. 
2000, 16, 261-267; discussion 268. 
[151] Fogarty, M. P.; Kessler, J. D.; Wechsler-Reya, R. J. Morphing into 
cancer: the role of developmental signaling pathways in brain tu-
mor formation. J. Neurobiol. 2005, 64, 458-475. 
[152] Marino, S. Medulloblastoma: developmental mechanisms out of 
control. Trends Mol. Med. 2005, 11, 17-22. 
[153] Johnson, R. L.; Rothman, A. L.; Xie, J.; Goodrich, L. V.; Bare, J. 
W.; Bonifas, J. M.; Quinn, A. G.; Myers, R. M.; Cox, D. R.; Ep-
stein, E. H., Jr.; Scott, M. P. Human homolog of patched, a candi-
date gene for the basal cell nevus syndrome. Science. 1996, 272, 
1668-1671. 
[154] Dahmane, N.; Ruiz i Altaba, A. Sonic hedgehog regulates the 
growth and patterning of the cerebellum. Development 1999, 126, 
3089-3100. 
[155] Pomeroy, S. L.; Tamayo, P.; Gaasenbeck, M.; Sturla, L. M.; 
Angelo, M.; McLaughlin, M. E.; Kim, J. Y.; Goumnerova, L. C.; 
Black, P. M.; Lau, C.; Allen, J. C.; Zagzag, D.; Olson, J. M.; Cur-
ran, T.; Wetmore, C.; Biegel, J. A.; Poggio, T.; Mukherjee, S.; 
Rifkin, R.; Califano, A.; Stolovitzky, G.; Louis, D. N.; Mesirov, J. 
P.; Lander, E. S.; Golub, T. R. Prediction of central nervous system 
embryonal tumour outcome based on gene expression. Nature 
2002, 415, 436-442. 
[156] Ruiz i Altaba, A.; Stecca, B.; Sanchez, P. Hedgehog--Gli signaling 
in brain tumors: stem cells and paradevelopmental programs in 
cancer. Cancer Lett. 2004, 204, 145-157. 
[157] Read, T. A.; Hegedus, B.; Wechsler-Reya, R.; Gutmann, D. H. The 
neurobiology of neurooncology. Ann. Neurol. 2006, 60, 3-11. 
[158] Kenney, A. M.; Cole, M. D.; Rowitch, D. H. Nmyc upregulation by 
sonic hedgehog signaling promotes proliferation in developing 
cerebellar granule neuron precursors. Development 2003, 130, 15-
28. 
[159] Kenney, A. M.; Widlund, H. R.; Rowitch, D. H. Hedgehog and PI-
3 kinase signaling converge on Nmyc1 to promote cell cycle pro-
gression in cerebellar neuronal precursors. Development 2004, 131, 
217-228. 
[160] Hooper, J. E.; Scott, M. P. Communicating with Hedgehogs. Nat. 
Rev. Mol. Cell Biol. 2005, 6, 306-317. 
[161] Kolpak, A.; Zhang, J.; Bao, Z. Z. Sonic hedgehog has a dual effect 
on the growth of retinal ganglion axons depending on its concentra-
tion. J. Neurosci. 2005, 25, 3432-3441. 
[162] Hatton, B. A.; Knoepfler, P. S.; Kenney, A. M.; Rowitch, D. H.; de 
Alboran, I. M.; Olson, J. M.; Eisenman, R. N. N-myc is an essential 
downstream effector of Shh signaling during both normal and neo-
plastic cerebellar growth. Cancer Res. 2006, 66, 8655-8661. 
[163] Oliver, T. G.; Grasfeder, L. L.; Carroll, A. L.; Kaiser, C.; Gilling-
ham, C. L.; Lin, S. M.; Wickramasinghe, R.; Scott, M. P.; 
Wechsler-Reya, R. J. Transcriptional profiling of the Sonic hedge-
hog response: a critical role for N-myc in proliferation of neuronal 
precursors. Proc. Natl. Acad. Sci. USA 2003, 100, 7331-7336. 
[164] Browd, S. R.; Kenney, A. M.; Gottfried, O. N.; Yoon, J. W.; Wal-
terhouse, D.; Pedone, C. A.; Fults, D. W. N-myc can substitute for 
insulin-like growth factor signaling in a mouse model of sonic hed-
gehog-induced medulloblastoma. Cancer Res. 2006, 66, 2666-
2672. 
[165] Polkinghorn, W. R.; Tarbell, N. J. Medulloblastoma: tumorigene-
sis, current clinical paradigm, and efforts to improve risk stratifica-
tion. Nat. Clin. Pract. Oncol. 2007, 4, 295-304. 
[166] Rouah, E.; Wilson, D. R.; Armstrong, D. L.; Darlington, G. J. N-
myc amplification and neuronal differentiation in human primitive 
neuroectodermal tumors of the central nervous system. Cancer Res. 
1989, 49, 1797-1801. 
[167] MacGregor, D. N.; Ziff, E. B. Elevated c-myc expression in child-
hood medulloblastomas. Pediatric Res. 1990, 28, 63-68. 
[168] Raffel, C.; Gilles, F. E.; Weinberg, K. I. Reduction to homozyosity 
and gene amplification in central nervous system primitive neuro-
ectodermal tumors of childhood. Cancer Res. 1990, 50, 587-591. 
[169] Badiali, M.; Pession, A.; Basso, G.; Andreini, L.; Rigobello, L.; 
Galassi, E.; Giangaspero, F. N-myc and c-myc oncogenes amplifi-
cation in medulloblastomas. Evidence of particularly aggressive 
behavior of a tumor with c-myc amplification. Tumori. 1991, 77, 
118-121. 
[170] Batra, S. K.; McLendon, R. E.; Koo, J. S.; Castelino-Prabhu, S.; 
Fuchs, H. E.; Krischer, J. P.; Friedman, H. S.; Bigner, D. D.; 
Bigner, S. H. Prognostic implications of chromosome 17p deletions 
in human medulloblastoma. J. Neuro-Oncol. 1995, 24, 39-45. 
[171] Scheurlen, W. G.; Schwabe, G. C.; Joos, S.; Mollenhauer, J.; 
Sörensen, N.; Kühl, J. Molecular analysis of childhood primitive 
neuroectodermal tumors defines markers associated with poor out-
come. J. Clin. Oncol. 1998, 16, 2478-2485. 
[172] Bayani, J.; Zielenska, M.; Marrano, P.; Kwan Ng, Y.; Taylor, M. 
D.; Jay, V.; Rutka, J. T.; Squire, J. A. Molecular cytogenetic analy-
sis of medulloblastomas and supratentorial primitive neuroecto-
dermal tumors by using conventional banding, comparative ge-
nomic hybridization, and spectral karyotyping. J. Neurosurg. 2000, 
93, 437-448. 
[173] Herms, J.; Neidt, I.; Lüscher, B.; Sommer, A.; Schürmann, P.; 
Schröder, T.; Bergmann, M.; Wilken, B.; Probst-Cousin, S.; Her-
naiz-Driever, P.; Behnke, J.; Hanefeld, F.; Pietsch, T.; Kretzsch-
mar, H. A. C-myc expression in medulloblastoma and its progn-
sotic value. Int. J. Cancer 2000, 89, 395-402. 
[174] Grotzer, M. A.; Hogarty, M. D.; Janss, A. J.; Liu, X.; Zhao, H.; 
Eggert, A.; Sutton, L. N.; Rorke, L. B.; Brodeur, G. M.; Phillips, P. 
C. MYC messenger RNA expression predicts survival outcome in 
childhood primitive neuroectodermal tumor/medulloblastoma. Clin. 
Cancer Res. 2001, 7, 2425-2433. 
[175] Eberhart, C. G.; Kratz, J.; Wang, Y.; Summers, K.; Stearns, D.; 
Cohen, K.; Dang, C. V.; Burger, P. C. Histopathological and mo-
lecular prognostic markers in medulloblastoma: c-myc, N-myc, 
TrkC, and anaplasia. J. Neuropathol. Exp. Neurol. 2004, 63, 441-
449. 
[176] Pession, A.; Tonelli, R. The MYCN oncogene as a specific and 
selective drug target for peripheral and central nervous system tu-
mors. Curr. Cancer Drug Targets 2005, 5, 273-283. 
[177] Reardon, D. A.; Michalkiewicz, E.; Boyett, J. M.; Sublett, J. E.; 
Entrekin, R. E.; Ragsdale, S. T.; Valentine, M. B.; Behm, F. G.; Li, 
H.; Heidemann, R. L.; Kun, L. E.; Shapiro, D. N.; Look, A. T. Ex-
tensive genomic abnormalities in childhood medulloblastoma by 
comparative genomic hybridization. Cancer Res. 1997, 57, 4042-
4047. 
[178] Brandes, A. A.; Palmisano, V.; Monfardini, S. Medulloblastoma in 
adults: clinical characteristics and treatment. Cancer Treat. Rev. 
1999, 25, 3-12. 
[179] Frühwald, M. C.; D'Orisio, M. S.; Dai, Z.; Rush, L. J.; Krahe, R.; 
Smiraglia, D. J.; Pietsch, T.; Elsea, S. H.; Plass, C. Aberrant hy-
permethylation of the major breakpoint cluster region in 17p11.2 in 
medulloblastoma but not supratentorial PNETs. Genes, Chromo-
somes & Cancer 2001, 30, 38-47. 
[180] Aldosari, N.; Bigner, S. H.; Burger, P. C.; Becker, L.; Kepner, J. 
L.; Friedman, H. S.; McLendon, R. E. MYCC and MYCN onco-
gene amplification in medulloblastoma. A fluorescence in situ hy-
bridization study on paraffin sections from the Children's Oncology 
Group. Arc. Pathol. Lab. Med. 2002, 126, 540-545. 
[181] Eberhart, C. G.; Kepner, J. L.; Goldthwaite, P. T.; Kun, L. E.; 
Duffner, P. K.; Friedman, H. S.; Strother, D. R.; Burger, P. C. 
Histopathologic grading of medulloblastomas: a Pediatric Oncol-
ogy Group study. Cancer 2002, 94, 552-560. 
[182] Bigner, S. H.; Friedman, H. S.; Vogelstein, B.; Oakes, W. J.; 
Bigner, D. D. Amplification of the c-myc gene in human medul-
loblastoma cell lines and xenografts. Cancer Res. 1990, 50, 2347-
2350. 
[183] Rutkowski, S.; von Bueren, A.; von Hoff, K.; Hartmann, W.; Sha-
laby, T.; Deinlein, F.; Warmuth-Metz, M.; Soerensen, N.; Emser, 
A.; Bode, U.; Mittler, U.; Urban, C.; Benesch, M.; Kortmann, R. 
D.; Schlegel, P. G.; Kuehl, J.; Pietsch, T.; Grotzer, M. Prognostic 
Relevance of Clinical and Biological Risk Factors in Childhood 
Medulloblastoma: Results of Patients Treated in the Prospective 
Multicenter Trial HIT'91. Clin. Cancer Res. 2007, 13, 2651-2657. 
12    Current Cancer Drug Targets, 2009, Vol. 9, No. 1 Grotzer et al. 
[184] Bigner, S. H.; Vogelstein, B. Cytogenetics and molecular genetics 
of malignant gliomas and medulloblastoma. Brain Pathol. 1990, 1, 
12-18. 
[185] Jay, V.; Squire, J.; Zielenska, M.; Gerrie, B. Molecular and cytoge-
netic analysis of a cerebellar primitive neuroectodermal tumor with 
prominent neuronal differentiation: detection of MYCN amplifica-
tion by differential polymerase chain reaction and southern blot 
analysis. Pediatric Pathol. Lab. Med. 1995, 15, 733-744. 
[186] Jay, V.; Squire, J.; Bayani, J.; Alkhani, A. M.; Rutka, J. T.; Zielen-
ska, M. Oncogene amplification in medulloblastoma: analysis of a 
case by comparative genomic hybridization and fluorescence in situ 
hybridization. Pathology 1999, 31, 337-344. 
[187] Avet-Loiseau, H.; Venuat, A. M.; Terrier-Lacombe, M. J.; Lel-
louch-Tubiana, A.; Zerah, M.; Vassal, G. Comparative genomic 
hybridization detects many recurrent imbalances in central nervous 
system primitive neuroectodermal tumours in children. Br. J. Can-
cer 1999, 79, 1843-1847. 
[188] Brown, H. G.; Kepner, J. L.; Perlman, E. J.; Friedman, H. S.; Stro-
ther, D. R.; Duffner, P. K.; Kun, L. E.; Goldthwaite, P. T.; Burger, 
P. C. "Large cell/anaplastic" medulloblastomas: a Pediatric Oncol-
ogy Group Study. J. Neuropathol. Experimental Neurol. 2000, 59, 
857-865. 
[189] Stearns, D.; Chaudhry, A.; Abel, T. W.; Burger, P. C.; Dang, C. V.; 
Eberhart, C. G. c-myc overexpression causes anaplasia in medul-
loblastoma. Cancer Res. 2006, 66, 673-681. 
[190] Grotzer, M. A.; Geoerger, B.; Janss, A. J.; Zhao, H.; Rorke, L. B.; 
Phillips, P. C. Prognostic significance of Ki-67 (MIB-1) prolifera-
tion index in childhood primitive neuroectodermal tumors of the 
central nervous system. Med. Pediatr. Oncol. 2001, 36, 268-273. 
[191] Grotzer, M. A. Current outcome predictors in childhood primitive 
neuroectodermal tumors. J. Pediatric Neurol. 2003, 1, 75-82. 
[192] Zhang, P.; Li, H.; Wu, M. L.; Chen, X. Y.; Kong, Q. Y.; Wang, X. 
W.; Sun, Y.; Wen, S.; Liu, J. c-Myc downregulation: a critical mo-
lecular event in resveratrol-induced cell cycle arrest and apoptosis 
of human medulloblastoma cells. J. Neurooncol. 2006, 80, 123-
131. 
[193] Wang, Q.; Li, H.; Wang, X. W.; Wu, D. C.; Chen, X. Y.; Liu, J. 
Resveratrol promotes differentiation and induces Fas-independent 
apoptosis of human medulloblastoma cells. Neurosci. Lett. 2003, 
351, 83-86. 
[194] von Bueren, A. O.; Shalaby, T.; Rajtarova, J.; Stearns, D.; Eberhart, 
C. G.; Helson, L.; Arcaro, A.; Grotzer, M. A. Anti-proliferative ac-
tivity of the quassinoid NBT-272 in childhood medulloblastoma 
cells. BMC Cancer 2007, 7, 19. 
[195] Rorke, L. B.; Packer, R. J.; Biegel, J. A. Central nervous system 
atypical teratoid/rhabdoid tumors of infancy and childhood: defini-
tion of an entity. J. Neurosurgery 1996, 85, 56-65. 
[196] Reddy, A. T. Atypical teratoid/rhabdoid tumors of the central nerv-
ous system. J. Neurooncol. 2005, 75, 309-313. 
[197] Oda, Y.; Tsuneyoshi, M. Extrarenal rhabdoid tumors of soft tissue: 
clinicopathological and molecular genetic review and distinction 
from other soft-tissue sarcomas with rhabdoid features. Pathol. Int. 
2006, 56, 287-295. 
[198] Versteege, I.; Sevenet, N.; Lange, J.; Rousseau-Merck, M. F.; Am-
bros, P.; Handgretinger, R.; Aurias, A.; Delattre, O. Truncating mu-
tations of hSNF5/INI1 in aggressive paediatric cancer. Nature 
1998, 394, 203-206. 
[199] Biegel, J. A.; Tan, L.; Zhang, F.; Wainwright, L.; Russo, P.; Rorke, 
L. B. Alterations of the hSNF5/INI1 gene in central nervous system 
atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid 
tumors. Clin. Cancer Res. 2002, 8, 3461-3467. 
[200] Bambakidis, N. C.; Robinson, S.; Cohen, M.; Cohen, A. R. Atypi-
cal teratoid/rhabdoid tumors of the central nervous system: clinical, 
radiographic and pathologic features. Pediatr. Neurosurg. 2002, 37, 
64-70. 
[201] Hilden, J. M.; Meerbaum, S.; Burger, P.; Finlay, J.; Janss, A.; 
Scheithauer, B. W.; Walter, A. W.; Rorke, L. B.; Biegel, J. A. Cen-
tral nervous system atypical teratoid/rhabdoid tumor: results of 
therapy in children enrolled in a registry. J. Clin. Oncol. 2004, 22, 
2877-2884. 
[202] Tekautz, T. M.; Fuller, C. E.; Blaney, S.; Fouladi, M.; Broniscer, 
A.; Merchant, T. E.; Krasin, M.; Dalton, J.; Hale, G.; Kun, L. E.; 
Wallace, D.; Gilbertson, R. J.; Gajjar, A. Atypical teratoid/rhabdoid 
tumors (ATRT): improved survival in children 3 years of age and 
older with radiation therapy and high-dose alkylator-based 
chemotherapy. J. Clin. Oncol. 2005, 23, 1491-1499. 
[203] Kalpana, G. V.; Marmon, S.; Wang, W.; Crabtree, G. R.; Goff, S. 
P. Binding and stimulation of HIV-1 integrase by a human ho-
molog of yeast transcription factor SNF5. Science 1994, 266, 2002-
2006. 
[204] Muchardt, C.; Sardet, C.; Bourachot, B.; Onufryk, C.; Yaniv, M. A 
human protein with homology to Saccharomyces cerevisiae SNF5 
interacts with the potential helicase hbrm. Nucleic Acids Res. 1995, 
23, 1127-1132. 
[205] Imbalzano, A. N.; Schnitzler, G. R.; Kingston, R. E. Nucleosome 
disruption by human SWI/SNF is maintained in the absence of con-
tinued ATP hydrolysis. J. Biol. Chem. 1996, 271, 20726-20733. 
[206] Cheng, S. W.; Davies, K. P.; Yung, E.; Beltran, R. J.; Yu, J.; Kal-
pana, G. V. c-MYC interacts with INI1/hSNF5 and requires the 
SWI/SNF complex for transactivation function. Nat. Genet. 1999, 
22, 102-105. 
[207] Biegel, J. A.; Zhou, J. Y.; Rorke, L. B.; Stenstrom, C.; Wainwright, 
L. M.; Fogelgren, B. Germ-line and acquired mutations of INI1 in 
atypical teratoid and rhabdoid tumors. Cancer Res. 1999, 59, 74-
79. 
[208] Zhang, H. S.; Gavin, M.; Dahiya, A.; Postigo, A. A.; Ma, D.; Luo, 
R. X.; Harbour, J. W.; Dean, D. C. Exit from G1 and S phase of the 
cell cycle is regulated by repressor complexes containing HDAC-
Rb-hSWI/SNF and Rb-hSWI/SNF. Cell. 2000, 101, 79-89. 
[209] Fernandez, P. C.; Frank, S. R.; Wang, L.; Schroeder, M.; Liu, S.; 
Greene, J.; Cocito, A.; Amati, B. Genomic targets of the human c-
Myc protein. Genes Dev. 2003, 17, 1115-1129. 
[210] Gansler, T.; Gerald, W.; Anderson, G.; Gramling, T. S.; Williams, 
C. H.; Sens, D.; Garvin, A. J. Characterization of a cell line derived 
from rhabdoid tumor of kidney. Hum. Pathology. 1991, 22, 259-
266. 
[211] Ota, S.; Crabbe, D. C.; Tran, T. N.; Triche, T. J.; Shimada, H. Ma-
lignant rhabdoid tumor. A study with two established cell lines. 
Cancer 1993, 71, 2862-2872. 
[212] Garvin, A. J.; Re, G. G.; Tarnowski, B. I.; Hazen-Martin, D. J.; 
Sens, D. A. The G401 cell line, utilized for studies of chromosomal 
changes in Wilms' tumor, is derived from a rhabdoid tumor of kid-
ney. Am. J. Pathol. 1993, 142, 375-380. 
[213] Rosson, G. B.; Hazen-Martin, D. J.; Biegel, J. A.; Willingham, M. 
C.; Garvin, A. J.; Oswald, B. W.; Wainwright, L.; Brownlee, N. A.; 
Wright, C. F. Establishment and molecular characterization of five 
cell lines derived from renal and extrarenal malignant rhabdoid tu-
mors. Mod. Pathol. 1998, 11, 1228-1237. 
[214] Facchini, L. M.; Penn, L. Z. The molecular role of Myc in growth 
and transformation: recent discoveries lead to new insights. FASEB 
J. 1998, 12, 633-651. 
[215] Laherty, C. D.; Yang, W. M.; Sun, J. M.; Davie, J. R.; Seto, E.; 
Eisenman, R. N. Histone deacetylases associated with the mSin3 
corepressor mediate mad transcriptional repression. Cell. 1997, 89, 
349-356. 
[216] Alland, L.; Muhle, R.; Hou, H., Jr.; Potes, J.; Chin, L.; Schreiber-
Agus, N.; DePinho, R. A. Role for N-CoR and histone deacetylase 
in Sin3-mediated transcriptional repression. Nature 1997, 387, 49-
55. 
[217] Ae, K.; Kobayashi, N.; Sakuma, R.; Ogata, T.; Kuroda, H.; Kawa-
guchi, N.; Shinomiya, K.; Kitamura, Y. Chromatin remodeling fac-
tor encoded by ini1 induces G1 arrest and apoptosis in ini1-
deficient cells. Oncogene 2002, 21, 3112-3120. 
[218] Versteege, I.; Medjkane, S.; Rouillard, D.; Delattre, O. A key role 
of the hSNF5/INI1 tumour suppressor in the control of the G1-S 
transition of the cell cycle. Oncogene 2002, 21, 6403-6412. 
[219] Zhang, Z. K.; Davies, K. P.; Allen, J.; Zhu, L.; Pestell, R. G.; Zag-
zag, D.; Kalpana, G. V. Cell cycle arrest and repression of cyclin 
D1 transcription by INI1/hSNF5. Mol. Cell Biol. 2002, 22, 5975-
5988. 
[220] Han, E. K.; Ng, S. C.; Arber, N.; Begemann, M.; Weinstein, I. B. 
Roles of cyclin D1 and related genes in growth inhibition, senes-
cence and apoptosis. Apoptosis 1999, 4, 213-219. 
[221] Lamb, J.; Ewen, M. E. Cyclin D1 and molecular chaperones: im-
plications for tumorigenesis. Cell Cycle 2003, 2, 525-527. 
[222] Sherr, C. J. Cell cycle control and cancer. Harvey Lect. 2000, 96, 
73-92. 
Targeting myc Oncogenes in Pediatric Solid Tumors Current Cancer Drug Targets, 2009, Vol. 9, No. 1      13 
[223] Tashiro, E.; Tsuchiya, A.; Imoto, M. Functions of cyclin D1 as an 
oncogene and regulation of cyclin D1 expression. Cancer Sci. 
2007, 98, 629-635. 
[224] Philipp, A.; Schneider, A.; Vasrik, I.; Finke, K.; Xiong, Y.; Beach, 
D.; Alitalo, K.; Eilers, M. Repression of cyclin D1: a novel func-
tion of MYC. Mol. Cell Biol. 1994, 14, 4032-4043. 
[225] Yu, J. T.; Foster, R. G.; Dean, D. C. Transcriptional repression by 
RB-E2F and regulation of anchorage-independent survival. Mol. 
Cell Biol. 2001, 21, 3325-3335. 
[226] Freemantle, S. J.; Vaseva, A. V.; Ewings, K. E.; Bee, T.; Krizan, K. 
A.; Kelley, M. R.; Hattab, E. M.; Memoli, V. A.; Black, C. C.; 
Spinella, M. J.; Dmitrovsky, E. Repression of cyclin D1 as a target 
for germ cell tumors. Int. J. Oncol. 2007, 30, 333-340. 
[227] de Fougerolles, A.; Vornlocher, H. P.; Maraganore, J.; Lieberman, 
J. Interfering with disease: a progress report on siRNA-based 
therapeutics. Nat. Rev. Drug Discov. 2007, 6, 443-453. 
[228] Gewirtz, A. M. RNA targeted therapeutics for hematologic malig-
nancies. Blood Cells Mol. Dis. 2007, 38, 117-119. 
[229] Li, S. D.; Chono, S.; Huang, L. Efficient oncogene silencing and 
metastasis inhibition via systemic delivery of siRNA. Mol. Ther. 
2008, 16, 942-946. 
 
 
 
 
Received: March 03, 2008 Revised: August 21, 2008 Accepted: November 25, 2008 
 
 
 Current Medicinal Chemistry, 2011, 18, ????-???? 1 
 
 0929-8673/11 $58.00+.00 © 2011 Bentham Science Publishers Ltd. 
Quassinoids: From Traditional Drugs to New Cancer Therapeutics 
G. Fiaschetti
1
, M.A. Grotzer
1
, T. Shalaby
1
, D. Castelletti
1
 and A. Arcaro*
,2
 
 
1
Department of Oncology, University Children’s Hospital, Zurich, Switzerland 
2
Department of Clinical Research, University of Bern, Switzerland 
Abstract: Quassinoids are a group of compounds extracted from plants of the Simaroubaceae family, which have been 
used for many years in folk medicine. These molecules gained notoriety after the initial discovery of the anti-leukemic ac-
tivity of one member, bruceantin, in 1975. Currently over 150 quassinoids have been isolated and classified based on their 
chemical structures and biological properties investigated in vitro and in vivo. Many molecules display a wide range of in-
hibitory effects, including anti-inflammatory, anti-viral, anti-malarial and anti-proliferative effects on various tumor cell 
types. Although often the exact mechanism of action of the single agents remains unclear, some agents have been shown 
to affect protein synthesis in general, or specifically HIF-1 and MYC, membrane polarization and the apoptotic machin-
ery. Considering that future research into chemical modifications is likely to generate more active and less toxic deriva-
tives of natural quassinoids, this family represents a powerful source of promising small molecules targeting key pro-
survival signaling pathways relevant for diverse pathologies. Here, we review available knowledge of functionality and 
possible applications of quassinoids and quassinoid derivatives, spanning traditional use to the potential impact on modern 
medicine as cancer therapeutics. 
Keywords: Anticancer therapeutics, quassinoids, Simaroubaceae, tumor. 
QUASSINOIDS AND ANTI-CANCER ACTIVITIES 
Natural products have been a popular source of medicinal 
agents for thousands of years [1, 2]. More than one thousand 
species of plants possess significant antineoplastic proper-
ties, and over 50% of the currently used anti-cancer agents 
are derived from natural sources [3]. We review what is 
known about the quassinoid family here. A class of nortriter-
penoids isolated exclusively from various species of the Si-
maroubaceae plant family, quassinoids possess various 
pharmacological properties including antitumor, antiviral, 
antimalarial, anti-ulcer, and anti-inflammatory activities [4-
9]. Since the discovery of quassin and neoquassin in 1937, 
hundreds of quassinoids have been isolated and classified 
[4]. Several novel quassinoids with antitumor properties 
have been described in the last decade, and new insights into 
the mechanisms of action are coming to light. 
Most quassinoids can be categorized into 5 groups, based 
on the carbon backbone (C18, C19, C20, C22 and C25 types) 
[10, 11]. (For detailed descriptions of structural characteris-
tics, chemical features, and biogenesis of quassinoids see [4, 
10]). Many quassinoids display a wide range of biological 
properties in vitro and in vivo, and structure-activity relation 
(SAR) studies have been performed to better clarify their 
bio-activities [4]. Here we focus on research investigating 
quassinoids possessing antitumoral properties conducted in 
the last decade. These efforts have isolated new compounds, 
conducted SAR studies and advanced understanding of bio-
logical mechanisms behind anti-cancer activity. 
That quassinoids are a class of inhibitor for eukaryotic 
protein synthesis is well supported [12-14], although how the 
distinct compounds exert this effect is still not fully under-
stood. The ability to interfere at the peptidyl-transferase site, 
thus preventing peptide bond formation and terminating  
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chain elongation, has been proposed as the major mechanism 
responsible for antineoplastic activity [13]. Recent findings 
show that quassinoids are not just protein synthesis inhibi-
tors, and that their anti-tumorigenic activity is likely associ-
ated with other properties. Biological effects including in-
duction of apoptosis, down-regulation of the MYC onco-
gene, inhibition of elF4E phosphorylation, and alteration of 
membrane polarization have been described. It has also been 
reported that quassinoids regulate DNA and RNA synthesis, 
however, inhibition of nucleic acid synthesis may be a direct 
consequence of the blocked protein synthesis [15, 16]. A 
recent study investigated several quassinoids in a high-
throughput screen for inhibitors of the AP-1 transcription 
factor, a known regulator of carcinogenesis [12]. The cyto-
toxic activity of these quassinoids did not correlate with only 
the inhibition of the AP-1 or NF-B transcription factors, 
indicating that other mechanisms of action may play a role. 
Generally, high cytotoxic activity is associated with 
molecules possessing 4-ring skeletons [10]. The ,-
unsaturated ketone and the -hydroxyl group adjacent to the 
carbonyl group in the A-ring (see compound 2 for ring no-
menclature) are structural features that correlate with a high 
potency against cancer. A hydroxyl at C-1 or C-3 (see com-
pound 1 for carbons nomenclature) appears to be important 
for anti-cancer activity. Potent compounds often possess an 
intramolecular hydrogen bond between the hydroxyl and the 
oxygen of the A-ring enone, rendering the enone more sus-
ceptible to nucleophilic attack. Kupchan proposed this [17] 
as a plausible mechanism behind anti-tumoral activity. An 
ester side chain at C-15 is also associated with drug potency 
and spectrum of response [10]. Free hydroxyl groups and an 
oxygen-methylene bridge in the C-ring are also correlated 
with higher biological activity. Analogs lacking the D-ring 
lactone have been shown to be less active [18]. It is likely 
that the selectivity for a particular cellular target or pathway 
member are driven by the structural differences of quassi-
noids. 
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NEW INSIGHTS ABOUT TRADITIONAL DRUGS 
Bruceantin (1) was first isolated from Brucea antidysen-
terica, a tree traditionally used in Ethiopia and Asia to treat 
cancer [19]. After the discovery of its potent anti-leukemic 
activity [17], several studies were performed to investigate 
the biological properties of bruceantin and the entire class of 
quassinoids. A new interest in bruceantin has arisen in the 
past decade, and bruceantin is currently the most investigated 
quassinoid [5, 15, 20]. It has been evaluated in three separate 
phase I clinical trials in patients with various types of solid 
tumors, and in two separate phase II trials for adult patients 
with metastatic breast cancer [21] and malignant melanoma 
[22]. These clinical trials failed due to toxicity (hypotension, 
nausea, vomiting and fever) and poor efficacy [12, 21]. 
Cuendet et al. identified new activities of bruceantin in 
2004, while investigating its effects on a number of leuke-
mia, lymphoma and myeloma cell lines [16]. Bruceantin 
induced apoptosis in leukemia cells (HL-60 and RPMI 8226) 
via the proteolytic processing of procaspases-3, -8, and -9, 
and the cleavage of the caspase-3 substrate, poly-(ADP-
ribose)-polymerase (PARP). Caspase-mediated proteolytic 
processing of the BH3-interacting domain death agonist 
(BID), a pro-apoptotic member of the Bcl-2 family responsi-
ble for amplification of the caspase cascade [23], was also 
observed. The activation of both caspase-mediated and mito-
chondrial apoptotic pathways was confirmed by the observa-
tion of disrupted mitochondrial membrane potential triggered 
by some quassinoids [24]. An in vivo multiple myeloma 
model (RPMI 8226 human xenografts in SCID mice) con-
firmed that apoptosis was significantly elevated in tumors 
derived from animals treated with bruceantin (2.5-5 mg/kg). 
Bruceantin treatment also led to a significant regression of 
these tumors [16]. 
Bruceantin may also be a potential new drug for treat-
ment of malignances characterized by over-expression of the 
MYC oncogene [16, 25]. The over-expression of this onco-
gene is associated with tumor aggressiveness and poor cellu-
lar differentiation [26]. MYC was down-regulated in both in 
vitro and in vivo cancer models upon bruceantin treatment, 
suggesting a key role for MYC in the mechanism of brucean-
tin-mediated cell death and cell differentiation. Many other 
quassinoids possess the ability to inhibit this oncogene. A 
mechanism of action involving the down-regulation of c-
MYC was associated with the brusatol-mediated induction of 
leukemic cell differentiation and observed cell cycle arrest in 
the G1 phase [27]. RNA transcripts for c-MYC were reduced 
to a lesser extent than the protein, suggesting that quassi-
noids regulate c-MYC expression at the translational and/or 
post-translational levels. 
Recently brucein-D (2), another member of the quassi-
noid family, has been extensively investigated [5, 28]. This 
compound is extracted from Brucea javanica, a shrub tradi-
tionally used in Asia to treat malaria and cancer [29]. 
Brucein-D differs from bruceantin by its lack of ester groups 
in positions 13 and 15. This molecule was shown to be the 
major chemical constituent of the ethanolic extract of Brucea 
javanica fruit in 2008, and it was shown to be responsible for 
the inhibition of cell proliferation and induction of apoptosis 
observed in a model of human pancreatic adenocarcinoma 
[5, 28]. Brucein-D also decreased the growth of human pan-
creatic tumors grown as xenografts in nude mice. In vitro, 
Brucein-D inhibited the growth of three pancreatic cancer 
cell lines (PANC-1, SW1990 and CAPAN-1), and exerted a 
low cytotoxicity in non-tumorigenic human Hs68 fibroblasts. 
Treated cells showed typical apoptotic morphology charac-
terized by chromatin condensation together with an increased 
amount of cleaved DNA/histone complexes. Similarly to 
bruceantin, exposure to brucein-D induced proteolytic acti-
vation of procaspases-3, -8 and -9. In addition, treatment 
attenuated expression of the anti-apoptotic protein, Bcl-2, 
while augmenting the expression of the pro-apoptotic pro-
tein, Bak. In 2010, Lau et al. more deeply delineated the 
mechanisms associated with brucein-D-mediated apoptosis 
in pancreatic cancer cells [30]. Brucein-D is capable of de-
pleting intracellular levels of glutathione, an antioxidant 
which protects cells from reactive oxygen species, resulting 
in increased generation of superoxide-free radicals. The oxi-
dative stress, in turn, provokes the activation of the p38-
mitogen-activated protein kinase (p38 MAPK). The MAPK 
cascade regulates a variety of cellular responses to stress, 
inflammation and other signals, and its activation is often 
necessary for cancer cell death induced by several che-
motherapeutics [31-33]. The ability of brucein-D to activate 
the p38-MAPK-regulated pro-apoptotic pathway underlines 
the potential of quassinoids as cell death inducers. 
Brucein-D was also found capable of altering another 
well known tumorigenesis-related pathway. The nuclear fac-
tor kappa B (NF-B) family of transcription factors is impli-
cated in regulation of cell proliferation, apoptosis, invasion 
and angiogenesis in a variety of tumor malignancies [32]. 
Many studies revealed an important role of NF-B in modu-
lating cancer cell resistance to drugs and radiation therapy 
[34]. Moreover, it has been shown that inhibition of NF-B 
can lead to tumor cell death and growth inhibition [35]. Im-
pairment of this pathway has been suggested as a good strat-
egy to treat certain cancer subtypes [36]. Brucein-D treat-
ment inhibits NF-B activity by augmenting the protein level 
of the IB inhibitory subunit, which sequesters NF-B in 
the cytoplasm preventing its nuclear translocation [30]. A 
distinct mechanism of action involving NF-B was described 
in a study on HL-60 leukemic cell differentiation induced by 
brusatol (3), a quassinoid extracted from brucea species [25, 
27]. In 2003, Cuendet et al. [25] showed that brusatol up-
regulates the mRNA levels of three members of the NF-B 
family, NF-B1 (p105/p50), NF-kB2 (p100/p52) and RelA 
(p65). Phosphorylation of the NF-B inhibitor, IB, was 
also induced, resulting in enhanced translocation of NF-B 
from the cytoplasm to the nucleus, transcriptional activation 
and the consequent induction of HL-60 cell differentiation. 
Searching for novel plant-derived chemotherapeutics and 
chemopreventive agents, in 2001 Mata-Greenwood et al. 
[37] investigated the structure-activity relationships of a set 
of natural quassinoids (including brusatol and bruceantin) 
and semi-synthetic analogs of brusatol (4-8), glaucarubolone 
(9-42) and quassin (43-47). Most of the quassinoids showed 
activity as either cytotoxic or antiproliferative agents and/or 
as inducers of cellular differentiation. The parental com-
pound, brusatol, was the most potent inducer of cellular dif-
ferentiation, and inhibition of proliferation was primarily 
achieved by inducing G0/G1 arrest in the cell cycle. From a 
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Fig. (1). Chemical structures of anticancer quassinoids described in this review. 
structure-activity perspective, an hydroxylated ring at the -
position of the ester side chain at C-15 was correlated with 
the ability to induce cellular differentiation, while low po-
tency and the ability to inhibit DNA synthesis were associ-
ated to the absence of a side chain at C-15 (6, 9, and 27). 
Quassinoids with low activity lacked either the epoxy-
methano bridge in the D-ring (43-47) or a free hydroxyl 
group at positions 1, 3, 11 and 12 (i.e. due to glycosylation, 
8, 35, and 39). Based on the comparison of members with 
varied positioning of the epoxy-methano bridge, the direc-
tion of the bridge appeared not to be correlated with inhibi-
tion of cell growth or protein synthesis, but the lack of an 
ether bridge was associated with inactivity [12]. Even though 
this study showed no correlation between the lipophilicity of 
the ester side chain and the induction of HL-60 cell differen-
tiation, the nature of the side chain appeared to be important. 
A branched side chain, resulting from the addition of alkyl 
groups (13, 18), and the presence of hydroxyl substituents at 
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the -position of the side chain (10, 17) correlated with in-
creased potency. Alkyl substituents in the -position (18, 22, 
26, 30-33) have been associated with an increased selectivity 
for anti-proliferative activity versus cytotoxicity, but de-
creased potency to induce differentiation. Analogs possess-
ing side chains with cyclic rings in the -position (13, 19, 20, 
and 24) showed increased selectivity for induction of differ-
entiation and anti-proliferative/cytotoxic activity. A smaller 
set of quassinoids (1, 3, 12, 16, 18, 20, 27, and 34) was in-
vestigated in the same study as inhibitors for the formation 
of pre-neoplastic lesions in the mouse mammary organ cul-
ture (MMOC) model [37]. Analogs possessing alkyl sub-
stituents at the -position of the C-15 ester side chain (1, 3, 
18, and 34) showed high activities, in contrast to what was 
observed in HL-60, where potency was correlated with the 
presence of -branched ester side chains. 
The reduction in effectiveness of chemotherapeutic drugs 
caused by drug-resistance is one of the major problems in the 
fight against cancer [38]. Murakami et al. [39] examined 23 
quassinoids (48-76) as inhibitors of three different 
multidrug-resistant human tumor cell lines. Compounds 49-
54 and 56-58 were significantly cytotoxic against all three 
drug-resistant variants, with compounds 53 and 56 exhibiting 
the highest activity. The reduction of the C-3 double bond 
(53) increased activity, while the loss of the C-15 side chain 
(48) and/or the interchange of the position of the C-1 hy-
droxyl and C-2 carbonyl groups (62) markedly reduced po-
tency. Moreover, the quassinoid glycosides (64-70) appeared 
to be less active than the corresponding aglycon quassinoids 
(56, 57). In the same work, six hydrogenated derivatives (71-
76) demonstrated significant inhibitory effects against 12-O-
tetradecanoylphorbol-13-acetate (TPA)-induced Epstein–
Barr virus early antigen (EBV-EA) activation. All the deriva-
tives showed slightly stronger inhibitory effects than the 
original compounds (49, 51, and 52), with compound 71 
being the most potent. From the structure–activity relation-
ship point of view, an -oriented methyl group at C-4 re-
sulted in stronger inhibitory effects than -oriented groups. 
The reduction of the double bond in the A-ring led to 
stronger inhibition of EBV-EA activation. 
NOVEL ANTI-TUMORAL QUASSINOIDS 
Simaroubaceae plants have remained an interesting 
source of novel potential anti-neoplastic agents [4]. In 2004, 
the group of Kuo et al. [40] undertook the chemical investi-
gation of the methanolic extract of the root of Eurycoma 
longifolia, a tree popular in Asia as a source of a wide spec-
trum of medications [41]. Along with 61 known compounds 
from several classes, four as yet undescribed quassinoids 
were isolated: two novel C19-skeleton quassinoids, euryco-
malide A (88) and eurycomalide B (89); and two klaine-
anone-type C20 quassinoids, 13b,21-dihydroxyeurycomanol 
(90) and 5a,1-4b,1-5b-trihydroxyklaineanone (91). These 
compounds showed cytotoxic activity against human lung 
cancer (A549) and breast cancer (MCF-7) cell lines. 
Miyake et al. [42] performed a detailed phytochemical 
investigation on Eurycoma longifolia in 2009. Twenty-four 
quassinoids were isolated, including ten new structurally 
diverse quassinoids. The new compounds included two eury-
comanone-type C20 quassinoids (78, 79), one klaineanone-
type C20 quassinoid (80), one C19 quassinoid (81) with a 
1,2-seco-1-nor-6(5f10)-abeo-picrasan-2,5-olide skeleton, and 
six eurycomalactone-type C19 quassinoids (82-87). For the 
first time, an -oriented hydroxyl group at C-14 (78) and a 
3,4-epoxy group (82, 83) were reported in eurycomalactone-
type quassinoids. The isolated compounds were tested for 
cytotoxic activity against the highly metastatic human fibro-
sarcoma cell line, HT-1080. Eurycomalactone-type quassi-
noids possessing an ,-unsaturated ketone carbonyl at C-2 
were found to be cytotoxic, confirming the ,-unsaturated 
ketone as a chemical feature associated with high anti-
proliferative activity. 
Rosati et al. [43] isolated a novel quassinoid, Picrasa-
3,13(21)-diene-2,16-dione-11,20-epoxy-1,11,12-
trihydroxy,(1,11 ,12)-(9Cl) (ailanthone) (92) from Ailan-
thus excelsa, a plant traditionally used to treat cancer in 
Asian folk medicine [44]. Ailanthone induced the appear-
ance of hypodiploid cells in 50% of Jurkat leukemia cell 
cultures. Apoptosis appeared to be induced by direct altera-
tion of mitochondrial membrane permeability, induction of 
mitochondrial membrane depolarisation and activation of 
caspase-3. 
Another novel quassinoid (AECHL-1) (93) was isolated 
from chloroform extract of Ailanthus excelsa by Lavhale et 
al. [45] in 2009. In vitro, AECHL-1 induced growth inhibi-
tion associated with a S/G2-M arrest in three different human 
tumor cell lines derived from breast carcinoma (MDA-MB-
231), breast adenocarcinoma (MCF-7) and prostate carci-
noma (PC3). AECHL-1 triggered G1 arrest in the mouse 
melanoma cell line, B16F10. The compound was tested in 
vivo on B16F10 allografts in C57BL/6 mice and on MCF-7 
xenografts in nude mice. Injections of AECHL-1 into the 
tumor sites inhibited tumor growth in both models. Apopto-
sis was induced together with an increase in the phosphoryla-
tion level of p53. A reduction in the expression of the MYC 
oncogene and of two cell cycle regulatory proteins, cyclin-
D1 and Cdk-4, was also observed. AECHL-1 also acts as a 
microtubule-damaging agent. Treated MCF-7 cells showed 
microtubule disruption, increased density of cellular micro-
tubules and formation of thick microtubule bundles sur-
rounding the nucleus. 
Ailanthus altissima is another plant of the Simaroubaceae 
family, which has been traditionally used in Asia to treat 
cancer [46]. From this plant, Tamura et al. [7] isolated two 
new quassinoid molecules, shinjulactone-B (102), and shin-
julactone-C (94). The latter possesses a unique skeleton 
among quassinoids, and the molecule has been used as pa-
rental compound to generate seven derivatives containing 
20-O-acyl groups with terminal acid functionalities (95-101). 
To investigate their anti-tumor activities, these compounds 
were tested in a short-term in vitro assay of TPA-EBV-EA 
activation in Raji cells. All compounds showed inhibitory 
effects on EBV activation, and were only weakly cytotoxic 
for the Raji cells. From the structure–activity relationship 
point of view, the succinate derivatives (95, 97) possessed 
higher inhibitory activities against EBV-EA activation than 
either the parental molecule or the glutarate derivatives (96, 
98–101). The strongest inhibitory effect was achieved by the 
3',3'-dimethylsuccinate (97) derivate. It was also reported 
that the inhibitory activity was lessened if the substituted 
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Table 1. Antitumoral Quassinoids: Biological Effects and Model of Investigations 
 
Quassinoid  Biological effects Model References 
1 (Bruceantin)   Protein Synthesis 
 Proliferation 
  Cell differentiation 
 Apoptosis 
 Caspase-3,-8-9 
 PARP; BID; Cytochrome c 
 MYC 
 Tumor (in vivo) 
 pre-neoplastic lesion 
 formation  
Leukemia cells (HL-60) 
Lymphoma cells (RPMI 8226) 
Myeloma cells (U266 and H929) 
 
  
 RPMI 8226 human-SCID xenograft 
Mouse mammary organ culture model  
[17] 
[15] 
[16] 
[21] 
[22] 
 
2 (Brucein-D)  Protein Synthesis 
 Proliferation 
  Apoptosis 
 Caspase-3,-8-9 
 Bcl-2 
 Bak 
 Intracellular GSH 
 NADPH oxidase 
 p38-MAPK 
 NF-kB ( IB) 
 Tumor (in vivo) 
  
Human pancreatic tumor cells 
(PANC-1, SW1990, CAPAN-1) 
 
 
  
  
 Xenograft human pancreatic tumor in nude mice 
 
[5] 
[30] 
[5] 
3 (Brusatol)  Protein Synthesis 
 DNA Synthesis 
 Proliferation 
  Cell differentiation 
 MYC 
 NF-kB ( IB) 
 pre-neoplastic lesion 
 formation  
Leukemia cells (HL-60) 
 
  
 Mouse mammary organ culture model 
[12] 
[27] 
[25] 
4 - 47 
 
 (18, 34) 
 DNA Synthesis 
 Proliferation 
  Cell differentiation 
 pre-neoplastic lesion 
 formation  
Leukemia cells (HL-60) 
 
 Mouse mammary organ culture model 
[37] 
48 – 76  Proliferation  Human nasopharynx epidermoid 
 carcinoma (KB) 
P-glycoprotein multidrug resistant variant 
 (KB-VIN) 
MRP multidrug resistant cells 
 (KB-7d and KB-CPT)  
[39] 
77 (NBT-272)  Proliferation 
  MYC 
G1 / S arrest 
 Protein translation 
 p-elF4E p-4EBP-1 
 AKT ERK 
 Autophagosome formation 
 Tumor growth 
Human embryonal tumor cell lines: 
Medulloblastoma (D341, D425, DAOY); 
Neuroblastoma (SK-N-BE, SH-SY5Y, WAC-2); 
Retinoblastoma (Y79, WERI); 
Ewing’s sarcoma(A673, TC71); 
Malignant rhabdoid tumor (LP, MON) 
 
[8] 
[59] 
[63] 
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Quassinoid  Biological effects Model References 
78 - 87  Proliferation Highly metastatic fibrosarcoma cells 
 (HT-1080) 
[42] 
88 - 91  Proliferation Lung cancer cells (A549) 
Breast cancer cells (MCF-7) 
[40] 
92 (Ailanthone)  Hypodiploidy 
 Apoptosis 
 Caspase-3 
Depolarization of 
 mitochondrial membrane 
Alteration of 
 membrane permeability 
 
Leukemia cells (Jurkat) [43] 
93 (AECHL-1) 
 
 Proliferation 
  Apoptosis 
S/G2-M arrest 
G1 arrest (B16F10 cells) 
 Apoptosis 
 phospho-p53 
 MYC 
 cyclin-D1 
 cdk4 
Microtubule disruption 
 Tumor (in vivo) 
Mouse melanoma cells (B16F10) 
Human breast carcinoma cells 
 (MDA-MB-231) 
Human breast adenocarcinoma cells 
 (MCF-7) 
Human prostate cells (PC3) 
Human embryonic kidney cells 
 (HEK 293) 
 Nude mice xenograft with MCF-7 cells 
C57BL/6 mice allograft with B16F10 
 cells 
 
[45] 
94 - 102 
(94 - Shinjulactone-C) 
(102 -Shinjulactone-B) 
 Tumor promoting 
 activity 
TPA-induced EBV-EA in Raji cells [7] 
103 (6-tigloyloxy-
chaparrinone) 
 HIF-1 
 VEGF 
 erythropoietin 
 MAPK 
 MNK-1 
 elF4E 
Human gastric adenocarcinoma cells 
 (MKN-45 and AGS) 
Human hepatocellular carcinoma cells 
 (Hep3B) 
Human breast cancer cells 
 (MDA-MB-435) 
 
[14] 
104  Proliferation Panel of tumor cell lines 
 
[58] 
105 - 110  Proliferation Leukemia cells (P-388) 
  
[57] 
Symbols: [( = Activation) ( = Inhibition)]. 
group of the glutarate became bulky, [3'-ethyl-3'-
methylglutarete (100) and 3'-tetramethylene-glutarate (101)]. 
A novel mechanism of action among quassinoid com-
pounds was described in 2008 by the group of Jin et al. [14]. 
They identified 6-tigloyloxychaparrinone (compound 103), 
a bruceantin analog carrying a tigloyloxy side chain in posi-
tion 6. This quassinoid is able to interfere with different cel-
lular mechanisms commonly altered in cancer [29, 47]. 
Compound 103 showed the particular ability to inhibit hy-
poxia-inducible factor-1 (HIF-1), a central mediator of 
cellular responses to low oxygen. The effect was achieved by 
suppressing the phosphorylation of upstream elements of 
HIF-1 (ERK1/2, MNK1 and eIF4E) [14]. HIF-1 and its 
upstream elements represent attractive targets for future can-
cer therapeutics. For this reason, 6-tigloyloxychaparrinone 
is a potentially interesting novel agent for future investiga-
tions [48, 49]. HIF-1 is over-expressed in certain human 
cancers, usually as a result of intratumoral hypoxia as well as 
genetic alterations, and it is crucial to many aspects of tumor 
biology, including angiogenesis, cell survival, glucose me-
tabolism and invasion [50, 51]. Various human cancer cell 
lines were used for preclinical testing of the 6-
tigloyloxychaparrinone quassinoid. The compound dose-
dependently decreased the hypoxia-induced accumulation of 
HIF-1 protein, and consequently, the expression of two 
HIF-1 target genes, vascular endothelial growth factor 
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(VEGF) and erythropoietin. HIF-1 inhibition was achieved 
without affecting the level of HIF-1 mRNA expression or 
HIF-1 protein degradation, suggesting a direct inhibition of 
HIF-1 protein synthesis. HIF-1 protein synthesis is regu-
lated by activation of the extracellular signal-regulated 
kinase-1/2 (ERK1/2). The levels of phosphorylation of 
ERK1/2, MAPK-interacting protein kinase-1 (MNK1) and 
eukaryotic initiation factor 4E (eIF4E) were significantly 
suppressed by the 6-tigloyloxychaparrinone treatment. The 
inhibition of this MAPK cascade (HIF-1 upstream ele-
ments) is likely responsible for HIF-1 protein inhibition. 
Different quassinoids are able to interfere with the MAPK 
pathway. This pathway is a potential target for cancer ther-
apy because it plays a role in the cell acquired growth signals 
autonomy [52]. 
Moreover, the mRNA cap-binding protein, eIF4E is over-
expressed in a variety of human tumors, and has been associ-
ated with cancer progression [53, 54]. Over-expression of 
eIF4E in experimental models dramatically alters cellular 
morphology, enhances cell proliferation, and induces cellular 
transformation, tumorigenesis, and metastasis. In preclinical 
tumor models, elF4E inhibition repressed tumor growth, and 
recently, elF4E has been proposed as a new candidate target 
for anticancer therapeutics [55]. The ability of 6-
tigloyloxychaparrinone to inhibit eIF4E phosphorylation 
might be the cause of inhibited HIF-1 translation, and thus, 
anticancer activity. The idea that a single compound can in-
hibit distinct molecular cascades correlated with tumorigene-
sis is fascinating, and highlights the need of a more accurate 
analysis of the broad capabilities of this quassinoid. Among 
the quassinoids with anti-tumor activities, this compound has 
a rare tigloyloxy group in position 6. This might be the rea-
son behind the activities exerted by this molecule. This com-
pound could be an important novel candidate for future in-
vestigations. 
SEMI-SYNTHETIC QUASSINOID ANALOGS 
Semi-synthesis plays a major role in the structural modi-
fication of natural products, and can lead to the discovery of 
more active and/or less toxic compounds [56]. Semi-
synthetic procedures to modify quassinoid molecules are 
presently well established [10]. The first investigations on 
semi-synthetic quassinoids involved dimeric derivatives. 
Connecting two molecules of bruceantin (1) or brusatol (3) at 
the C-3 hydroxy group through malonate, glutarate, adipate 
and sebacate esters, Lee et al. generated bis-esters (105-110) 
active against leukemic cells (P-388) [57]. Brusatol dimers 
had higher potency as antineoplastic agents than brusatol 
itself, while brusatol was more active as an anti-
inflammatory or differentiating agent. 
As previously discussed, the identity of the C-15 ester 
side chain is a structural feature which was shown to be im-
portant for the cytotoxic activity of quassinoids. It has been 
postulated that oxidation of the C-15 side chain can cause 
quassinoid inactivation. To circumvent a possible deactiva-
tion occurring through this mechanism, trifluoro-methyl 
groups have been incorporated into the C-15 side chain [58]. 
The most potent trifluoro-analog was 15-[3-
(trifluoromethyl)butanoyl]bruceolide (104), which had a 
similar potency to bruceantin against a panel of human can-
cer cell lines. A lipophilic ester side chain at C-15 appeared 
to be important for both potency and spectrum of response, 
because it aided the transport across cell membranes. A lipo-
philic derivative, NBT-272 (77), was found to be 2- to 10-
fold more potent than the parental compound, bruceantin, in 
inhibiting the cellular proliferation of a variety of cancer cell 
lines [8, 59]. Similarly to bruceantin, the derivative also 
down-regulates the MYC oncogene. The effect of this com-
pound on different types of tumors, in which MYC plays an 
important role, has been investigated. In particular, it was 
tested on in vitro models of neuroblastoma and medulloblas-
toma, two childhood cancers of the nervous system fre-
quently characterized by MYC deregulation associated with 
aggressiveness and poorly differentiated tumors [60-62]. The 
derivative demonstrated a highly potent anti-proliferative 
effect. Cells with MYC amplification or over-expression 
have been found to be more sensitive and prone to apoptosis 
upon NBT-272 treatment. However, all cell lines tested were 
strongly affected, suggesting that MYC expression is not the 
only factor regulating cellular sensitivity to NBT-272 [8]. A 
more recent study described the wide range of biological 
activities exerted by the quassinoid derivative NBT-272 on a 
panel of embryonal tumor cell lines [63]. The inhibition of 
protein synthesis appeared to be associated with alteration in 
the protein translation machinery, caused by the inhibition of 
the phosphorylation of elF4E and its binding protein 4EBP-
1. The depletion of MYC protein was associated with cell 
cycle arrest and occured via an indirect mechanism involving 
the inhibition of two pro-proliferative pathways, i.e. the AKT 
and the MEK/extracellular signal-regulated kinase (ERK) 
pathways. Moreover, the compound triggered auto-
phagosome formation and arrested tumor growth in a 
xenograft model of neuroblastoma. 
CONCLUSIONS AND FUTURE PERSPECTIVES 
Quassinoids represent a heterogeneous group of mole-
cules with the ability to interfere with different pathways 
implicated in tumorigenesis. As discussed in the present re-
view, protein synthesis inhibition and cytotoxicity appear to 
be common characteristics of quassinoids, shared by com-
pounds belonging to different C-type classes. The induction 
of apoptosis also appears to be a common feature among 
quassinoids. Several apoptosis-related processes have been 
found altered upon treatment with members of this class of 
compounds. Cell death could be related to treatment-induced 
stress, but on the other hand, the activation of different com-
ponents of the apoptotic machinery appears to be associated 
with specific structural characteristics of the individual 
molecules. For instance, both bruceantin (1) and brucein-D 
(2) induce the proteolytic activation of caspase-3, -8 and -9 
and proteolytic processing of BID. However, brucein-D in-
duces cell death via a complex mechanism involving GSH 
depletion, oxidative stress and p38-MAPK activation, to-
gether with prevention of NF-B translocation into the nu-
cleus and the consequent inhibition of anti-apoptotic gene 
expression. It is interesting to note that the quassinoid, brusa-
tol (3), induces an opposite effect, promoting NF-B translo-
cation into the nucleous via induction of phosphorylation of 
IB. These diverse effects on the NF-B pathway may also 
reflect differences in the cellular models used to study the 
mechanism of action of the two quassinoids. 
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The down-regulation of the MYC oncogene is frequently 
observed upon quassinoid treatment [8, 16, 25, 27, 45]. 
Down-regulation of MYC is commonly induced by a subset 
of C20-type quassinoids [e.g. bruceantin (1), brusatol (3), 
NBT-272 (77) and AECHL-1 (93)]. The MYC family of 
genes encodes transcription factors that play essential roles 
in cell proliferation, differentiation, apoptosis and many 
other cellular processes [64-66]. The deregulation of this 
oncogene contributes to the genesis of many human cancers, 
with the development of more aggressive tumors, and is of-
ten correlated with poor patient prognosis [67, 68]. Moreo-
ver, MYC suppression has been associated with proliferative 
arrest and tumor regression in a variety of cancer models [69, 
70]. Therefore, MYC is an attractive target for cancer treat-
ment [71], and further advances in understanding the mecha-
nism of action of quassinoids could lead to potentially selec-
tive derivatives capable of specific inhibition of this onco-
gene family. 
In addition to the induction of apoptosis, cell growth in-
hibition and MYC reduction, a new mechanism of action 
among quassinoids has been described for AECHL-1 (93), 
which appears to be a promising microtubule damaging 
agent. For this reason, we classify the quassinoids as “multi-
targeted agents” [72], a class of molecules targeting multiple 
signaling pathways and cellular processes necessary for the 
life of a cancer cell (Fig. 2). The available data have been 
generated by studying quassinoids in different models, and 
most of these studies have never been systematically com-
pared. So, it is not possible to exclude that the specific cellu-
lar effects, which have been described for one or a few 
members of the quassinoid family, are more generally 
shared. However, the broad spectrum of biological effects 
highlights a need for more accurate and systematic screening 
of these molecules, and a rational drug design-based study to 
identify leads for the synthesis or semi-synthesis of new ana-
logs with increased activity, decreased toxicity and/or im-
proved pharmacological profiles for the development of fu-
ture cancer therapeutics. 
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